Pentoxifylline in anaemia resistant to erythropoietin (PEAR) study A double blind placebo controlled randomised trial by Kaushik, T
	 1	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Thesis	submitted	for	the	degree		
Doctor	of	Medicine	(Research)	
Queen	Mary	University,	London	
	
	
	
Tarun	Kaushik	
Translational	Medicine	and	Therapeutics	
William	Harvey	Research	Institute	
Queen	Mary	University,	London	
United	Kingdom	
	
	
	
Pentoxifylline	in	anaemia	resistant	
to	erythropoietin	(PEAR)	study	
	
A	double	blind	placebo	controlled	
randomised	trial	
	
	 2	
	
Declaration	and	Acknowledgements		
	
The	work	presented	in	this	thesis	is	my	own	(unless	stated).	It	was	conducted	in	
the	Department	of	Nephrology,	The	Royal	London	Hospital,	London,	UK	.	
	
I	would	like	to	express	my	gratitude	to	National	Institute	of	Health	Research	for	
funding	this	project.	 	
	
This	work	would	not	have	been	possible	without	the	continued	help,	guidance	
and	support	of	my	colleagues.	In	particular	I	would	like	to	thank:		
	
The	nurses,	doctors	and	administrative	staff	of	the	Royal	London	dialysis	units	
who	despite	their	large	workload	were	extremely	helpful	and	supportive	
throughout	this	work.	
	
Mrs.	Neringa	Vilimiene,	research	nurse	for	help	in	conducting	the	trial.		
	
Dr	Ceri	Davies	and	Dr	Hikmat	Jan	for	their	guidance	and	support	in	conducting	
and	analysing	Cardiac	MRI	and	FDG	PET	CT	scans.	
	
Dr	Steven	Harwood	for	help	and	support	in	setting	up	the	mechanistic	endpoint	
analysis.			
	
Dr	Stanley	Fan,	Department	of	Nephrology	at	The	Royal	London	Hospital–	my	
academic	supervisor	who	has	been	a	constant	support	and	mentor.	
	
Professor	Magdi	Yaqoob,	William	Harvey	Research	Institute	and	Department	of	
Nephrology		at	The	Royal	London	Hospital-	my	academic	supervisor,	a	great	
teacher	and	mentor.	His	constant	motivation	has	made	this	project	possible.	
	
My	family	and	friends,	in	particular,	my	wife,	who	has	continuously,	encouraged	
and	supported	me.		
	
Dr	Tarun	Kaushik	
MBBS,	MRCP	Nephrology	(UK)			
Sept	2018	
	
	
	
	
	
	 3	
Statement	of	originality		
I,	Tarun	Kaushik,	confirm	that	the	research	included	within	this	thesis	is	my	
own	work	or	that	where	it	has	been	carried	out	in	collaboration	with,	or	
supported	by	others,	that	this	is	duly	acknowledged	below	and	my	contribution	
indicated.	Previously	published	material	is	also	acknowledged	below.		
I	attest	that	I	have	exercised	reasonable	care	to	ensure	that	the	work	is	original,	
and	does	not	to	the	best	of	my	knowledge	break	any	UK	law,	infringe	any	third	
party’s	copyright	or	other	Intellectual	Property	Right,	or	contain	any	
confidential	material.		
I	accept	that	the	College	has	the	right	to	use	plagiarism	detection	software	to	
check	the	electronic	version	of	the	thesis.		
I	confirm	that	this	thesis	has	not	been	previously	submitted	for	the	award	of	a	
degree	by	this	or	any	other	university.		
The	copyright	of	this	thesis	rests	with	the	author	and	no	quotation	from	it	or	
information	derived	from	it	may	be	published	without	the	prior	written	consent	
of	the	author.		
		
Tarun	Kaushik	
Date:	26.	September.	2018	
Details	of	publications:			
November	2015:	Poster	presentation	at	American	Society	of	Nephrology	
meeting							“Incidental	Findings	on	15	Fluorodeoxyglucose	Positron	Emission	
Tomography	Along	with	Low	Dose	Computerized	Tomography	(FDG	PET	CT)	
Scans	Among	Clinically	Stable	Haemodialysis	with	Erythropoietin	Stimulating	
Agent	(ESA)	Hypo	Responsiveness	(ESA-R)”	
T	Kaushik,	S	Fan,	M	Yaqoob		
	 4	
Abstract		
Background		
Hyporesponsiveness	 to	 erythropoiesis-stimulating	 agents	 (ESA)	 and	 its	
association	 with	 adverse	 cardiovascular	 outcomes	 remains	 a	 considerable	
problem	 in	 patients	 with	 end-stage	 renal	 disease	 (ESRD)	 undergoing	
haemodialysis.	Pentoxifylline	has	been	shown	to	have	some	beneficial	effect	on	
ESA	Hyporesponsiveness	by	reducing	inflammation	in	ESRD	patients.	
Methods		
We	conducted	a	single	centre,	double-blind,	placebo-controlled	randomised	trial	
to	 study	 the	effect	of	Pentoxifylline	on	Erythropoietin	stimulating	agent	 (ESA)	
requirement	of	stable	haemodialysis	patients.		Inclusion	criteria	were	equivalent	
ESA	dose	of	greater	than	or	equal	to	6000	International	Units	(I.U)	per	week	or	
ESA	resistance	index		greater	than	or	equal	to	6.5	I.U	/kg/wk/Hb	(g/dl)	and	stable	
Hb	 between	 9	 to	 12	 g/dl.	 	 The	 primary	 study	 endpoint	was	 ESA	 requirement	
relative	 to	 Haemoglobin	 (Hb)	 level	 at	 the	 end	 of	 study	 period	 of	 6	 months.	
Secondary	 endpoints	 included	 safety	 analysis,	 Hb	 values,	 ESA	 dose	 and	
cardiovascular	 imaging	 biomarkers	 such	 as	 vascular	 PET	 CT	 and	 cardiac	MRI	
scan.	Cytokine	profile	was	also	analysed	during	the	study.		
Results		
A	total	of	69	patients	underwent	randomisation.	At	the	end	of	the	study	period,	
there	was	no	statistically	significant	(p	value=	0.26)	difference	in	ESA	/Hb	ratio	
between	pentoxifylline	and	placebo	group	 (Mean	 (SD)	3.98	mcg/gm/dl	 (3.09)	
versus	4.91	mcg/gm/dl	(3.49)	respectively).	 	The	secondary	outcomes	did	not	
show	 any	 statistically	 significant	 change	 between	 pentoxifylline	 and	 placebo	
group.	 There	 were	 no	 concerns	 regarding	 the	 safety	 of	 pentoxifylline	 in	
haemodialysis	patients.	The	cytokine	profile	showed	a	reduction	in	inflammatory	
cytokines	titres	and	rise	in	anti-inflammatory	cytokines	in	the	entoxifylline	group	
analysed	as	slopes	of	cytokine	variability	longitudinally.	
Conclusions		
Pentoxifylline	 did	 not	 improve	 the	 ESA	 requirement	 in	 ESA	 hyporesponsive,	
stable	haemodialysis	patients	over	six	months	period.	There	was	no	statistically	
significant	change	in	cardiovascular	imaging	biomarkers	between	Pentoxifylline	
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and	 placebo	 group.	 Cytokine	 profile	 showed	 a	 favourable	 response	 to	
Pentoxifylline	therapy.	
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List	of	abbreviations	
	
Abbreviation																			Meaning	
	
ACEinh	 Angiotensin	converting	enzyme	inhibitor	
ARB	 Angiotensin	receptor	blocker	
AD	 Aortic	distensibility	
AE	 Adverse	events	
Ao	 Aorta	
ATP																													 Adenosine	triphosphatase		
Akt	 Protein	Kinase	B	
AVF	 Arteriovenous	fistula	
B.C.	 Before	Christ	
BFU-E	 Erythroid	burst	forming	units	
Bcl-	xL	 B-cell	lymphoma-extra			
BMP	6	 Bone	morphogenetic	protein	6	
cAMP	 cyclic	adenosine-3,5-monophosphate	
C.E.	 Common	Era	
CFU-E	 Erythroid	colony	forming	units	
CKD	 Chronic	kidney	disease	
CMR	 Cardiac	magnetic	resonance	
CREB	 cAMP	-	response	element	binding	protein	
CRF	 Case	report	form	
CRP	 C-	reactive	protein	
CT	 Computed	tomography	scan	
CVC	 Central	vascular	catheter	
cAMP	 Cyclic	adenosine	3,5-monophosphate							
DMT	 Divalent	metal	transporter	
DNA	 Deoxyribonucleic	acid	
dl	 Decilitres	
EKLF	 Erythroid	Kruppel	like	factor	
EPO	 Erythropoeitin	
EPO-R	 EPO	receptor	
ELK-1	 ETS	domain-containing	protein	gene-1	
ERK	 Extracellular	signal	regulated	
ERFE	 Erythroferrone	
ESA	 Erythropoeitin	stimulating	agents	
ESRD	 End	stage	renal	disease	
18	FDG	 18	Fluorodeoxyglucose	
FIH-1	 Factor	inhibiting	HIF-1	
FOG	-	1	 Friend	of	GATA	1	
GATA		1&	2	 Transcription	factors	with	ability	to	bind	GATA	sequence	
of	DNA	
GDF	15	 Growth	differentiating	factor		15	
GM-CSF	 Granulocyte	macrophage	colony	stimulating	factor	
gm	 Grams	
GN	 Glomerulonephritis	
GRB	 Growth	factor	receptor-bound	protein	
GLUT	 Glucose	transporter	
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Hb	 Haemoglobin	
HIF-1	 Hypoxia	inducible	factor	1	
HIF	2	 Hypoxia	inducible	factor	2	
HJV		 Hemojuvelin	
HNF	4	 Hepatocyte	nuclear	factor	4	
hs-CRP	 Highly	sensitive	C	reactive	protein	
IFN-g	 Interferon	gamma	
IFN	gamma	 Interferon	gamma	
IL-3	 Interleukin	3	
IL-6	 Interleukin	6	
ITT	 Intention	to	treat	
I.V.	 Intravenous	
IMP	 Investigational	medicinal	product	
ITT	 Intention	to	treat	
JAK	2	 Janus	Kinase	2	
Kg	 Kilogram	
kDa	 Kilodalton	
kt/v	 Dialyser	clearance	of	urea	X	time	on	dialysis	/	volume	of	
distribution	of	urea	
LDL	 Low	density	lipoprotein	particles	
LM	 Left	main	artery	
LV	 Left	ventricle	
LVH	 Left	ventricular	hypertrophy	
LVEDV	 Left	ventricular	end	diastolic	volume	
LVESV	 Left	ventricular	end	systolic	volume	
LVEF	 Left	ventricular	ejection	fraction	
LVSV	 Left	ventricular	systolic	volume	
MAPK	 Mitogen	activated	protein	kinase	
MBq	 Megabecquerel	
mg	 Milligram	
mm	 Millimeter	
MMPs	 Matrix	metalloproteinases	
ml	 Millilitres	
mSv	 Millisievert	
NO	 Nitric	oxide	
NF-KB	 Nuclear	factor	kappa-light-chain-enhancer	of	activated	B	
cells	
ns	 P	value	not	siginifcant	
OD	 Omne	in	die	or	once	daily	
PET	 Positron	emission	tomography	
pg	 Picograms	
pH	 Pouvoir	hydrogène	(power	of	hydrogen)	
PHD	2	 Prolyl	hydroxylase	domain	2	
p-IgA	1	 Polymeric	immunoglobulin	A	1	
PI-3K	 Phosphoinositide	3-Kinase	
PKA	 Phosphokinase	A	
PWV	 Pulse	wave	velocity	
RAAS	 Renin-angiotensin	aldosterone	system	
RBC	 Red	Blood	cells	
RCT	 Randomised	controlled	trial	
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RHEX	 Regulator	of	human	erythroid	cell	expansion	
ROI	 Region	of	interest	
SAE	 Serious	adverse	event	
S.C.	 Subcutaneous	
SCF	 Stem	cell	factor	
SD	 Standard	deviation	
SHC	 Src	homology	2	domain	containing	transforming		protein	
1	
SOS	 Son	of	Sevenless	homolog	
SMAD	 Signal	transducer	proteins	fir	receptors	TGF	beta	
SMC	 Smooth	muscle	cells	
Spi	 Serine	protease	inhibitor	
SSFP	 Steady	state	free	precision	
STAT	 Signal	Transducer	and	Activator	proteins	
SUV	 Standardised	uptake	value	
SUVmax	 Maximum	standardised	uptake	value	
SVC	 Superior	vena	cava	
TAC	 Total	arterial	compliance	
Tal-1/SCL	 T-cell	leukaemia	1	/	stem	cell	leukaemia	
TBR	 Target	to	background	ratio	
TFR	1	 Transferrin	receptor	1	
TFR	2	 Transferrin	receptor	2	
TMPRSS6	 Transmembrane	protease,	serine	6;	matriptase-2	
TNF-a	 Tissue	necrosis	factor	alfa	
TGF	 Transforming	growth	factor	
THL	 Tunnelled	haemodialysis	line	
TIN	 Tubulo	interstitial	nephritis	
µm	 Micrometer	
µg	 Microgram	
URR	 Urea	reduction	ratio	
VCAM-1	 Vascular	cell	adhesion	molecule	1	
VHL	 Von	Hippel-	Lindau	(VHL)	protein	
VEGF	 Vascular	endothelial	growth	factor	
Wk	 Week	 	
WMD	 Weighted	mean	difference	
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1. Introduction	
Blood	has	always	been	a	source	of	great	fascination	in	human	history.	Over	the	
centuries,	it	has	occupied	minds	of	scientists,	philosophers,	scribes	and	artists.	
The	importance	of	blood	in	the	preservation	of	life	appears	to	have	been	
recognised	as	early	as	Paleolithic	times.	Perhaps	the	circulation	of	blood	was	
first	mentioned	in	the	ancient	Chinese	and	Indian	medical	literature.	One	of	the	
Hippocratic	writings	from	approximately	400	B.C.	describe	blood	as	being	a	part	
of	four	‘humors’	which	form	the	composition	of	the	human	body.	Subsequently,	
there	were	significant	contributions	by	Roman	scientist	Galen	(born	169	C.E),	
Iranian	scientists	Rhazes	and	Haly	Abbas	around	10TH	century	C.E.	towards	
increased	knowledge	of	circulation,	which	formed	the	foundation	of	modern	
theories	on	circulation[1-4].		
	
In	modern	medical	literature,	the	discovery	of	the	blood	circulation	by	English	
Physician	William	Harvey	(1578-1657	C.E.)	is	regarded	as	a	turning	point	in	the	
history	of	modern	medicine.	The	cellular	composition	of	blood	was	first	
recognised	by	a	Dutch	microscopist	Leeuwenhoek	who	was	able	to	observe	red	
blood	cells	under	a	microscope	and	described	size	and	shape	of	red	corpuscles	
in	an	illustration	in	1695.	The	discovery	of	white	blood	cells	and	platelets	
followed	after	microscope	lenses	were	improved.	Karl	Vierordt	in	1852	
reported	the	first	quantitative	results	of	blood	cell	analysis[5,	6].		
The	growth	of	knowledge	of	the	physiology	of	blood	and	improved	methods	of	
blood	examinations	allowed	anaemia	and	other	blood	related	disorders	to	be	
studied	on	a	rational	basis.	In	1900,	the	discovery	of	blood	groups	by	Dr	
Landsteiner	paved	the	way	for	successful	crossmatched	blood	transfusion.	The	
subsequent	improvements	in	techniques	of	blood	transfusion	have	made	it	a	
safe	treatment	for	anaemia.	However,	this	treatment	was	not	without	
complications[7].		
	
1.1 Red	Blood	cells	
	
The	four	main	components	of	human	blood	are	plasma,	red	blood	cells	(RBC)	or	
erythrocytes,	white	blood	cells	(WBC)	and	platelets.	Human	RBC	is	biconcave	or		
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discocyte	shaped.	The	discocyte	shape	of	human	RBCs	is	approximately	7.5	to	
8.7	μm	in	diameter	and	1.7	to	2.2	μm	in	thickness.	Haemoglobin	[8]	molecules,	
essential	for	gas	transport	within	the	circulation,	are	contained	in	the	RBC	
cytosol	[9].	Haemoglobin	is	an	iron-containing	oxygen	transport	metalloprotein	
and	forms	96%	of	the	red	cell	content	by	dry	weight.		
	
Haemoglobin	[8]	a	64.4	kiloDalton	metalloprotein	tetramer	consisting	of	4	
subunits:	two	pairs	of	globin	polypeptide	chains	-	a	pair	of	alpha-like	chains	and	
a	pair	of	non-alpha-like	chains.	Each	subunit	consists	of	a	haem	protein	chain	
tightly	associated	through	covalent	bonding	with	a	non-protein	haem	group.	
The	haem	group	consists	of	a	single	molecule	of	protoporphyrin	coordinately	
bound	to	a	single	ferrous	(Fe
2+
)	ion,	which	carries	oxygen	and	other	gases. 
	
Red	blood	cells	enable	transportation	of	sufficient	oxygen	from	between	lungs	
and	metabolising	tissues	through	their	high	intracellular	content	of	Hb	[8]	and	
allosteric	interaction	between	ligand	(oxygen,	carbon	dioxide	and	Hydrogen	
ion)	binding	sites	in	Hb	molecule.	The	tetrameric	Hb	molecule	is	in	equilibrium	
between	two	quaternary	structures,	relaxed	‘R’	structure	with	high	oxygen	
affinity	and	the	tense	‘T’	structure	with	low	oxygen	affinity.	The	oxygen-
transporting	properties	of	RBCs	show	considerable	plasticity	and	can	be	
adjusted	to	variable	tissue	O2	needs	and	environmental	constraints	via	changes	
in	intra	erythrocytic	pH	and	organic	phosphates.	
	
Red	blood	cells	also	contribute	to	the	phenomenon	of	hypoxic	vasodilatation	
when	passing	through	microcirculation	ensuring	fast	matching	of	local	oxygen	
supply	and	demand.	The	RBCs	can	regulate	their	own	distribution	in	the	
microcirculation	through	mechanisms	such	as	deoxygenation	dependent	release	
of	adenosine	triphosphatase	(ATP)		from	RBC,	which	stimulates	production	of	
nitric	oxide	(NO)	and	other	vasodilators	in	the	endothelium;	release	of	
vasoactive	NO	from	S-nitroso-Hb	upon	deoxygenation;	and	reduction	of	
naturally	occurring	nitrite	to	vasoactive	NO	by	deoxygenated	Hb [10].			
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1.2				Anaemia		
	
Anaemia	is	defined	as	an	absolute	reduction	in	the	number	of	circulating	red	
blood	cells.	For	practical	purposes,	anaemia	is	defined	as	the	reduction	in	
haemoglobin,	haematocrit	or	red	blood	cell	count	(usually	measured	as	millions	
of	RBCs	per	microliters).	World	health	organisation	definition	of	anaemia	for	
men	and	women	are	haemoglobin	less	than	13	gm/dl	and	less	than	12	gm/dl	
respectively.	This	definition	has	limitations	particularly	in	a	patient	population	
with	chronic	diseases	affecting	erythropoiesis.		
	
Causes	of	anaemia	broadly	classified	into	a)	abnormal	RBC	production	b)	
increased	destruction	of	circulating	mature	RBCs	c)	blood	loss.		
In	the	absence	of	nutritional	deficiencies,	genetic	RBC	disorders	and	bone	
marrow	disorders,	anaemia	in	chronic	kidney	diseases	occurs	as	a	result	of	
decreased	effective	red	cells	production.	Hence	anaemia	in	chronic	kidney	
disease	could	occur	as	a	result	of	relative	or	absolute	erythropoietin	deficiency	
and	inflammation.		
	
Treatment	options	for	anaemia	in	CKD	are	as	follow:	
1. Frequent	blood	transfusions:	Although	blood	transfusion	is	an	effective	way	of	
treating	anaemia.	However,	complications	associated	with	recurrent	blood	
transfusions	such	as	iron	overload,	immunologic	sensitization,	volume	overload	
in	non-dialysis	patients	and	transfusion	associated	infections	are	undesirable.		
2. Androgens:	Androgens	by	their	effect	on	increased	endogenous	EPO	production,	
increased	sensitivity	of	erythroid	progenitor	cells	to	EPO	in	bone	marrow	were	
the	mainstay	of	treatment	of	anaemia	associated	with	CKD	before	the		discovery	
of	ESAs.	However,	side	effects	associated	with	androgen	limited	their	use.		
3. ESA:	As	mentioned	earlier	ESAs	revolutionised	the	treatment	of	anaemia	in	CKD	
patients.	ESA	eliminated	the	need	for	blood	transfusion	in	the	majority	of	CKD	
patients.		
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2 Erythropoiesis	
	
Erythropoiesis	(from		'erythro'	meaning	"red"	and	'poiesis'	meaning	"to	make"	
in	the	Greek	language)	is	the	process	of	producing	red	blood	cells	or	
erythrocytes.	The	mature	red	cell	is	the	final	phase	of	a	complex	but	orderly	
series	of	genetic	events	that	initiates	when	a	multipotent	stem	cell	commits	to	
the	erythroid	program.	During	steady-state	haematopoiesis,		adequate	number	
of	red	blood	cells	are	produced	per	hour	in	the	bone	marrow	to	maintain	the	
haemoglobin	level	within	reasonably	narrow	limits.	The	RBC	production	is	
rapidly	increased	in	the	setting	of	ongoing	blood	loss	or	hemolysis.	This	process	
happens	in	bone	marrow,	which	provides	ideal	microenvironment	consisting	of	
stromal	cells,	haematopoietic	accessory	cells	and	extracellular	matrix.			
	
The	erythroid	progenitor	cell	compartment	is	situated	functionally	between	the		
multipotent	stem	cells	and	the	morphologically	distinguishable	erythroid	cells,	
contains	a	spectrum	of	cells	with	a	parent	to	progeny	relationship,	all	
committed	to	erythroid	differentiation.		This	process	is	regulated	by	
transcription	factors	and	growth	factors	acting	at	various	stages	of	development	
of	an	erythrocyte	from	a	multipotent	stem	cell.	(Figure	2.1)1	
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Figure	2.1.		Development	of	an	erythrocyte	from	a	multipotent	stem	cell	
	
The	transcription	factors,	which	act	at	the	level	of	hematopoietic	stem	cells,	
include	T-cell	leukaemia	1	/	stem	cell	leukaemia	(Tal-1/SCL)	and	GATA2,	while	
GATA1,	friend	of	GATA	1	(FOG-1)	and	Erythroid	Kruppel	like	factor	(EKLF)	are	
more	critical	for	erythropoiesis.		The	growth	factors	play	an	essential	role	in	
regulating	the	proliferation	and	maturation	of	erythroid	progenitor	cells.	
Growth	factors	include	erythropoietin	(EPO),	stem	cell	factor	(SCF),	insulin	and	
insulin	like	growth	factors,	transforming	growth	factor	(TGF)	beta	gene	family,	
interleukin	3	(IL-3)	and	granulocyte	macrophage	colony	stimulating	factor	(GM-
CSF).		
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Erythroid	burst	forming	units	(BFU-E)	are	the	most	primitive	cell	lineage	
committed	erythroid	progenitors,	which	respond	to	EPO.	The	BFU-E	arise	from	
multipotent	stem	cells.	Under	the	influence	of	EPO	and	other	growth	factors,	
BFU-E	forms	subpopulations	of	erythroid	colony	forming	units	(CFU-E).		Greater	
than	80%	of	cells	in	CFU	E	population	have	EPO	receptors,	indicative	of	the	role	
of	EPO	in	early	stages	of	erythrocyte	development.	Transferrin	receptor	
expression	is	also	at	peak	at	this	stage	as	iron	is	essential	for	heme	synthesis.			
	
The	earliest	recognisable	erythroid	cell	is	pro-erythroblast,	which	after	four	to	
five	mitotic	divisions	and	following		morphologic	changes,	gives	rise	to	mature	
erythroid	cells.	Its	progeny	includes	basophilic	erythroblasts	followed	by	
polychromatophilic	erythroblasts	and	orthochromatic	erythroblasts.	Their	
morphologic	characteristics	reflect	the	accumulation	of	erythroid	specific	
proteins	(i.e.	Haemoglobin)	and	a	decline	in	nuclear	activity.		
	
After	the	last	mitotic	division,	the	inactive	dense	nucleus	of	the	erythroblast	is	
expelled	and	ingested	by	macrophages,	and	the	resulting	enucleated	cell	is	a	
reticulocyte.		There	is	a	maturation-associated	decline	in	the	number	of	EPO	
receptors,	which	parallels	the	declining	influence	of	EPO	on	erythroid	cells	
during	the	terminal	phase	of	maturation.	Reticulocytes	do	not	show	detectable	
binding	to	EPO	[11].	Erythropoiesis	is	regulated	by	a	complex	sequence	of	
growth	factors	such	as	erythropoietin	and	cytokines.		
2.1	Erythropoietin		
	
Erythropoietin	(EPO)	is	a	35-kd	glycoprotein	[12],	which	is	a	physiologically	
essential		growth	factor	for	red	cell	production	[13].	It	is	a	true	hormone	as	it	is	
mainly	produced	in	peritubular	cells	in	the	kidneys	in	adult	life,	transported	
through	the	bloodstream	and	then	acts	in	the	bone	marrow	[14].	EPO	is	
responsible	for	both	maintaining	normal	erythropoiesis	and	increasing	red	cell	
production	in	response	to	intracellular	oxygen	needs.		
	
EPO	stimulation	elicits	two	types	of	measurable	responses:	changes	in	the	
proliferative	activity	including	improved	survival	and	changes	in	maturation	
	 18	
rates	of	CFU-E	and	erythroid	precursors	which	are	extremely	sensitive	to	EPO.	
Virtually	all	these	cells	are	already	in	the	cycle.	Therefore,	rise	of	their	numbers	
cannot	be	achieved	by	increasing	their	fraction	in	the	cycle.	Hence	enhanced	
survival	of	CFU-E	could	be	linked	to	the	crucial	role	of	EPO	in	terminal	
differentiation	of	erythroid	progenitors.	
	
In	studies	done	on	mice	with	homozygous	null	mutations	for	EPO	or	EPO	
receptor	(EPO-R)	genes,		the	BFU-E	and	CFU-E	colonies	fail	to	differentiate	into	
mature	erythrocytes[15].	In	vitro	studies	have	shown	that	EPO	and	other	
hematopoietic	growth	factors	act	synergistically	to	enable	terminal	maturation	
of	erythrocyte	progenitor	cells	by	suppression	of	apoptosis	[16-18].	EPO	plays	
an	evolutionarily	conserved	role	in	promoting,	survival	and	appropriate	timing	
of	terminal	maturation	of	primitive	erythroid	precursors	[19].	
	
2.1 	EPO	expression	
	
All	nucleated	cells	in	the	body	sense	&	respond	to	hypoxia.	The	rate	of	oxygen	
delivery	and	the	level	of	oxyhaemoglobin	remain	the	fundamental	regulator	of	
erythropoiesis.	Under	hypoxic	conditions,	hypoxia-inducible	factor	1	(HIF-1)		
[20]		regulates	expression	of	genes	that	mediate	adaptive	response.	HIF-1	acts	
as	a	regulator	of		EPO,	vascular	endothelial	growth	factor	(VEGF)	and	glycolytic	
enzyme.	HIF-1	may	play	a	role	in	the	regulation	of	more	than	2	per	cent	of	all	
human	genes	[21].		
	
The	interstitial	cells	in	the	inner	cortex	and	outer	medulla	of	the	kidney	respond	
to	hypoxia	by	producing	erythropoietin.	Hypoxia	activates	production	of	HIF-1	
in	these	specialised	cells,	which	in	turn	leads	to	activation	of	EPO	gene	
expression	following	carefully	choreographed	sequence	of	events.	HIF	1	is	
composed	of	a	constitutively	expressed	HIF	1	β	subunit	and	oxygen	regulated	
HIF	1	α	subunit	or	HIF	2	α	which	has	a	similar	role	as	HIF	1	α.		HIF	1	α		is	only	
detectable	under	hypoxic	conditions	[20,	22].	Figure	2.2	describes	the	
mechanism	of		HIF-1	control	and	activation.		
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Hepatocyte	nuclear	factor	4	or	HNF	4	also	plays	a	critical	role	in	hypoxia	
induced	activation	of	EPO	gene	expression[23].	The	Von	Hippel-Lindau	(VHL)-
HIF	pathway	also	mobilises	iron	to	support	erythropoiesis	by	down	regulation	
of	hepcidin	production	and	up	regulation	of	ferroportin,	facilitating	iron	
absorption	and	mobilisation	[24]	
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Figure	2.2.	EPO	regulation	through	HIF	pathway	
	
	
Figure	2.2			
In	well-oxygenated	cells,	HIF	1	α	is	ubiquinated	and	degraded	by	proteasomes	as	shown	
in	figure	2	A.	In	mammalian	cells,	the	oxygen	sensing	propyl	hydroxylase	domain	2	(PHD	
2)	uses	oxygen	to	hydroxylate	HIF-1	α	on	proline	residue	(Pro-OH).	The	von	Hippel-
Lindau	(VHL)	protein	binds	to	HIF-1		and	subsequently	recruits	a	ubiquitin	E3	ligase.	26s	
proteasome	enzyme	then	degades	HIF-1	α	protein	as	a	result	of	polyubiquitination.		In	
the	presence	of	oxygen,	factor	inhibiting	HIF-1	(FIH-1)	hydroxylates	HIF-1α	on	an	
asparagine	residue	(Asn–OH).	This	tep	inhibits	binding	of		HIF-1α	by	the	coactivator	
protein	p300	resulting	in	prevention	of	HIF-1α	from	activating	gene	transcription	(Figure	
2.2	A).		
Under	hypoxic	conditions	(Figure	2.2	B),	the	Pro	and	Asn	hydroxylation	reactions	are	
inhibited.	The	HIF-α	(i.e.,	either	HIF-1α	or	HIF-2α)	rapidly	accumulates,	dimerizes	with	
HIF-1β	and	recruits	p300,	which	binds	to	hypoxia	response	elements,	and	activates	the	
transcription	by	RNA	polymerase	II	(Pol	II)	of	hundreds	of	target	genes,	such	as	EPO	
encoding	genes;	VEGF	and	pyruvate	dehydrogenase	kinase	1	(PDK1)	encoding	gene,	
encoding	pyruvate	dehydrogenase	kinase	1,	which	inhibits	the	conversion	of	pyruvate	to	
acetyl	coenzyme	A	for	oxidation	in	the	mitochondrion	[1].		
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2.3	EPO	receptor	&	downstream	signalling	
	
EPO	receptor	(EPO-R)	is	a	66-kDa	polypeptide	membrane	protein	that	is	a	
member	of	the	cytokine	receptor	superfamily	[25].	EPO-R	is	present	on	the	
surface	of	erythroid	progenitors	as	a	homodimer,	even	in	the	absence	of	ligand.	
On	binding	to	EPO,	the	receptor	undergoes	a	conformational	change	that	brings	
its	intracellular	domains	into	close	apposition	enabling	cross	phosphorylation	
via	the	binding	of	Janus	Kinase	2	(JAK	2)	and	the	initiation	of	the	signal	
transduction	cascade	(Figure	2.3).	
	
Proteomic	analyses	of	biotin-	EPO/EPO-R	complexes	have	identified	transferrin	
receptor	2	(TFR	2)	as	an	EPO-R	partner.	In	UT7epo	cells,	TFR	2	facilitates	EPO-R	
processing	and	transport	to	the	cell	surface.	Erythroid	progenitor	cells	from			
TFR	2	knockout		mice	exhibit	decreased	EPO-sensitivity	and	CFU-E	formation.	
During	iron	deficiency,	TFR	2	also	acts	to	balance	erythrocyte	production	with	
available	iron.	Beyond	its	established	roles	in	hepatocyte	iron	transport,	TFR	2	
also,	therefore,	modulates	EPO-dependent	erythropoiesis.			
	
Transferrin	receptor	1	(TFR1)	can	also	modulate	EPO-R	signalling.	Specifically,	
TFR1	ligation	by	polymeric-Immunoglobulin	A	1	(p-IgA1)	in	murine	
erythroblasts	increases	EPO/EPO-R	dependent	mitogen-activated	protein	
kinases	(MAPK)	and	phosphoinositide	3-	kinase	(PI3K)	signalling.	This	occurs	in	
the	absence	of	transferrin	binding	but	depends	upon	a	TFR1	endocytic	motif	
[26].		
Protein	regulator	of	human	erythroid	cell	expansion	(RHEX)	has	recently	been	
described	as	a	new	EPO-R	associated	factor.	It	promotes	erythroid	progenitor	
expansion	and	late-stage	haemoglobinised	erythroblast	development.	In	UT7	/	
epo	cells,	RHEX	is	associated	with	EPO-R/JAK2	complexes,	and	its	tyrosine	
phosphorylation	is	strongly	induced	up	to	>20	fold	by	EPO	exposure.	In	primary	
erythroid	progenitor	cells,	RHEX	exhibits	lineage-restricted	expression,		and	its	
knockdown	attenuates	extracellular	signal-regulated	kinases	(ERK)	1/2	
activation	as	well	as	late-stage	human	erythroblast	development	[27].	
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Figure	2.3.	EPO-	Receptor	signalling	and	modulating	factors	[26]		
	
	
	
	
JAK	2	phosphorylation	creates	the	docking	site	for	signalling	adaptors	&	
mediators.	Upon	activation	of	EPO-R,	multiple	signalling	molecules	/	pathways	
are	activated.	The	biological	consequences	attributed	to	these	pathways	include	
anti-apoptosis,	proliferation	and	differentiation.	Prominent	pathways	include	
PI3	Kinase	/protein	kinase	B	(Akt),	RAS/RAF/Mitogen-activated	protein	kinase	
(MAPK)	and	signal	transducer	and	activator	proteins	(STAT)	5	pathway.	
	
	
	
Figure	2.3.	On	binding	to	EPO,	the	EPO	receptor	undergoes	a	conformational	change	that	enables	cross	
phosphorylation	via	the	binding	of	Jak2	kinase	and	the	initiation	of	the	signal	transduction	cascade.	
TFR	1	and	TFR	2	also	modulate	EPO	receptor	signaling.		RHEX	is	associated	with	EPO	R	and	promotes	
EPO	dependent	erythroblast	formation.	
	
	
	 23	
	
EPO/EPO-R/STAT	5	activation	leads	to	transcription	of	B-cell	lymphoma	extra	
large	(Bcl-xL)	gene	[28].	This	pathway	is	seen	as	a	prominent	downstream	
pathway	of	EPO-R	and	its	antiapoptotic	properties	probably	explain	major	
viability	response	associated	with	EPO	action[29].	However,	in	in-vitro	studies,	
EPO	can	efficiently	protect	Bcl-xL	knockout	erythroid	progenitor	cells.	Hence	
raising	a	possibility	of	additional	mediators	in		EPO-EPO	R	associated	
cytoprotection	[30].		
	
Intracellular	Spi	2A	serpin	(Serine	protease	inhibitor)	has	been	identified	as	
new	EPO/EPO-R/STAT	5	target	and	cytoprotective	factor.	It	inhibits	B-	&	L-	
cathepsins	which	when	leached	from	damaged	lysosomes	can	trigger	apoptosis.		
EPO/EPO-R/STAT	5	also	induce	expression	of	a	cytokine	called	erythroferrone	
(ERFE)	which	leads	to	reduced	hepcidin	production	subsequently	leading	to	
better	iron	availability	for	erythropoiesis	[26].		
	
EPO/EPO-R/RAS/RAF	/MAPK	pathway	
	
Binding	of	Src	homology	2	domain	containing	transforming	protein	1	(SHC)	/	
growth	factor	receptor-bound	protein	(GRB)	2/son	of	sevenless	homolog	(SOS)	
complex	to	activated	EPO-R	eventually	leads	active	MAPK	to	the	nucleus.	This	
results	in	phosphorylation	of	transcription	factors	such	as	ETS	domain-
containing	protein	gene	(ELK-1)	that	promote	cell	cycle	progression	and	
proliferation.	The	Phosphoinositide	phospholipase	pathway	is	also	activated	via	
EPO-R	and	appears	to	feed	predominantly	into	RAS/RAF/MAPK	pathway	
promoting	proliferation.		
	
EPO/EPO-R/PI-3	kinase/Akt	pathway	
	
The	Phosphoinositide-3	kinase	(PI-3	kinase)	is	recruited	to	EPO-R	by	binding	of	
the	p85	regulatory	subunit	to	the	EPO-R.	PI-3	kinase	/Akt	pathway	has	been	
implicated		in	controlling	both	proliferation	and	differentiation	responses	of	
erythroid	cells.	Activated	PI3-kinase	and	Akt	activated	by	EPO,	phosphorylates	
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and	activates	GATA-1.		
	
Active	GATA	-1	promotes	the	establishment	of	an	erythroid	phenotype	and	
suppresses	alternative	lineage	/	multipotent	progenitor	capacity	of	the	cells	
through	the	positive	feedback	loops	where	GATA-1	promotes	EPO-R	expression.	
Further	degradation	and	loss	of	GATA-1	appear	to	be	required	at	the	late	stages	
of	erythroid	differentiation,	illustrating	stage-specific	effects	of	many	intrinsic	
and	extrinsic	factors	involved	in	erythropoiesis.		
	
Growth	factors:	other	cytokines	
Cytokines	such	as	stem	cell	factor,	interleukin	3,	GM	CSF	and	insulin-like	growth	
factor	1	enhance	erythropoiesis	in	the	presence	of	EPO.		
	
3 Iron	Metabolism	
	
Iron	is	a	vital		element	required	for	energy	production,	oxygen	utilisation	and	
cellular	proliferation.	Although	all	cells	require	iron,	quantitatively	most	of	the	
iron	in	the	body	is	found	in	erythroid	cells	and	most	of	the	daily	movements	of	
iron	cycles	through	the	erythroid	compartment.		
	
Iron	is	a	tightly	regulated	metal	as	deficiency	and	excess	can	lead	to	anaemia	
and	haemochromatosis	respectively.	There	is	no	iron	loss	from	the	body	except	
in	the	presence	of	blood	loss.	Most	of	the	iron	transported	to	erythroid	cells	is	
directed	towards	the	mitochondria	for	heme	synthesis.	Heme	(ferrous	
protoporphyrin	IX)	is	a	planar	molecule	consisting	of	an	atom	of	ferrous	iron	in	
the	centre	of	a	tetrapyrrole	ring.	Most	of	the	heme	is	then	bound	to	alfa	or	beta	
globin	subunits	that	combine	to	form	alfa-beta	dimers	that	in	turn	join	to	form	
the	functional	alfa-2	beta-2	tetramer	of	haemoglobin.		
	
Iron	is	absorbed	primarily	from	duodenum	where	enterocytes	absorb	iron	from	
the	diet	through	the		divalent	metal	transporter	(DMT)	-1	receptor.	Enterocytes	
then	export	iron	to	circulation	in	ferric	form.	Transferrin	transports	iron	in	a	
soluble	form	to	erythroid	bone	marrow	or	other	iron	requiring	cells	expressing	
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TFR	1	receptor.	Cells	regulate	the	absorption	of	transferrin-bound	iron	by	
altering	TFR	1	on	the	cell	surface.		Reticuloendothelial	macrophages	are	
involved	in	iron	storage	and	recycling	through	the	breakdown	of	senescent	
RBCs.	Reticuloendothelial	macrophages	provide	a	significant	source	of	iron	(25-
30	mg).		
	
Hepatocytes	play	a	central	role	in	iron	regulation	through	secretion	of	Hepcidin	
to	iron	concentration	in	the	body	as	well	as	storage	and	release	of	surplus	iron.		
Iron	export	from	all	the	cells	occurs	through	the	basolateral	transporter	called	
ferroportin.		
	
Ferroportin	is	post-translationally	regulated	by	hepcidin.	Hepcidin	acts	as	
central	iron-regulating	hormone	which	leads	to	endocytosis	of	Ferroportin	
leading	to	reduced	availability	of	iron	in	the	circulation.	The	consequent	iron	
retention	in	enterocytes	reduces	iron	absorption,	and	a	similar	effect	happens	in	
reticuloendothelial	macrophages	leading	to	decreased	iron	turn	over.	Hepcidin	
is	upregulated	in	response	to	increased	transferrin	saturation,	inflammation,	
infection	and	endotoxins.	Hepcidin	is	downregulated	in	iron	deficiency,	
ineffective	erythropoiesis,	hypoxia,	increased	levels	of	erythropoietin	or	growth	
differentiating	factor	(GDF)	15	[11].	Hepcidin	regulation	in	hepatocytes	is	
thought	to	occur	through	the	following	major	pathways:	
	
1. Iron	status:		Bone	morphogenic	protein	6	(BMP-6)	produced	by	hepatocytes	and	
enterocytes	in	response	to	iron	availability,	acts	by	binding	to	BMP	type	1	&	2	
receptor	while	interacting	with	co-receptor	hemojuvelin	(HJV).	This	leads	to	
phosphorylation	of	SMAD	1/5/8	which	then	interacts	with	SMAD	4	resulting	in	
a	transcriptional	complex	that	activates	hepcidin	production	in	the	nucleus.	
Circulating	iron	signal	is	provided	by	transferrin	binding	to	TFR	1	&	2.		Hepcidin	
production	is	modulated	by	the	binding	of	these	receptors	to	haemochromatosis	
protein	(HFE).	
	
2. Inflammation:	Inflammatory	cytokine	such	as	IL-6	induce	hepcidin	expression	
through	JAK	signal	transducer	to	phosphorylate	STAT-3,	which	in	turn	interacts	
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with	the	promoter	of	the	hepcidin	gene	in	the	nucleus[31].		
	
3. Hypoxia:	Under	hypoxic	conditions,	HIF	transcription	factors	upregulate	
expression	of	TMPRSS6	(transmembrane	protease,	serine	6;	matriptase-2)	
which	inhibits	the	action	of	BMP	6	by	cleaving	HJV	from	the	cell	membrane.		
	
4. Erythropoietin:	Erythropoiesis	drive	stimulated	by	erythropoietin	down	
regulates	hepcidin	in	a	dose-dependent	manner	[32].	TFR	2	in	association	with	
EPO-R	is	involved	in	the	production	of	GDF	15,	a	suppressor	of	hepcidin	
production	by	hepatocytes	which	in	turn	leads	to	greater	iron	availability[33].	
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Figure	3.1	Hepcidin	regulation		
	
	
	
Figure	3.1:	Hepcidin	regulation		
Positive	regulation:	Increased	iron	availability	leads	to	upregulation	of	Hepcidin	synthesis	
through	BMP	6	pathway	and	transferrin	receptors.	Inflammation	(IL-6)	also	induces	
hepcidin	expression	through	JAK	signal	transducer	leading	of	phosphorylation	of	STAT-3.		
Negative	regulation:	Increased	EPO	leads	to	Hepcidin	suppression	by	GDF	15	production	
through	TFR	2	which	is	associated	with	EPO-R.	Hypoxia	leads	HIF	transcription	factor	to	
increase	production	of	TMPRSS6	which	in	turn	inhibits	BMP	6	mechanism	by	cleaving	HJV	
associated	with	Bone	morphogenic	receptor	(BMPR)	1	&	2.	
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4 Anaemia	and	chronic	kidney	disease	
	
Richard	Bright	first	observed	Anaemia	in	chronic	kidney	disease	patients	in	
1836	at	Guy’s	Hospital	who	stated	that	‘after	a	time,	the	healthy	colour	of	the	
countenance	fades’[34].	
	
As	chronic	kidney	disease	progresses,	there	is	an	increasing	prevalence	of	
anaemia.	Anaemia	in	CKD	is	typically	normochromic,	normocytic	and	hypo	
proliferative.	In	1948	and	early	1950s	erythropoietin	was	identified	as	a	
humoral	factor	which	stimulated	red	cell	production.	Subsequently,	in	1955	the	
first	quantitative	and	specific	assay	for	EPO	was	developed	[35].	In	1957,	
kidneys	were	identified	as	the	primary	site	of	EPO	production	in	animal	studies	
[36].		Subsequently	in	the		late	1970s	to	mid-1980s,	purification	and	cloning	of	
EPO	led	to	the	development	of	immunological	assays	for	quantifying	the	level	of	
circulating	EPO	[37,	38].	EPO	levels	were	considered	inappropriately	low	in	
patients	with	anaemia	with	CKD	compared	to	anaemic	patients	with	normal	
kidney	function	who	had	10-100	times	higher	EPO	levels	[39].		
	
Availability	of	EPO	and	iron	in	bone	marrow	are	essential	for	red	cell	
production.	Anaemia	in	CKD	is	primarily	because	of	reduction	of	EPO	
production	by	peri-tubular	fibroblast	cells	in	the	kidney.		Available	iron	at	bone	
marrow	is	also	one	the	major	factors	which	affect	red	cell	synthesis	in	CKD	
patients.	As	described	above	systemic	and	cellular	iron	levels	are	very	tightly	
controlled.	CKD	patients	on	haemodialysis	have	increased	iron	loss	of	
approximately	1-3	gm	per	year	due	to	chronic	bleeding	secondary	to	uraemia	
associated	platelet	dysfunction,	blood	loss	in	haemodialysis	circuits	and	
frequent	blood	tests	[39].		Therefore,	iron	therapy	remains	a	mainstay	of	
treatment	for	anaemia	of	CKD	along	with	EPO	therapy.		
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5 CKD	&	Inflammation	
	
Inflammation	is	prevalent	among	Haemodialysis	patients	[40].	Chronic	kidney	
disease	is	known	to	be	a	state	of	sterile	inflammation.	This	generalised	increase	
in	inflammatory	response	in	particular	with	haemodialysis	patients	occurs	
because	of	various	factors	including	decreased	clearance	of	pro-inflammatory	
cytokines,	endotoxemia	as	a	result	of	volume	overload,	oxidative	stress,	old	
unused	arteriovenous	fistula	or	grafts,	biofilm	in	dialysis	catheters,	old	kidney	
transplants	and	blood	dialyser	interface.	
	
Elevated	cytokine	levels	in	CKD	patients	could	be	as	a	result	of	decreased	
clearance	or	increased	production.	A	study	of	176	patients	with	advanced	CKD	
(median	GFR,	6.5	±	0.1	mL/min)	analysed	the	relationship	between	
inflammation	and	severity	of	renal	function	impairment.	Level	of	inflammation	
was	measured	by	highly	sensitive	C-reactive	protein	(hs-CRP),	tumour	necrosis	
factor-α	(TNF-α),	interleukin-6	(IL-6),	hyaluronan,	and	neopterin	
levels	checked	after	overnight	fasting.		There	were	significantly	higher	levels	of	
hs-CRP,	hyaluronan,	and	neopterin	levels	in	the	subgroup	with	lower	GFRs.	
Statistically	significant	negative	correlations	were	also	noted	between	GFR	and	
IL-6	(rho	=	−0.18;	P	<	0.05),	hyaluronan	(rho	=	−0.25;	P	<	0.001),	and	neopterin	
(rho	=	−0.32;	P	<	0.0005)	[41,	42].	This	study	favours	the	theory	of	reduced	
clearance	of	cytokines	in	advanced	CKD	patients.		
 
Chronic	fluid	overload	also	contributes	to	the	burden	of	inflammatory	status	in	
CKD	patients.	In	haemodialysis	patients	with	loss	of	residual	urine	output,	
chronic	fluid	overload	is	commonly	seen	in	practice.	Studies	in	patients	with	
fluid	overload	due	to	congestive	cardiac	failure	have	shown	increased	levels	of	
pro-inflammatory	cytokines	and	bacterial	endotoxins	[41,	43].		
	
In	CKD	patients	gut	flora	is	altered	due	to	dietary	restrictions,	and	there	is	a	
change	in	enteric	permeability	as	a	result	of	fluid	overload.	Hence	
gastrointestinal	tract	is	another	source	of	chronic	inflammation	in	CKD.	Gut	
bacterial	deoxyribonucleic	acid	(DNA)	fragments	have	been	detected	in	the	
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blood	of	both	pre-dialysis	CKD	and	chronic	haemodialysis	patients.	Using	D	
lactate	as	a	marker	of	gut	permeability,	Shi	et	al.	detected	bacteria	which	were	
mainly	of	gut	origin	in	plasma	of	12	out	of	52	chronic	dialysis	patients	using	16s	
ribosomal	DNA	amplification	and	pyrosequencing.	The	presence	of	bacteria	
correlated	well	with	CRP	and	IL-6	levels	[44].		
	
Dialysis	is	associated	with	increased	generation	of	oxidants	which	in	turn	gives	
rise	in	cytokine	production.	The	rise	in	the	markers	of	oxidative	stress	
correlated	well	with	CRP	levels	in	haemodialysis	patients	in	a	study	by	Levin	et	
al.	[45].		
	
Haemodialysis	access	is	an	important	contributor	to	the	inflammatory	milieu	of	
haemodialysis	patients.	Central	vascular	catheters	(CVC)	and	arteriovenous	
grafts	compared	to	arteriovenous	fistula	(AVF)	are	associated	with	the	greater	
burden	of	inflammation	and	mortality	among	haemodialysis	patients	[46,	47].	A	
small	study	also	demonstrated	the	presence	of	infection	in	old	clotted	unused	
grafts	even	in	the	absence	of	clinical	signs	of	infection	among	haemodialysis	
patients	[48].	Failed	transplant	grafts	in	patients	on	haemodialysis	are	also	
shown	to	be	associated	with	inflammation	and	EPO	resistance.	Transplant	
nephrectomy	is	associated	with	amelioration	of	markers	of	chronic	
inflammation	[49].		
	
Currently,	there	is	no	consensus	regarding	the	measurement	or	assessment	of	the	
degree	 of	 inflammation	 in	 CKD	 patients.	 Most	 of	 the	 guidelines	 recommend	
individual	 patient	 approach	 towards	 monitoring	 inflammation	 among	
haemodialysis	patients.	Acute	phase	reactants	such	as	highly	sensitive	CRP	and	
proinflammatory	cytokines	such	as	IL	-6	levels	correlate	with	other	markers	of	
inflammation	in	CKD	patients[50].		
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6.	Consequences	of	inflammation	in	CKD		
6.1	ESA	resistance		
	
Unfortunately,	 about	 10-20%	 of	 haemodialysis	 patients	 show	 resistance	 or	
inadequate	 response	 to	 ESAs	 and	 hence	 require	 higher	 dosage.	 High	 ESA	
requirement	is	associated	with	increased	cardiovascular	mortality	and	morbidity	
[51,	52].	Moreover,	the	health	economic	consideration	for	the	treatment	of	ESA-
resistant	patients	with	ever-increasing	amounts	of	ESA	was	also	very	significant.	
In	2010	as	a	part	of	the	internal	audit	in	Barts	Health	NHS	Trust,	the	cost	for	ESA	
alone	for	250	ESA-resistant	patients	amounted	to	£2.5	million	per	year	which	is	
the	same	cost	as	for	the	remaining	950	ESA-sensitive	patients.	Fortunately	since	
the	adoption	of	tendering	process	in	our	unit,	the	purchase	price	of	ESA	has	fallen	
but	 still	 cost	 of	 care	 of	 such	 group	 of	 patient	 is	 high	 due	 to	 their	 frequent	
hospitalisations.	
	
Chronic	 inflammation	 is	 one	 of	 the	 major	 factors	 associated	 with	 ESA	
hyporesponsiveness	in	patients	with	CKD	and	end	stage	renal	disease	(ESRD)[53-
55].	 Higher	 ESA	 requirements	 are	 indicative	 of	 the	 risks	 associated	 with	 the	
potential	 cause	of	 ESA	 resistance	 such	 as	 high	 inflammation	 burden	 and	 non-
erythropoietic	effects	of	higher	ESA	dose.		
	
Several	 studies	 have	 also	 shown	 that	 there	 is	 a	 correlation	 between	 elevated	
levels	of	cytokines	such	as	TNF-α,	IFN-γ,	IL-1,	IL-6	and	erythropoietin	resistance	
in	haemodialysis	patients	[56-58].	Pro-inflammatory	cytokines	inhibit	erythroid	
progenitor	 cell	 proliferation	 and	 antagonise	 the	 anti-apoptotic	 action	 of	
erythropoietin	 [56,	 59].	 The	 direct	 negative	 effect	 on	 erythroid	 progenitors	 is	
primarily	due	to	alterations	in	the	sensitivity	to	EPO.		TNF-α	and	IL-1	affect	EPO	
synthesis	in	vitro	and	cause	a	dose-dependent	inhibition	of	hypoxia-induced	EPO	
production	in	the	Hep3b	cell	line	[60].		
	
Hepatic	hepcidin	synthesis	increases	due	to	inflammation	as	a	consequence	of	IL-
6	 induction,	mediated	 through	BMP	signalling.	Raised	hepcidin	 concentrations	
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lead	 to	 functional	 iron	 deficiency	 as	 a	 consequence	 of	 down	 regulation	 of	
ferroportin	resulting	 in	 intracellular	accumulation	of	 iron	 in	macrophages	and	
enterocytes.	This	 functional	non-availability	of	 iron	 for	erythropoiesis	leads	to	
impaired	haemoglobin	synthesis	[61].		
	
Earlier	work	in	our	laboratory	by	Allen	et	al	showed	that	in	an	in-vitro	study,	CFU-
E	 colony	 growth	was	 suppressed	 when	 incubated	 with	 serum	 from	 inflamed	
uraemic	patients	compared	to	those	incubated	with	serum	from	control	subjects.	
The	effect	was	reversed	in	a	similar	co-culture	experiment	by	adding	neutralising	
polyclonal	antibodies	against	TNF-α	and	IFN-γ.	This	experiment	suggests	a	direct	
correlation	between	pro-inflammatory	cytokines	and	ESA	response	[62].		
	
High	ESA	requirement	is	associated	with	poor	outcomes	and	high	cardiovascular	
morbidity	and	mortality	in	patients	on	haemodialysis	[63].	Therefore	addressing	
ESA	resistance	is	a	promising	treatment	option	for	patients	with	ESRD.	
	
Various	adjuvant	therapies	have	been	investigated	in	the	past	such	as	L-carnitine,	
vitamin	 C	 and	E	 in	 order	 to	 treat	 ESA	hyporesponsiveness	 but	 unfortunately,	
there	is	no	clear	evidence	to	support	any	of	these	interventions.	This	finding	has	
been	 confirmed	 by	 a	 recent	 Cochrane	 review	 that	 concluded	 that	 there	 is	
inadequate	evidence	to	recommend	any	intervention	for	ESA	resistance.	Further,	
adequately	powered	randomised	controlled	trials	(RCT)	are	therefore	required	
[64].	
6.2	Cardiovascular	risk	
	
Over	the	last	two	decades,	inflammation	has	been	implicated	as	a	risk	factor	for	
developing	 atherosclerosis	 and	 subsequently	 leading	 to	 plaque	 rupture	 and	
developing	 the	 dreaded	 complications	 such	 as	 acute	 coronary	 syndrome	 and	
stroke	[65,	66].	In	animal	studies,	leukocyte	recruitment	and	expression	of	pro-
inflammatory	 cytokines	 characterise	early	atherogenesis,	 and	 the	 inhibition	of	
inflammatory	mediators	mutes	 atheroma	 formation[67].	 Inflammation	 in	 CKD	
patients	 undergoing	 haemodialysis	 is	 associated	 with	 poor	 outcomes	 due	 to	
enhanced	cardiovascular	risks	and	mortality[68,	69].			
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There	is	a	very	high	prevalence	of	coronary	artery	disease	in	CKD	patients.	The	
severity	of	obstructive	coronary	artery	lesion	rises	with	increasing	severity	of	
disease	[70-72].		Traditional	risk	factors	are	present	in	most	of	the	incident	
advanced	CKD	patients.	These	risk	factors	do	not	explain	the	higher	incidence	of	
cardiovascular	disease	in	CKD	patients	as	previously	known	tools	which	use	
traditional	risk	factors	for	predicting	cardiovascular	risks	such	as	Framingham	
equation	demonstrate	poor	overall	accuracy	in	predicting	cardiac	events	in	
individuals	with	CKD[73].			
	
In	a	prospective	study	of	80	non-diabetic	uraemic	pre-dialysis	patients,	the	
relationship	between	markers	of	inflammation	&	oxidative	stress	such	as	
plasma	levels	of	CRP,	fibrinogen	and	advanced	oxidation	protein	products	and	
the	incident	first	occlusive	cardiovascular	event	was	studied.	At	a	median	follow	
up	of	seven	years,	adverse	outcomes	in	all	21	patients	were	independently	
associated	with	age	and	markers	of	inflammation	and	oxidative	stress	[74].		
Similarly,	in	a	study	of	45	haemodialysis	patients	observed	over	12	months	
showed	worsening	of	carotid	intima-media	area	in	common	carotid	artery	was	
associated	with	elevated	IL-6	levels[75].				
	
A	study	of	a	historical	cohort	of	393,451	US	dialysis	patients	demonstrated	that	
septicaemia	resulting	in	inflammation	was	associated	with	increased	
cardiovascular	deaths[76].	There	is	evidence	to	support	that	inflammatory	state	
measured	by	elevated	acute	phase	reactants	is	associated	with	increased	
cardiovascular	morbidity	&	mortality	among	CKD	patients	[77,	78].	Therefore	
inflammation	may	be	the	missing	link	in	cardiovascular	risk	prediction	in	
patients	with	advanced	CKD.		
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7. Cardiovascular	morbidity	and	mortality	in	CKD	patients	
	
Apart	from	CKD	being	an	independent	predictor	of	high	cardiovascular	risk,	
patients	with	CKD	usually	have	a	very	high	burden	of	comorbidities	such	as	
diabetes,	hypertension	and	chronic	inflammation	predisposing	them	for	
atherosclerotic	disease	process[79].		
	
Cardiovascular	events	occur	as	a	result	of	atheromatous	plaque	rupture	in	the	
arterial	wall,	which	leads	to	narrowing	or	occlusion	of	the	vessel	lumen.	This	
leads	to	downstream	catastrophic	ischaemia	resulting	in	myocardial	infarctions,	
strokes	and	critical	limb	ischaemia.		However,	atherosclerotic	disease	leading	to	
vaso-occlusive	events	such	as	acute	myocardial	infarction	itself	does	not	
account	for	the	majority	of	cardiovascular	mortality	in	patients	with	advanced	
CKD	and	ESRD.	This	is	also	demonstrated	by	the	poor	outcomes	following	PCI	in	
ESRD	patients	compared	to	non-CKD	patient	cohort	[79].	
	
Congestive	cardiac	failure,	arrhythmias	and	sudden	death	account	for	the	
major	cause	of	mortality	and	morbidity	in	patients	with	CKD	and	ESRD	
patients	as	published	in	recent	United	States	Renal	Data	System	(USRDS	
report	in	2016.		74%	of	patients	with	CKD	5	have	left	ventricular	hypertrophy	
(LVH)	at	the	time	of	initiation	of	haemodialysis.		Pathogenic	factors	for	LVH	in	
patients	with	advanced	CKD	and	dialysis	include	chronic	volume	overload,	
intradialytic	fluctuation	of	circulating	volume,	anaemia	and	arterioscelrosis	
[80].		Both	atherosclerosis	and	arteriosclerosis	contribute	to	cardiovascular	
morbidity	in	CKD	patient	through	overlapping	mechanisms.	
7.1	Atherosclerosis	
	
Development	of	atheromatous	plaques	is	referred	to	as	atherogenesis,	which	in	
turn	leads	of	atherosclerosis.	Atherogenesis	starts	as	changes	in	endothelial	
layer	of	blood	vessels.	The	endothelial	cells	when	subjected	to	irritative	stimuli	
such	as	dyslipidaemias,	hypertension	or	pro	inflammatory	cytokines	start		
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expressing	adhesion	molecules	such	vascular	cell	adhesion	molecule	1	(VCAM-
1)	for	leucocytes.	Once	adherent	to	endothelium	chemo	attractant	molecules	
direct	transfer	of	the	leucocytes	(majority	monocytes),	which	penetrate	into	the	
innermost	layer	of	artery	tunica	intima.	Growth	factors	such	as	macrophage	
colony	stimulating	factor	1	stimulate	blood	derived	monocytes	in	the	arterial	
wall	differentiate	into	tissue	macrophages	[81].	
	
Changes	in	endothelial	permeability	and	the	composition	of	extracellular	matrix	
beneath	the	endothelium	promote	the	entry	and	retention	of	cholesterol	
containing	low-density	lipoprotein	particles	(LDL)	in	the	vessel	wall	particularly	
in	the	areas	of	strain.		Phospholipids	produced	as	a	result	of	modification	of	LDL	
can	induce	endothelial	cells	to	express	leucocyte	adhesion	molecules.		
	
The	macrophages	in	the	intima	have	scavenger	receptors	for	LDL	particles.		
Macrophages	engulf	lipoprotein	particles	and	resulting	in	the	formation	of	foam	
cells.	The	macrophages	in	the	atheroma	may	also	have	a	pro	inflammatory	
function	by	release	of	inflammatory	cytokines	and	free	oxygen	radicals.		T	cell	
activation	as	a	result	of	various	antigens	presented	with	in	the	atherosclerotic	
plaque	leads	to	production	of	interferon	gamma	(IFN-γ),	which	activates	
macrophages	and	vascular	cells	leading	to	further	inflammation	in	the	plaque	
[82].	Macrophage	accumulation	largely	define	the	fate	of	an	atherosclerotic	
plaque	and	is	proportional	to	plaque	size	[83].		Inflammation	leads	to		
Akt/protein	kinase	B	activation	of	hexokinase-1	and	hexokinase-2	in	
mitochondria	and	inhibit	pro	apoptotic	Bcl-2	associated	X	protein	(Bax).	This	
pathway	prevents	apoptosis	consequently	increasing	macrophage	population	in	
the	plaque.	
	
Smooth	muscle	cells	(SMCs),	which	are	presented	in	tunica	media,	are	recruited	
into	intima	as	a	result	of	inflammatory	stimulus	with	in	the	atheromatous	
plaque.	In	the	intima	SMCs	produce	extracellular	matrix	molecules	such	as		
interstitial	collagen	and	elastin	and	form	a	fibrous	cap	of	that	covers	the	plaque.	
The	cap	overlies	a	collection	of	foam	cells,	accumulation	of	cellular	debris	and	
extracellular	lipids,	which	form	necrotic	core	of	the	plaque.		
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Increase	in	atherosclerotic	plaque	size	causes	complications	by	producing	
narrowing	of	the	vessel	lumen	resulting	in	downstream	ischaemia	or	
catastrophic	occlusion	of	the	vessel	lumen	as	result	of	plaque	rupture	causing	
thrombosis.		The	activated	immune	cells	in	the	atherosclerotic	produce	
inflammatory	cytokines	resulting	in	production	of	IL-6.	IL	-6	in	turn	stimulates	
production	of	acute	phase	reactants	such	as	CRP	and	serum	amyloid	A	[66,	84-
86].	
	
7.1.1	Quantification	of	atherosclerotic	plaque	inflammation	
	
Currently	in	clinical	practice	atherosclerosis	can	only	be	assessed	by	
angiography	of	the	blood	vessels,	which	measures	intraluminal	stenosis	of	the	
blood	vessel.		However,	this	approach	does	not	provide	any	indication	of	plaque	
activity	or	overall	inflammation	load	in	the	vasculature.	Newer	disease-
modifying	treatments	such	as	statins	act	upon	plaque	inflammatory	activity	
leading	to	plaque	stabilisation.		
	
18	Fluorodeoxyglucose	(FDG)	positron	emission	tomography	(PET)	[87,	88]	
combined	with	computed	tomography	scan	(CT)	is	a	molecular	non-invasive	
imaging	technique	which	is	highly	sensitive	to	locate	metabolically	active	
processes	[89].		After	intravenous	injection,	18	FDG	is	taken	up	by	glucose	
transporters	(GLUT	1	&3)	into	the	cells	[90].		In	the	cytosol,	18	FDG	is	
phosphorylated	by	hexokinase	into	18	FDG-6-phosphate,	which	cannot	undergo	
glycolysis	because	it	lacks	the	necessary	2’hydroxyl	group	and	remains	trapped	
within	the	target	cells	where	it	accumulates	in	proportion	to	metabolic	demand.		
	
In	a	landmark	study,	Rudd	et	al.	demonstrated	higher	metabolic	activity	in	
atherosclerotic	plaque	in	symptomatic	carotid	artery	disease	measured	with	18	
FDG	intake	compared	to	asymptomatic	plaque	[91].		Arterial	18	FDG	PET	CT	
scan	allows	quantification	of	arterial	inflammation	and	has	a	significant	role	in	
monitoring	the	response	of	atherosclerosis	inflammation	to	intervention	[87]	
[92].		
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The	vascular	FDG	uptake	occurs	as	a	result	of	increased	pro-inflammatory	
macrophage	metabolic	activity	leading	to	increased	glucose	turnover	facilitated	
by	up	regulation	of	glucose	transporter	protein	(GLUT)	transporters	within	the	
macrophages.		Ex	vivo	studies	have	shown	the	histological	correlation	between	
18	FDG	uptake	and	macrophage	density	as	well	as	increased	gene	expression	
markers	of	glycolysis	and	inflammation.	
	
FDG	signal	is	likely	to	be	most	prominent	in	the	early	stages	of	atherosclerosis,	
during	foam	cell	formation	and	subside	after	plaque	calcification	is	established.	
Arterial	18	FDG	PET	does	not	usually	co-localise	with	calcification	seen	on	the	
CT	portion	of	combined	PET-CT	scan.	Hence	supporting	the	concept	that	
inflammation	and	calcification	occur	at	different	stages	in	atherosclerosis.		
	
The	degree	of	18	FDG	uptake	correlates	with	many	of	cardiovascular	risk	
factors	as	well	as	with	Framingham	cardiovascular	risk	scores,	inflammatory	
biomarkers	(such	as	CRP,	Matrix	metalloproteinases	(MMPs)	and	adeponectin),	
gene	expression	markers	of	glycolysis	and	inflammation.	Aortic	inflammation	
detected	by	18	FDG	PET	is	also	related	to	increased	aortic	stiffness	determined	
by	aortic	pulse	wave	velocity,	which	is	a	reliable	prognostic	indicator	of	
cardiovascular	events.			
	
PET	imaging	can	provide	a	global	measure	of	vascular	inflammation	by	
averaging	18	FDG	SUV	readings	over	multiple	segments	of	an	index	vessel	(such	
as	the	aorta).	Focused	evaluation	of	a	plaque	could	also	be	obtained	from	a	
single	investigation	(Figure	7.1)	[93].			
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Figure	7.1:	FDG	PET	CT	image	demonstrating	focal	atherosclerotic	plaque	FDG	
uptake	along	the	wall	of	descending	aorta	(arrows)[94].		
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In	a	retrospective	observational	study	of	513	cancer-free	patients	undergoing	
PET	CT	scan	as	a	part	of	the	oncological	evaluation,	aortic	18	FDG	TBR	strongly	
predicted	cardiovascular	events	independent	of	traditional	risk	factors	(HR	
4.71,	P<0.001)	with	20	to	30	%	net	reclassification	improvement	over	
Framingham	risk	score	alone	in	the	highest	risk	group.	Arterial	FDG	uptake	
along	the	ascending	aorta	measured	as	target	to	background	ratio	(TBR)	
provided	information	regarding	the	potential	of	a	subsequent	cardiovascular	
event	as	shown	in	Figure	7.2	[95].		
	
Figure	7.2:	Association	between	aortic	wall	inflammation	and	timing	of	
cardiovascular	events.	
	
	
Figure	7.2.	Association	between	aortic	wall	inflammation	and	timing	of	
cardiovascular	events	[95]	The	bar	graphs	show	mean	(standard	deviation)	TBR	
in	relation	to	timing	of	cardiovascular	events	in	months	and	no	events	at	79	
months	from	the	time	of	scan.		
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Serial	18	FDG	plaque	imaging	has	been	used	to	evaluate	changes	in	
atherosclerotic	plaque	inflammatory	activity	as	a	result	of	intervention	leading	
to	a	detectable	reduction	in	vascular	18	FDG	uptake.	18	FDG	PET	vascular	
imaging	has	been	used	as	a	surrogate	endpoint	in	several	clinical	trials	involving	
anti-atherosclerotic	drugs	such	as	statins	[96,	97].		
	
As	discussed	above	traditional	risk	factor	assessment	tool	such	as	the	
Framingham	risk	score	are	not	valid	in	patients	with	advanced	CKD.		In	a	
retrospective	study	with	64	patient	with	Stage	3	chronic	kidney	disease	and	64	
controls	undergoing	FDG	PET	CT	scan,	CKD	is	associated	with	increased	arterial	
wall	inflammation[98].		Measurement	of	plaque	inflammation	with	18	FDG	PET	
CT	vascular	imaging	has	a	potential	to	become	a	useful	prognostic	marker	for	
cardiovascular	risk.		
7.2	Arteriosclerosis	
	
Arteriosclerosis	or	arterial	wall	stiffening	of	aorta	resulting	in	elevated	afterload	
is	a	major	contributor	to	cause	of	LVH,	diastolic	dysfunction,	impaired	coronary	
artery	flow	during	the	diastolic	phase	in	CKD	patients[99].		
	
	Arterial	stiffness	is	a	condition,	which	is	commonly	noticed	in	patients	with	
CKD	and	ESRD.	Other	risk	factors	associated	with	increased	aortic	stiffness	are	
age,	hypertension	and	diabetes	[100-102].		A	recently	published	large	
observational	study	with	2933	participants	with	CKD	observed	over	four	years	
failed	to	show	a	correlation	of	baseline	level	of	inflammation	with	arterial	
stiffness	during	the	study	period.	One	of	the	criticisms	of	this	study	was	that	
single	baseline	measurement	of	the	study	might	not	reflect	true	degree	of	
inflammation	as	it	fluctuates	over	a	period	[103].		
	
Other	studies	investigating	inflammatory	conditions	such	as	rheumatoid	
arthritis	have	established	a	correlation	between	the	systemic	inflammatory	
state	with	aortic	stiffness	and	vessel	wall	inflammation.	In	small	studies,	
interventions	to	reduce	inflammation	such	as	anti	TNF-a	therapy	in	patients	
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with	rheumatoid	arthritis	have	resulted	in	improvement		of	arterial	stiffness	
[104]	[105].		
	
Arterial	stiffness	or	arteriosclerosis	is	associated	with	end-organ	damage	and	
subsequent	cardiovascular	adverse	events	as	a	result	of	various	risk	factor	
exposure.			Arterial	stiffness	is	associated	with	wide	pulse	pressure	which	gets	
transmitted	to	microvasculature	resulting	in	increased	pulse	wave	velocity	
leading	to	reflective	wave	causing	increased	after	load	&	LVH.	This	resulting	
tensile	stress	can	lead	to	microvascular	damage,	endothelial	dysfunction	and	
resulting	chronic	inflammation[106].		Aortic	stiffness	leads	to	loss	of	delicate	
balance	between	of	physiologically	matched	aortic	distensibility	which	
accommodates	for	stroke	volume	blood	flow	from	the	left	ventricle	into	aorta	
during	systole	and	smooth	forward	blood	flow	during	diastole.		Increase	in	
cardiac	afterload	as	a	result	of	aortic	stiffness	leads	to	LVH	and	
dilatation[107].		
	
Aortic	stiffness	is	characterised	by	thickening	and	concentric	calcification	of	
the	medial	arterial	layer	in	CKD.	Hyperplasia	and	hypertrophy	of	smooth	
muscle	cells	and	increased	collagen	tissue	in	the	arterial	wall	also	contribute	
to	loss	of	arterial	elasticity.	The	exact	mechanism	of	increased	arterial	
stiffness	in	CKD	is	still	uncertain.	However,	the	role	of	advanced	glycated	
products,	endothelial	dysfunction,	renin-angiotensin	aldosterone	system	
(RAAS),	vascular	calcification,	disorders	of	bone	and	mineral	metabolism	and	
chronic	inflammation	have	been	shown	to	be	associated	with	increased	
arterial	stiffness	in	CKD	patients	[108].	
	
In	one	of	the	first	studies	establishing	aortic	stiffness	as	a	predictor	of	all	cause	
and	cardiovascular	mortality,	London	et	al.	conducted	a	study	on	241	subjects	
undergoing	haemodialysis	over	a	period	of	10	years.	Aortic	pulse	wave	analysis	
was	measured	by	ultrasonography	along	with	echocardiogram	and	other	lab	
parameters,	at	the	time	of	entry	in	the	study.	Age	and	aortic	pulse	wave	velocity	
(PWV)	were	noted	to	be	predictors	of	all	cause	and	cardiovascular	mortality	
based	on	Cox	analysis.	For	cardiovascular	mortality,	Odds	ratio	for	PWV	>12.0	
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versus	<9.4	m/s	was	5.9	(95%	CI,	2.3	to	15.5).	For	all-cause	mortality,	the	odds	
ratio	was	5.4	(95%	CI,	2.4	to	11.9).	In	the	given	population,	for	each	increase	of	
1m/s	in	the	PWV,	the	all-cause	mortality	adjusted	OR	was	1.39	(95%	CI,	1.19	to	
1.62)	[109].		
	
7.2.1	Aortic	stiffness	quantification	
	
Carotid-femoral	pulse	wave	velocity	measurement	by	applanation	tonometry	
was	studied	and	proven	to	be	a	surrogate	marker	for	adverse	cardiovascular	
outcomes	despite	interobserver	variability	[109,	110].	
	
The	Dallas	heart	study	has	shown	that	measurement	of	aortic	stiffness	by	
cardiac	MRI	allows	a	measure	of	total	arterial	compliance	(TAC),	a	measure	of	
global	arterial	stiffness	and	ascending	aortic	distensibility	(AD)	and	aortic	
arch	pulse	wave	velocity	(PWV),	a	measure	of	aortic	stiffness.	Total	arterial	
compliance	and	aortic	distensibility	may	be	stronger	predictors	of	cardiac	
adverse	events.		Pulse	wave	velocity	is	considered	to	be	a	predictor	of	
nonfatal	extra-cardiac	vascular	events.	It	was	one	of	the	pioneering	studies	to	
study	the	association	of	aortic	stiffness	measured	with	CMR	with	adverse	
cardiovascular	outcomes[111].		
	
CMR	allows	good	repeatability	of	the	scans	with	precisely	placed	imaging	
planes.	Interobserver	variability	is	also	minimised	as	a	result.	Full	
visualisation	of	the	vessel	allows	studying	different	sections	of	the	aorta,	
which	may	have	different	prognostic	value.	When	the	heart	is	also	studied	in	
the	CMR	protocol,	the	accurate	assessment	of	myocardial	function	and	could	
be	made	which	is	directly	associated	with	aortic	stiffness.		However,	MRI	scan	
is	limited	by	its	contraindications	such	as	presence	of	pacemakers	and	
claustrophobia.	It	is	an	expensive	test	which	is	not	widely	available.		
	
7. Pentoxifylline	
	
There	is	emerging	evidence	for	Pentoxifylline,	a	non-selective	
phosphodiesterase	inhibitor	as	a	potential	treatment	for	ESA	hypo-
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responsiveness.	It	is	currently	licenced	for	the	treatment	of	peripheral	vascular	
disease.	Pentoxifylline	is	associated	with	a	reduction	of	pro-inflammatory	
cytokines	such	as	TNF-α,	IFN-γ	and	IL-6	in	haemodialysis	and	non-dialysis	
dependent	patients	with	CKD	as	well	as	improving	haemoglobin	status	[112,	
113].	Before	PEAR	study	was	planned,	the	evidence	in	favour	of	Pentoxifylline	
treatment	was	based	upon	following	uncontrolled	studies	
	
• Navarro	 et	 al.	 treated	 7	 anaemic	 CKD	 patients	 not	 on	 dialysis	 with	
Oxypentoxifylline	 (oral	400	milligram	 (mg)	 daily)	 for	 6	months.	Haemoglobin	
levels	significantly	 increased	from	9.9	±	0.5	to	10.6	±	0.6	g	/decilitre	(dl)	(p	<	
0.01).[113]	
	
• A	study	by	Cooper	et	al.	showed	that	Pentoxifylline	administration	resulted	 in	
improvement	 of	 haemoglobin	 in	 ESA	 resistant	 haemodialysis	 patients.	 16	
patients	on	 chronic	haemodialysis	were	given	pentoxifylline	400	mg	OD	 for	4	
months.		All	patients	had	Hb	of	<10.7g	/dl	for	6	months	before	recruitment	to	the	
study	while	on	ESA	dose	of	>12000	International	Units	(IU)/week	(wk).	Mean	Hb	
concentration	increased	from	9.5	±	0.9	to	11.7	±	1.0	g/L	(p	=	0.0001)	for	the	12	
patients	who	completed	the	study.	There	was	a	statistically	significant	reduction	
in	ex	vivo	T	 cell	expression	of	TNF	alfa	and	 interferon	gamma	after	 treatment	
compared	to	baseline	levels	[8].	
	
• In	a	study	by	Ferrari	et	al.	published	in	2010,	14	CKD	patients	(e	GFR	23±6	
ml/min)	not	on	ESAs	were	treated	with	Pentoxifylline	400	mg	daily	for	4	weeks.	
Cause	of	CKD	was	non-inflammatory	renal	disease	and	none	of	the	patients	had	
received	parenteral	iron	or	immunosuppressive	therapy.	Total	10	patients	
completed	the	study.	There	was	an	increase	in	Hb	from	a	baseline	of	11.1±5	g/dl	
to	12.3±6	g/dl	(p	<0.001)	by	the	end	of	study	follow	up	period.	This	trial	also	
demonstrated	a	reduction	in	IL-6	in	the	cohort	from	a	baseline	of	10.6±3.8	
picogram	(pg)/ml	to	6.6	±	1.6	pg/ml	(p<0.01).	There	was	also	an	improvement	
in	transferrin	saturations	from	baseline	of	15±3%	to	20±5%	(p<0.003)	and	
statistically	non-significant	reduction	in	ferritin	levels	compared	to	baseline.	
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This	small	study	again	supported	the	hypothesis	of	inflammation	driven	
inhibition	of	erythropoiesis	[112].	
	
Subsequently	in	the	first	double-blind	placebo	controlled	randomised	controlled	
trial	(RCT)	by	Gonzalez-Espinoza	et	al.	(2012)	showed	that	in	18	haemodialysis	
patients	with	matched	controls,	administration	of	Pentoxifylline	400	mg	per	day	
is	associated	with	significant	reduction	(p<0.05)	in	concentration	of	TNF-α,	IL-6	
and	C	reactive	protein	(CRP)	after	4	months	of	treatment.	Haemoglobin	or	ESA	
dose	changes	were	not	an	endpoint	for	this	study.	No	significant	adverse	events	
were	noted	during	the	study	[114].		
	
The	exact	mechanism	of	action	of	Pentoxifylline	in	inflammation	cascade	is	still	
not	known.	Phosphodiesterase	inhibition	leads	to	intracellular	accumulation	of	
cyclic	adenosine-3,5-monophosphate	(cAMP)	resulting	in	activation	of	Protein	
kinase	A	(PKA).		Activated	PKA	then	leads	to	phosphorylation	of	the	
transcription	factor	cAMP-response	element	binding	protein	(CREB)	and	
transmission	of	signals	to	the	nucleus,	and	the	subsequent	modulation	of	gene	
transcription,	contributing	to	down	regulation	of	TNF-α	production.	Role	of	
phosphodiesterase	inhibitors	in	downregulating	NF-kB	transcriptional	activity	
has	also	been	explored[115,	116].			
	
Effect	of	Pentoxifylline	on	ESA	hypo-responsiveness	could	also	be	explained	
with	the	hypothesis	that	it	could	be	exerting	an	inhibitory	effect	on	hepcidin	
levels	by	the	reduction	in	inflammation.	The	current	clinical	evidence	is	
equivocal	but	there	is	a	need	for	more	focused	studies	to	understand	this	aspect	
of	Pentoxifylline	[69,	117].	The	available	data	suggest	that	Pentoxifylline	in	
haemodialysis	patients	could	be	associated	with	the	reduction	in	inflammation	
by	reduction	of	pro-inflammatory	and	inflammatory	cytokines	leading	to	
reduced	ESA	requirements.		
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8. Hypothesis	
	
Anaemia	is	a	common	complication	of	Chronic	Kidney	Disease	(CKD).	Usually,	the	
cause	of	anaemia	in	CKD	is	the	reduced	production	of	erythropoietin	after	other	
reasons	such	as	iron	deficiency,	vitamins	B12	and	folate	deficiency,	inadequate	
dialysis,	 severe	 hyper-parathyroidism,	 myelosuppressive	 medications,	 active	
infection	and	haematological	conditions	are	ruled	out.	Anaemia	of	CKD	is	treated	
with	 administration	 of	 erythropoietin	 stimulating	 agents	 (ESA).	 ESAs	 have	
revolutionised	the	treatment	of	renal	anaemia	since	the	late	1980’s.	Use	of	ESA	is	
associated	with	better	quality	of	life	and	a	reduced	need	for	blood	transfusions.		
	
Suboptimal	hematologic	response	to	treatment	with	ESA	[51]	remains	a	
problem	in	considerable	proportion	of	end	stage	renal	disease	(ESRD)	patients	
on	haemodialysis.	Hyporesponsiveness	to	ESA	has	been	attributed	to	chronic	
inflammation	in	CKD	and	ESRD	patients.		High	ESA	requirement	and	chronic	
inflammation	are	associated	with	increased	cardiovascular	morbidity	and	
mortality	in	patients	with	ESRD.		
	
Pentoxifylline	administration	has	been	shown	to	reduce	inflammation	in	ESRD	
patients	by	down	regulating	the	production	of	cytokines.	Pentoxifylline	could	
potentially	reduce	the	burden	of	chronic	inflammation	in	haemodialysis	
patients	possibly	resulting	in	reduced	ESA	requirement	and	improved	
cardiovascular	outcomes	in	haemodialysis	patients.		
	
With	 this	 hypothesis,	 a	 single	 centre	 randomised	 placebo-controlled,	 double-
blinded	study	was	planned	to	assess	the	effect	of	Pentoxifylline	on	ESA	dose,	on	
surrogate	 markers	 of	 cardiovascular	 outcomes,	 safety	 and	 cytokine	 profile	 in	
clinically	 stable	 haemodialysis	 patients	 with	 high	 ESA	 requirement.	 Patients	
included	in	the	study	were	clinically	stable	adult	haemodialysis	patients	who	had	
been	requiring	equivalent	ESA	dose	greater	than	or	equal	to	6000	international	
units	(I.U)	equivalent	of	ESA	per	week	or	if	ESA	resistance	index	is	greater	than	
or	equal	to	6.5	I.U/kilograms(Kg)	/Hb	(gram/decilitre)	per	week.	Haemoglobin	
(Hb)	for	equivalent	ESA	dose	was	between	9	to	12	gm	/	dl	and	patients	were	iron	
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replete	 before	 entering	 the	 study.	 Patients	were	 randomised	 to	 receive	 either	
Pentoxifylline	400mg	once	a	day	or	a	matched	placebo	for	six	months	in	1:1	ratio.			
	
Randomisation	was	stratified	for	diabetes	mellitus	status	and	ESA	requirement.		
The	primary	study	end	point	was	ESA	requirement	relative	to	haemoglobin	
level	at	6	months.	Secondary	end	points	were	safety	analysis,	Hb	values,	ESA	
doses	and	Cardiovascular	imaging	to	assess	the	effect	of	pentoxifylline	on	
changes	in	cardiovascular	biomarkers	after	six	months	of	intervention.	Besides,	
cytokine	profile	was	also	analysed	during	the	course	of	the	study.		
	
	
	 47	
	
9. Methods	&	Materials	
	
10.1	Aim		
Aim	of	the	study	was	to	evaluate	the	impact	of	anti-inflammatory	effects	of	
Pentoxifylline	on	ESA	responsiveness	on	ESA	resistant	haemodialysis	patients.		
The	trial	was	a	double	-blind	placebo-controlled	randomised	study	based	at	a	
single	site.	Patients	were	divided	into	four	groups	according	to	ESA	
requirements	and	diabetes	status.		In	each	group	patients	were	randomly	
assigned	to	placebo	or	pentoxifylline	in	1:1	ratio	in	blocks	of	10	patients	for	
each	group.	The	patients	who	were	randomised	to	experimental	group	received	
encapsulated	Pentoxifylline	sustained	release	400	mg	OD	(Trental,	
manufactured	by	Sonafi	Aventis	imported	from	Portugal)	while	the	patients	
randomised	to	placebo	group	received	identical	matching	capsule	for	6	months.	
Patients	were	supplied	investigational	medicinal	product	(IMP)	every	month.		
	
Blood	samples	were	taken	during	the	study	at	the	following	time	points	
1)	Weekly	during	run	in	period	of	2	week	for	baseline	value		
2)	Once	monthly	during	the	intervention	period	for	6	months		
3)	Fortnightly	during	wash	out	period	of	1	month.		
Total	11	visits	were	scheduled	for	the	duration	of	study	per	patient.	
FDG	PET	CT	and	Cardiac	MRI	scans	were	performed	at	baseline	and	6	months.	
	
Trial	was	conducted	in	accordance	with	the	Research	Governance	Framework	for	
Health	 &	 Social	 Care	 (2005),	 the	 World	 Medical	 Association	 Declaration	 of	
Helsinki	(1996),	Principles	of	ICH-GCP,	and	the	current	regulatory	requirements,	
as	detailed	in	the	Medicines	for	Human	Use	(Clinical	Trials)	Regulations	2004	(UK	
S.I.	2004/1031)	and	any	subsequent	amendments	of	the	clinical	trial	regulations.	
Prior	 to	 initiation	 of	 the	 study	 ethical	 approval	 was	 obtained	 from	 the	 East	
London	and	City	Research	Ethic	Committee	and	the	study	was	approved	by	the	
Medicines	 Health	 Regulatory	 Authority	 (REC	 number:	 12/LO/1635,	 EudraCT	
Number:	2011/006168/30).	Trial	was	sponsored	by	Joint	Research	Management	
Office	(JRMO)	at	Barts	Health	NHS	Trust.		
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Another	study	was	conducted	in	association	of	the	PEAR	study,	named	as	PEAR	
study-	experimental	outcomes.	As	a	part	of	this	study,	blood	samples	collected	
and	stored	for	 future	research	 in	PEAR	study	were	 later	analysed	for	cytokine	
profile	 included	 Transforming	 growth	 factor	 (TGF)	 gamma,	 Tumour	 necrosis	
factor	 (TNF)	alfa,	 Interferon	 (IFN)	gamma,	 Interleukin	 (IL)	6,	 and	 IL-4.	Ethical	
approval	was	obtained	from	the	East	London	and	City	Research	Ethic	Committee.		
	
10.2	Inclusion	and	Exclusion	criteria	
	
Inclusion	Criteria	
	
Eligibility	for	study	participation	was	based	upon	data	obtained	from	the	most	
recent	clinical	visit(s).	In	addition,	recent	medical	history	was	obtained	prior	to	
enrolment.	 The	 eligibility	 criteria	 for	 patient	 enrolment	 in	 the	 study	 was	 as	
follows:	
• The	 subject	 should	 be	 able	 to	 read	 and	 understand	 the	written	 consent	 form	
(with	the	help	of	a	translator	if	necessary),	complete	study-related	procedures,	
and	communicate	with	the	study	staff.	
• Willing	to	comply	with	study	restrictions.	
• Between	18	and	85	years	of	age	(inclusive).	
• Diagnosis	of	clinically	stable	ESRD,	as	determined	by	the	investigator.	
• Requiring	 regular	 dialysis	 therapy	 for	 at	 least	 12	 weeks	 prior	 to	 first	
administration	of	study	agent.	
• Last	haemoglobin	concentration	at	 time	of	consent	between	9.0	and	12.0	g/dL	
before	entering	the	study.	
• Receiving	 treatment	 with	 intravenous	 (I.V.)	 or	 sub-cutaneous	 (S.C.)	
erythropoietin	stimulating	agent	(ESA)	at	least	weekly	(i.e.	exclude	Mircera™	or	
other	 ESAs	 given	 fortnightly	 or	monthly)	 for	 a	minimum	 of	 8	weeks	 prior	 to	
administration	 of	 study	 agent,	 requiring	 doses	 to	 remedy	 ESA-resistance	
(requiring	greater	than	or	equal	to	6000	International	Units	(I.U)	equivalent	of	
ESA	 per	 week	 or	 if	 ESA	 resistance	 index	 is	 greater	 than	 or	 equal	 to	 6.5	 I.U	
/kg/wk/g	 Hb	 for	 equivalent	 EPO	 dose),	 with	 evidence	 of	 stable	 Hb	
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concentrations.		
• Serum	folate	and	vitamin	B12	levels	concentrations	which	are	checked	annually	
as	part	of	clinical	practice,	were	normal	and	transferrin	saturations	greater	or	
equal	to	25%	and	/	or	ferritin	>	200	µg/L	(last	result	prior	to	consent),	as	per	
departmental	protocol	at	The	Royal	London	Hospital.		
	
Exclusion	Criteria		
	
Ineligibility	for	study	participation	was	based	upon	data	obtained	from	the	most	
recent	clinical	visit(s).	In	addition,	recent	medical	history	was	obtained	prior	to	
enrolment.	If	a	subject	displayed	any	of	the	following	criteria,	he	or	she	was	not	
enrolled	in	the	study:	
• Clinically	 relevant	 abnormal	 history	 of	 physical	 and	mental	 health	 other	 than	
conditions	related	to	CKD	of	the	patient,	as	determined	by	medical	history	taking	
(as	judged	by	the	investigator).	
• Clinically	 relevant	 abnormal	 laboratory	 results,	 electrocardiogram	 (ECG),	 vital	
signs,	 or	 physical	 findings	other	 than	 conditions	 related	 to	 CKD	of	 patient	 (as	
judged	by	the	investigator).	
• Subject	had	uncontrolled	hypertension	(in	the	opinion	of	the	clinician);	subject	
was	unable	to	refrain	from	the	use	of	disallowed	concomitant	medication	(such	
as	immunosuppression	/	anti-inflammatory	drugs)	from	one	week	prior	to	the	
first	study	drug	administration	until	follow	up	assessments.	
• Participation	 in	 an	 investigational	 drug	 trial	 in	 the	 3	 months	 prior	 to	
administration	of	the	initial	dose	of	study	drug.	
• Subject	 had	 undergone	major	 surgery	within	3	months	 prior	 to	 screening	 for	
eligibility	for	study	participation.	
• Females	of	child-bearing	potential	who	were	not	willing	to	use	contraception	for	
the	duration	of	the	study.	
• Females	who	were	breast	feeding.	
• Subject	known	to	be	hypersensitive	to	the	active	constituent,	Pentoxifylline,	other	
methyl	xanthines	or	any	of	the	additives.	
• Subjects	 with	 recent	 (3	 months)	 cerebral	 haemorrhage,	 extensive	 retinal	
haemorrhage,	acute	myocardial	infarction	and	severe	cardiac	arrhythmias.	
• Contraindications	 to	 magnetic	 resonance	 imaging	 (e.g.	 severe	 claustrophobia,	
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pacemaker,	defibrillators).	
• Subjects	 who	 were	 on	 (or	 are	 due	 to	 start)	 immunosuppressive	 and	 anti-
inflammatory	drugs	except	asprin	at	a	dose	of	≤	300	mg/d.	
• Any	other	condition	that	in	the	opinion	of	the	investigator	would	complicate	or	
compromise	the	study	(e.g.	known	haemoglobinopathy),	or	the	wellbeing	of	the	
subject.	
	
Premature	withdrawal	from	the	study	
	
Systematic	 non-compliance	 to	 medications	 was	 the	 primary	 criterion	 for	
premature	withdrawal	 from	the	study.	End-point	 tests	were	performed	(blood	
and	radiology)	if	the	patient	agreed	prior	to	formal	withdrawal	from	the	study.	
The	 1	 month	 safety	 follow-up	 period	 (blood	 tests)	 investigations	 were	 also	
performed	if	the	patient	agreed.	
	
10.3	Intervention	and	study	design	
	
Placebo	or	pentoxifylline	400	mg	taken	once	a	day	for	6	months.	
	
Concomitant	Therapy:	
During	 the	study,	 the	patients	 continued	all	 their	 regular	 therapy.	 	 Initiating	a	
drug	with	 known	 anti-inflammatory	 properties	was	 avoided.	 If	 this	had	 to	 be	
done	because	of	the	clinical	condition	of	the	patient,	study	drug	administration	
was	to	be	discontinued,	and	replacement	of	the	patient	was	to	be	considered.		
	
Concomitant	medications	were	 expected	 to	 include	 iron	 therapy	 on	 a	 regular	
basis	to	maintain	T	Sats	>25%	and/or	ferritin	>200	microgram	(µg)/L,	phosphate	
binders,	 statins,	 medication	 to	 treat	 hyperparathyroidism,	 anti-hypertensive	
agents	and	other	drugs	to	treat	known	complications	of	renal	failure.	In	general,	
concomitant	medication	resulting	in	non-eligibility	included	all	medication	that	
in	the	opinion	of	the	investigator	would	complicate	or	compromise	the	study	or	
interfere	with	the	study	objectives.	
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Study	design:	
This	 study	was	a	single-centre,	 randomised	double	blinded	placebo-controlled	
trial	of	100	patients	with	ESRD	on	dialysis.	Patients	received	either	Pentoxifylline	
sustained	release	tablet	400	mg	once	a	day	or	placebo	for	6	months	with	a	further	
1month	 follow-up	 after	 therapy	 is	 stopped.	 Randomisation	 was	 stratified	 for	
diabetes	mellitus	status	and	ESA	requirement	(adjusted	for	Hb).	
	
Randomisation	process	
	
1:1	 randomisation	 was	 stratified	 for	 diabetes	 status	 and	 ESA	 requirement.	
Patients	were	classified	into	four	groups	based	on	ESA	requirement	and	presence	
of	 diabetes.	 Patients	 were	 allocated	 into	 high	 ESA	 group	 if	 equivalent	 ESA	
requirement	was	>14,000	units	/	week.	Patients	were	allocated	to	study	drug	
according	 to	 recruitment	 sequence	 in	 each	 group.	 The	 drugs	 sequence	 had	
already	been	randomized	by	the	investigational	medicinal	product	IMP	supplier.	
Patients	 in	 each	 group	 were	 randomised	 in	 blocks	 of	 10	 each.	 	 Patients	 and	
investigators	were	blinded	to	treatment	allocation.	Sealed	unblinding	envelopes	
were	supplied	with	IMP.		
	
Monitoring	during	the	study	
	
							Subjects	were	entered	in	a	“run-in”	period	for	2	weeks	where	blood	tests	were	
measured	weekly	to	establish	a	baseline.	All	blood	tests	were	taken	prior	 to	a	
dialysis	session	and	preferably	after	an	inter-dialytic	gap	of	48	hrs.	If	the	ESA	dose	
changed	in	the	run-in	period,	the	patients	were	withdrawn.		
							Following	the	run-in	period,	subjects	were	treated	with	either	IMP	or	placebo	
for	6	months	and	they	were	reviewed	monthly	along	with	blood	tests	in	addition	
to	their	routine	monthly	blood	profile	as	per	the	local	policy.	IMP	or	placebo	were	
provided	to	the	patients	during	the	monthly	visits.	Subjects	were	asked	to	return	
unused	medication	for	compliance	check.	
								
After	6	months	treatment	(IMP	or	placebo)	was	stopped.	Subjects	were	asked	to	
return	 any	 remaining	 unused	medication.	 Patients	were	 reviewed	 fortnightly.	
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This	“Off-Treatment	Follow-up	Period”	lasted	for	one	month.	Changes	in	the	ESA	
doses	were	done	according	to	departmental	guidelines.	
Any	 adverse	 events	 were	 recorded	 and	 acted	 upon	 in	 accordance	 with	
pharmacovigilance	guidelines	of	relevant	supervising	authorities.	
10.4	Study	Endpoints		
	
Primary	 study	 endpoint	 was	 the	 ESA	 requirement	 relative	 to	 the	 Hb	
concentration.	
Secondary	endpoints	included:	
• Safety	analysis.	
• Hb	values	and	ESA	doses	after	6	months	of	treatment.	
• Cardiovascular	imaging	performed	at	baseline	and	at	6	months.	The	effect	IMP	
had	on	the	following	cardiovascular	parameters	were	examined:	
a) Mean	target-to-background	ratio	across	a	substantial	portion	of	artery	(typically	
aorta,	 supra	aortic	vessels	 and	 femoral	 arteries)	using	18	Fluorodeoxyglucose	
(FDG)	positron	emission	tomography	18-FDG-PET	(time-of-flight).	This	allowed	
us	to	assess	whether	IMP	has	an	anti-inflammatory	effect	on	the	blood	vessels.	
b) Vascular	stiffness	measures	using	magnetic	resonance	imaging	
c) Measures	 of	 systolic	 and	 diastolic	 function,	 using	 cardiac	magnetic	 resonance	
(CMR)	tagging	techniques	(strain	(%)	and	strain-rate	(s-1).	
	
Mechanistic	end	points:		
	
		Analysis	of	cytokine	trends	(IL-6,	TNF	alfa,	TGF	beta,		IFN	gamma)	during		the	
course	of	study.	
10.5	Statistical	considerations	
	
Power	of	the	study	calculation:	
From	internal	audit	data	on	ESA	usage,	we	assumed	the	average	equivalent	dose	
of	 ESA	will	 be	 12000	 I.U./week	 (with	 standard	 deviation=500).	 If	 the	 placebo	
group	 have	 Hb=10g/dl,	 the	 ESA/Hb	 ratio	 =	 1200.	 The	 study	 by	 Cooper	 et	 al.		
showed	that	4	months	treatment	increased	Hb	levels	by	25%	[8].	We	aimed	to	
power	this	study	to	demonstrate	that	IMP	will	increase	ESA	response	by	5%.			
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If	we	assumed	the	SD	for	ESA/Hb	=	100,	this	would	mean	that	for	an	alpha	level	
of	5%	(95%	confidence	interval)	and	a	beta	level	of	5%	(statistical	power	of	95%)	
we	needed	30	patients	in	each	group.	We	assume	that	there	will	be	a	50%	“drop	
out”	 (transplantation	 and	 patient	 withdrawal)	 so	 we	 planned	 to	 recruit	 100	
patients	
	
Statistical	analysis	plan	
	
Primary	End-Point		
	
The	primary	study	endpoints	was	ESA	requirement	relative	to		Hb	level.		
Statistical	analysis	was	done	by	unpaired	student	t-test	comparing	values	ESA	
dose	per	week	(mcg)	/	Hb	(in	g/dl),	Control	vs	IMP.		P	values	of	<	0.05	will	be	
considered	statistically	significant		
Conversion	factor	ESA	IU	=	Aranesp	dose	in	mcg	x200		
	
This	was	calculated	for	both:	
	
1) Intention	to	Treat	(ITT)	Analysis	
2) Per	Protocol	Analysis	
	
For	Intention	to	Treat,	we	will	use	last	2	available	data	points	for	patient	that	
withdrew	early	from	the	study.	For	Per	Protocol	Analysis,	we	will	use	last	2	
available	data	points	when	patient	took	their	assigned	treatment.	If	patients	did	
not	have	more	than	1	visit	after	randomisation,	they	will	not	be	included	in	
analysis.		
	
Secondary	end	points	
	
1. Safety	analysis:	
	
Overall	adverse	events	(AE)	and	serious	adverse	events	(SAE)	rates	were	
calculated	based	on	the	number	of	each	event	/	duration	subject	was	in	the	
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study	after	randomisation.	AE	and	SAE	were	categorised	into	categories	as	per	
case	report	form	(CRF).		The	rates	of	AE/SAE	for	each	category	were	calculated.		
Control	vs	Investigational	medicinal	product	(IMP)	rates	were	compared	using	
Poisson	regression,	with	no	adjustment	for	multiple	events	per	subject.	
Statistical	significance	if	P-value	<0.05	after	Bonferroni	correction	was	applied.		
	
2)	PET-CT		
	
The	following	parameters	were	compared:		
a)	Standardised	uptake	value	(SUV)	max	at	end	of	study		
b)	Target	to	background	ratio	(TBR)	at	end	of	study		
c)	Δ	SUVmax	(percentage	difference	in	SUVmax)	
d)	Δ	TBR	(percentage	difference	in	TBR)	
	
These	parameters	were	compared	on	the	ITT	dataset	using	Student	t-test.		
P	values	of	<	0.05	was	considered	statistically	significant		
	
3)	CMR		
	
The	following	parameters	were	compared:		
a)	Aortic	compliance	(area/systolic	BP),		
b)	Left	ventricular	(LV)	end	diastolic	volume		
c)	LV	end	systolic	volume		
d)	LV	systolic	volume		
e)	LV	ejection	fraction		
f)		LV	mass		
	
These	parameters	were	compared	on	the	ITT	dataset	using	Student	t-test.	P	
values	of	<	0.05	was	considered	statistically	significant.	
	
Mechanistic		end	points:	
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Cytokine	levels	were	compared	at	baseline	and	follow	up	phase.	Cytokine	
variability	along	the	entire	duration	of	study	was	also	analysed	as	per	protcol.		
	
Baseline	Demographics	and	Biochemical	parameters		
	
Continuous	variables	were	tested	for	normality	using	D'Agostino-Pearson	
normality	test.	Mean	(standard	deviation)	or	median	(interquartile	ranges)	
were	displayed.	Statistical	analysis	was	done	by	student	t-test	(unpaired)	or	
Mann-Whitney	U	test.	Categorical	data	was	analysed	by	Chi	Square.	Statistical	
significance	if	P-value	<0.05	after	Bonferroni	correction	was	applied		
	
Demographic	information:		
a)	Age	at	randomisation		
b)	Ethnicity:	Categorical-	White,	Black,	Indian	sub-continent	(Asians),	Others.		
c)	Gender:	Categorical-	Male	vs	Female		
d)	Residual	renal	function	at	randomisation:	categorical-	anuric	vs	uric		
					(threshold=200mL/d)		
e)	Dialysis	vintage:	continuous		
f)		Diabetic	Mellitus:	Categorical-	Y/N		
g)	Access	Type:	Categorical-	AVF	/	Tunnelled	haemodialysis	line	(THL)	
h)	Cause	of	ESRF:	Categorical-	Unknown,	Chronic	glomerulonephritis	(GN),	
					Tubulo	interstital	nephritis	(TIN)	/chronic	pyelonephritis,	cancer/trauma,		
					congenital/familial,	polycystic	kidney	disease,	hypertension,	diabetes	
					mellitus	and	others		
	
Treatment	parameters:	
a)	ESA	(weekly	dose)	(mean	of	the	2	run-in	values)	
b)	Last	dialysis	checked	dialysis	adequacy	(kt/v)	:	continuous		
c)	Prescribed	hours	of	dialysis	
d)	Prescribed	angiotensin	converting	enzyme	inhibitor	(ACEi)	or	angiotensin	
receptor	blocker	(ARB):	categorical	–	Y/N		
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Biochemical	parameters	(last	available	result	prior	to	randomisation	unless	
specified):	
a)	Haemoglobin	(mean	of	the	2	run-in	period	values)		
b)	Hematocrit		
c)	Transferrin	saturation	
d)	Serum	Ferritin		
e)	Vitamin	B12	level	
f)	Folate	level	
g)	C-	reactive	protein		
h)	Parathyroid	hormone			
i)	Corrected	calcium		
j)	Phosphate		
k)	Total	alkaline	phosphatise		
l)		Pre-dialysis	urea		
m)	Pre-dialysis	creatinine		
n)	Pre-dialysis	potassium	
o)	Albumin		
p)	kt/v	
q)	Urea	reduction	ratio	(URR)	
	
Associated	primary	outcome	measures:	
Haemoglobin,	ESA	dose	and	ERI	(ratio	for	weekly	ESA	dose	corrected	for	weight	
divided	by	Hb)	were	also	analysed	as	associated	primary	outcome	measures.		
	
10.5	Cardiac	magnetic	resonance	imaging	scan	protocol	
	
All	cardiac	magnetic	resonance	(CMR)	scans	were	undertaken	on	a	Philips	
Achieva	1.5	T	scanner	(Best,	Netherlands).	All	scans	were	ECG	gated	and	
performed	with	a	dedicated	32-channel	cardiac	coil	(Philips)	using	standardised	
protocols.	
	
From	coronal,	sagittal	and	axial	scout	images,	the	short	axis	plane	of	the	LV	was	
identified	and	steady	state	free	precision	(SSFP)	movie	images	were	acquired	
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covering	the	entire	LV	from	base	to	apex.	There	were	at	least	24	phases	
acquired	per	cardiac	cycle.		
	
Slice	thickness	was	6	millimeter	(mm),	with	a	4mm	gap	between	slices.	Parallel	
imaging	technology	was	utilised	to	ensure	a	reasonable	breath-hold	time	
(around	10-15s	per	slice).	10-12	slices	were	required	to	cover	the	LV.	An	axial	
plane	was	acquired	at	the	level	of	the	pulmonary	artery	bifurcation.	High	
definition	phase	contrast	imaging	(50	phases	per	cardiac	cycle)	was	performed	
over	the	ascending	aorta	and	the	descending	thoracic	aorta	at	this	level.		A	
further	true	axial	plane	was	acquired	in	the	mid	abdominal	aorta	and	phase	
contrast	images	were	also	acquired	at	this	level.	
	
CMR	analysis	
	
All	data	was	anonymised	and	analysed	by	a	single,	experienced	operator	who	
was	blinded	to	the	patient	information	using	CVi42	analysis	software	(Circle,	
Calgary).	The	end	diastolic	and	end	systolic	frames	of	the	short	axis	movie	stack	
were	identified.	Manual	contours	were	drawn	around	the	epicardial	surface	of	
all	the	end	diastolic	frames	and	the	endocardial	surface	of	all	end	diastolic	and	
end	systolic	frames.	The	basal	slice	was	defined	as	the	slice	with	at	least	50%	
circumferential	myocardial	coverage.		
	
Papillary	muscles	were	included	in	the	blood	pool	and	excluded	from	the	
myocardium.	From	these	areas,	the	analysis	software	automatically	calculated	
Left	ventricular	end	diastolic	volume	(LVEDV),	Left	ventricular	end	systolic	
volume	(LVESV),	Left	ventricular	systolic	volume	(LVSV),	Left	ventricular	
ejection	fraction	(LVEF)	and	Left	ventricular	(LV)	mass.	
	
Contours	were	drawn	around	the	aortic	region	of	the	phase	contrast	images	at	
ascending	thoracic	aorta,	descending	thoracic	aorta	and	abdominal	aorta	levels	
(Figure	10.1).	The	time	delay	between	end-diastole	(the	beginning	of	the	QRS	
complex	on	the	ECG)	and	the	peak	aortic	flow	at	all	3	levels	were	calculated	
automatically.	End	diastolic	and	end	systolic	aortic	areas	at	each	level	were	also	
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derived,	to	give	a	measure	of	aortic	compliance.	Aortic	compliance	was	
calculated	as	fractional	change	in	aortic	size	at	an	area	divided	by	pulse	
pressure	multiplied	to	minimum	aortic	size.	Aortic	compliance	value	at	
ascending	aorta	was	used	in	analysis.		
	
The	perpendicular	distance	between	the	thoracic	descending	aorta	and	the	
abdominal	aorta	was	measured	using	coronal	scout	images.	The	time	difference	
between	the	2	respective	flow	peaks	divided	by	the	distance	equaled	blood	flow	
velocity	in	second/centimetres	.	20	randomly	assigned	scans	were	re	analysed	
by	the	same	operator	to	determine	the	intra-observer	reproducibility.	
	
Figure	10.1.	Aortic	pulse	velocity	measurement	levels	
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10.6	FDG	PET	CT	scan	protocol	
	
All	PET	acquisitions	were	accompanied	by	a	low-dose	CT	procedure	to	allow	for	
attenuation	correction	and	co-localisation	of	PET	data.	The	parameters	of	these	
CT	acquisitions	had	estimated	effective	dose	of	no	more	than	5	millisievert	
(mSv)	each.		
	
As	plasma	clearance	in	these	patients	is	delayed,	dynamic	imaging	from	0	to	60	
minutes	over	the	area	starting	from	the	Arch	of	the	Aorta	(upper	limit:	arch	of	
the	aorta	and	lower	limit:	the	axial	extent	of	PET	Field-of-View)	was	performed	
followed	by	whole	body	imaging	at	90	minutes	during	initial	study	period.	
	
Patients	undergoing	FDG-PET	CT	scan	had	blood	glucose	measurement	carried	
out	prior	to	administration	of	18FDG.	All	patients	were	fasted	for	6	hours	before	
imaging.	Patients	with	blood	sugars	>10	mmol	prior	to	imaging	were	excluded	
from	PET	CT	imaging.		The	administered	activity	of	18F-FDG	was	<	200	
megabecquerel	(MBq)	due	to	renal	failure	in	these	patients.	200MBq	was	not	be	
exceeded.	Helical	CT	acquisition	for	the	low-dose	CT	was	from	the	base	of	the	
skull	to	the	knee	joints.	
	
Whole	Body	PET	data:	Multiple	bed	positions	were	acquired	from	the	knee	
joints	to	the	base	of	the	skull.	The	time	per	bed	position	was	2	minutes	and	the	
PET	data	acquisition	did	not	exceed	a	total	of	30	minutes.		Dynamic	scan	started	
at	injection	time	(20	seconds	delay);	followed	by	whole	body	scan	at	90	minutes	
from	injection	time.	No	more	than	1	x	60	minutes	and	1	x	35	minutes	(max.	30	
min	PET	emission).	Blood	sampling:	3	samples	(3mls	each)	at	minutes	1,	2	and	3	
form	the	injection	of	activity;	then	3	samples	(3mls	each)	at	minutes	5,	7	and	9	
followed	by	5	samples	at	19,	29,	39,	49	and	59	minutes)	(total	11	samples	=33	
mls	blood	sample	per	scan).	Dynamic	imaging	protocol	was	stopped	after	first	
10	dynamic	PET	CT	tests.	Subsequently	scan	data	was	acquired	at	90	minutes	
following	18F-FDG	administration.		
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Image	analysis	
	
Image	analysis	were	performed	on	a	dedicated	workstation.	Using	the	CT	
images,	the	vasculature	was	divided	into	carotid	arteries,	the	aorta,	iliac	and	
femoral	arteries.	The	common	and	external	iliac	arteries	were	combined	and	
treated	together	as	‘‘iliac	artery’’;	similarly,	the	common	femoral	and	superficial	
femoral	arteries	were	amalgamated	into	the	single	label	of	‘‘femoral	artery.’’	The	
transition	point	between	iliac	and	femoral	arteries	was	inguinal	ligament.	
Arterial	18F-FDG	uptake	(as	a	measure	of	arterial	inflammation)	was	measured	
by	drawing	a	region	of	interest	(ROI)	around	the	artery	on	every	slice	of	the	co	
registered	trans	axial	PET/CT	images.	On	each	image	slice,	the	mean	and	
maximum	standardized	uptake	values	(SUVs)	of	18F-FDG	in	the	ROI	(containing	
the	arterial	wall	and	the	lumen)	was	calculated	as	the	mean	and	maximum	pixel	
activity.	The	SUV	is	the	decay-corrected	tissue	concentration	of	18F-FDG	(in	
kBq/g),	adjusted	for	injected	18F-FDG	dose	and	body	weight	(in	kBq/g),	and	is	a	
well-recognized	method	for	quantification	of	18F-FDG	PET	data.	
	
By	averaging	SUVs	for	all	artery	slices	within	an	arterial	territory,	mean	and	
maximum	SUVs	can	be	derived	for	each	region.	These	SUVs	are	normalized	to	
blood	18F-FDG	activity	by	division	by	an	average	blood	ROI	(at	least	8	venous	
ROI	measurements),	estimated	from	either	the	inferior	vena	cava	(leg	studies)	
or	the	superior	vena	cava.	This	calculation	results	in	an	arterial	TBR	measure,	
which	was	reported	subsequently.	Figure	10.2	demonstrates	an	example	of	
calculation	of	TBR	along	the	ascending	aorta	section	[95].	Similarly,	this	
calculation	was	done	along	all	artery	sections	described	above.	
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Figure	10.2:	Calculation	of	Target	to	Background	ratio	(TBR)	[95]	
	
	
	
	
	
	
Figure	10.2		
	
Example	for	calculation	of	the	target	to	background	ratio	(TBR)	along	section	of	
ascending	aorta.	Axial	sections	were	taken	at	approximately	5	mm	thickness.	
Subsequently	region	of	interest	(ROI)	was	drawn	around	the	wall	of	the	artery.	
Maximum	standardised	uptake	value	for	FDG	uptake	was	recorded	as	SUVmax	
for	each	axial	section	(depicted	on	rings	next	to	arrows).	Venous	blood	SUVmax	
was	obtained	from	superior	vena	cava	(SVC)	over	10	sections	(ROIs)	and	
averaged	to	get	blood	compartment	contribution.	TBR	was	obtained	by	dividing	
mean	SUV	max	from	axial	slices	with	SUVmax	obtained	from	SVC.	(Ao	=	aorta;	
LM	=	left	main	artery;	SVC	=	superior	vena	cava)	
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10.7	Specimen	Analysis		
	
Haematology		
Haematological	indices	were	measured	routinely	in	the	Haematology	
laboratories	of	the	Royal	London	Hospital	on	a	Sysmex	XE-2100	Haematology	
Analyser	(Syzmex	Uk	Ltd,	Milton	Keynes,	UK).		
	
Biochemistry		
All	biochemistry	analysis	was	performed	in	the	Biochemistry	Laboratories	of	
the	Royal	London	Hospital	on	a	Roche	Modular	E019	P-Unit	Analyser	or	a	Roche	
Modular	E170	Analytics	EVO	Analyser	(Roche	Diagnostics	Ltd,	Burgess	Hill,	UK).	
Serum	and	urine	creatinine	was	measured	by	a	kinetic	colorimetric	assay	
modified	from	the	Jaffe	reaction	described	in	1886	and	standardised	in	1945.	
Urine	protein	was	measured	using	a	turbidometric	assay.	
	
Mechanistic	end	points:	Cytokine	analysis	
	
EMD	Millipore’s	MILLIPLEX®	MAP	Human	Cytokine	/	Chemokine	Panel	which	
is	based	upon	Luminex	xMAP	technology	was	used	for	the	simultaneous	
quantification	of	cytokines	using	pre-mixed	Magnetic	Beads	for	selected	
cytokines.	The	xMAP	technology	analyses	reactions	over	3	dimensional	
structures	of	magnetic	microspheres	when	passed	through	a	flow	analyser	
armed	with	two	lasers.	Subsequently	high	speed	digital	processing	and	
computer	software	convert	florescent	information	from	magnetic	beads	into	
numerical	results.	
	
Reagents	supplied	with	cytokine	analysis	kit	were	Human	cytokine	/	chemokine	
standard,	Human	cytokine	quality	controls	1	and	2,	Serum	Matrix	(0.08%	
Sodium	Azide),	Wash	Buffer	(0.05%	Procyclin),	Human	cytokine	detection	
antibodies,	Streptavidin-Phycoerythrin	and	Premixed	human	cytokine	/	
chemokine	antibody	immobilised	magnetic	beads.		
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Frozen	serum	sample	was	mixed	by	vortexing	and	centrifuge	after	thawing	
completely	to	room	temperature.	96	well	plate	was	used	for	assay.	Standards,	
controls	and	samples	were	placed	in	a	vertical	configuration.	Plates	were	run	on	
Luminex®	200™	analyser	with	xPONENT®	software.	Median	Fluorescent	
Intensity	(MFI)	data	using	a	5-parameter	logistic	or	spline	curve-fitting	method	
for	calculating	cytokine	concentrations	in	samples	was	obtained.		Two	assays	
were	done	for	each	sample	which	were	subsequently	compared	for	quality	
control.	Detailed	analysis	protocol	is	demonstrated	in	figure	10.3.	
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Figure	10.3:	Cytokine	analysis	protocol																																									
																																																						
																																
	
	
	
	
	
	
	
	
	
	
	 	
	
																								
	
	
	
	
	
	
	
	 	
	
	
	
	
	
								
	
	
	
	
	
	
	
											
	
	
	
	
	
						
	
	
	
	
	
Add	200	µL	wash	buffer	per	
well	
Shake	for	10	min	at	room	
temperature;		Decant	
	
Add	25μL	Standard	or	control	to	
appropriate	wells	
Add	25μL	Assay	Buffer	to	
background	and	sample	wells	
Add	25μL	appropriate	Matrix	
Solution	to	background,	
standards,	and	control	wells	
Add	25μL	Samples	to	sample	
wells	
Add	25μL	Beads	to	each	well	
	
	
	
Incubate	overnight	at		
4	C	or	2	hours	at	room	temperature	with	shaking	
Wash	well	contents	twice		with	200	
µL	of	wash	buffer	after	removing	
well	contents		
	
	 Incubate	for	1	hour	at	room	
temperature		
Add	25	µL	Streptavidin	Phycoerythrin	
per	well	
Incubate	30	minutes	at	room	
temperature		
Wash	well	contents	twice	with	200	
µL	of	wash	buffer	after	removing	
well	contents		
	
	
Add	150	µL	Drive	fluid	per	well.	
Resuspend	the	beads	on	a	plate	
shaker	for	5	minutes	
	
Run	plate	on	Luminex®	200™	analyser	
with	xPONENT®	software	
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10.8	Summary	of	study	design	
	
Figure	10.4	describes	study	design.	Blood	investigations	were	done	at	every	
visit	as	per	the	study	protocol.	Additional	blood	samples	were	taken	during	each	
study	visit	for	future	research.	These	samples	were	stored	at	-80	C	temperature.	
Subsequently	these	stored	samples	were	analysed	for	cytokine	levels	during	the	
course	of	study.		
	
Initially	end	point	for	analysis	of	investigation	results	and	ESA	dose	was	
planned	to	be	the	mean	of	values	at	visit	10	(week	26)	&	11	(week	28)	during	
the	follow	up	phase.	However,	thesis	examiners	suggested	to	reanalyse	end	
point	data	at	visit	9	(week	24)	to	avoid	any	drug	washout	effect	during	the	
follow	up	phase.	Hence	results	given	below	are	after	reanalysis	of	relevant	data	
at	visit	9	(week	24).	
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Figure	10.4.		Summary	of	study	design.	
																									Investigations	and	other	study	parameters	were	recorded	on	every	visit	(V1	to	V11)	
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10.9	Amendments	to	study	inclusion	criteria	
		
Along	with	the	newer	emerging	trends	and	guidance	in	the	field	of	ESA	
hyporesponsiveness	research	in	CKD	population,	we	also	came	across	practical	
challenges	during	early	recruitment	phase.	Hence	inclusion	criteria	defining	
ESA	hyporesponsiveness	was	revised.	This	was	also	done	for	the	study	results	
to	remain	relevant	for	planning	further	research	based	on	the	trends	of	other	
research	studies	published	at	that	time.	Substantial	amendments	made	to	
inclusion	criteria,	after	the	start	of	patient	recruitment	are	summarised	below:	
	
10.9.1	Definition	of	ESA	hyporesponsiveness	and	change	to	inclusion	
criteria	
	
At	present	there	is	no	widely	accepted	guideline	to	define	ESA	
hyporesponsiveness	world-wide.	This	is	reflected	by	variation	among	
international	guidelines.	K/DOQI	guidelines	define	ESA	Hyporesponsiveness	as	
weekly	ESA	requirement	greater	or	equal	to	450	units/kg	or	300	units/kg	for	
intravenous	and	subcutaneous	administration	respectively[118].		
	
European	guidelines	define	ESA	hyporesponsive	state	as	weekly	ESA	
requirement	of	300	units/Kg	for	recombinant	erythropoietin	(EPO)	or	1.5	
mcg/kg	for	Darbepoeitin	treated	patients[119].	
	
On	the	other	hand,	KDIGO	guidelines	do	not	provide	any	absolute	cut	off	dose	to	
define	ESA	hypo	responsiveness.	KDIGO	defines	initial	ESA	hyporesponsiveness	
as	no	increase	in	haemoglobin	concentration	after	first	month	of	appropriate	
weight-based	ESA	dosing.	Acquired	hyporesponsiveness	is	defined	as	
requirement	of	2	increments	in	ESA	dosing	up	to	50%	beyond	the	dose	at	which	
Haemoglobin	had	been	stable	originally[120].	
	
Multiple	clinical	trials	investigating	ESA	hyporesponsiveness	have	considered	
definition	of	ESA	hyporesponsiveness	based	on	the	ESA	dose	trends	in	the	local	
cohort	of	patients.	The	RISCAVID	study	classified	patients	with	erythropoietin	
resistance	index	(ERI)	values	falling	into	fourth	quartile	(>15.4	IU	weekly	dose	
divided	by	weight	and	Hb	value)	as	ESA	hypo	responsive	in	a	cohort	of	757	
dialysis	patients	with	dialysis	vintage	of	more	than	90	days[121].		
	
	
Slow	recruitment	in	a	trial	investigating	ESA	hyporesponsiveness	resulted	in	
change	in	inclusion	criteria	from	an	initial	definition	of	Hb	concentration	less	
than	or	equal	to	110	g/l		for	at	least	3	months	despite	erythropoietin	dose	of	
greater	or	equal	to	200	IU	/	Kg	/	week	or	darbepoetin	dose	greater	or	equal	to	
1mcg/kg/week	for	atleast	1	month	to	Hb	concentration	less	than	or	equal	to	
120	g/l		and	ERI	value	greater	or	equal	to	1	IU	/	Kg	/	week	/g/L		or		
1mcg/kg/wk/	g	/	L	for	darbepoetin	treated	patients[122,	123].		
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We	also	anticipated	that	PEAR	study	recruitment	may	be	slowed	down	with	our	
initial	inclusion	criteria.	Therefore,	in	the	light	of	emerging	trends	for	the	
definition	of	ESA	resistance	in	multiple	trials,	the	inclusion	criteria	for	PEAR	
study	was	also	amended	from	
	
“Receiving	treatment	with	IV	or	SC	erythropoietin	receptor	agonist	at	least	weekly	
(ie	exclude	Micera	or	other	ESAs	given	fortnightly	or	monthly)	for	a	minimum	of	8	
weeks	prior	to	administration	of	study	agent,	requiring	doses	to	remedy	EPO	
resistance	(requiring	greater	than	or	equal	to	12,000	iu	equivalent	of	EPO	per	
week	or	if	ESA	dose	is	greater	than	or	equal	to	150	iu	equivalent	of	EPO/kg	body	
weight/week),	with	evidence	of	stable	haemoglobin	levels”		
to	a	revised	criterion	of		
“Receiving	treatment	with	IV	or	SC	erythropoietin	receptor	agonist	at	least	weekly	
(ie	exclude	Micera	or	other	ESAs	given	fortnightly	or	monthly)	for	a	minimum	of	8	
weeks	prior	to	administration	of	study	agent,	requiring	doses	to	remedy	EPO-
resistance	(requiring	greater	than	or	equal	to	6000	iu	equivalent	of	EPO	per	week	
or	if	ESA	resistance	index	is	greater	than	or	equal	to	6.5	iu	/kg/wk/g	Hb	for	
equivalent	EPO	dose),	with	evidence	of	stable	haemoglobin	levels”		
We	chose	our	new	threshold	because	internal	audit	data	showed	that	our	
proposed	threshold	represents	the	median	ESA	requirement	in	all	the	
haemodialysis	patients	with	arteriovenous	fistula	in	our	unit.	ESA	resistance	
index	(ERI)	is	a	better	indicator	of	ESA	dose	relative	to	haemoglobin	level	as	it	
gives	exact	ESA	load	for	the	individual	patient	to	achieve	per	gram	of	
haemoglobin.	We	therefore	included	ERI	in	the	new	inclusion	criteria	to	define	
ESA	hyporesponsiveness.		
10.9.2	Removal	of	non-highly	sensitive	C	reactive	protein	from	the	
inclusion	criteria	
Unfortunately,	the	central	lab	at	The	Barts	Health	NHS	Trust	did	not	routinely	
measured	non-highly	sensitive	CRP.	There	is	evidence	to	suggest	non-highly	
sensitive	CRP	is	not	a	good	marker	of	inflammation	in	haemodialysis.	New	
literature	had	identified	other	biomarkers	such	as	hepcidin	and	pro	
inflammatory	cytokines	to	correlate	with	ESA	hypo	responsiveness	(but	not	non	
highly	sensitive	CRP)[124,	125].		
Therefore,	using	CRP	>5	as	an	inclusion	criterion	would	have	resulted	in	under	
representation	of	the	ESA	hypo	responsiveness	secondary	to	inflammation	in	
our	cohort	of	haemodialysis	patients).		
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11.	Results		
11.1	Patient	allocation	
	
A	total	of	750	patients	were	screened	for	ESA	hyporesponsiveness.	84	eligible	
patients	consented	to	participate	in	the	study	after	screening	of	haemodialysis	
database	on	regular	intervals.	10	patients	withdrew	consent	voluntarily	prior	to	
start	of	study	protocol.	Further	5	patients	were	found	to	be	not	eligible	for	study	
during	2	weeks	of	run	in	period	prior	to	randomisation.		
69	patients	entered	randomisation	phase.	30	patients	were	allocated	to	
Pentoxifylline	group	while	39	patients	were	allocated	to	placebo	group.		
	
In	the	Pentoxifylline	group,	2	patients	were	transplanted	during	the	course	of	
study	and	1	patient	withdrew	consent	due	to	dyspepsia	symptoms.	2	patients	
died	in	Pentoxifylline	group.	
	
In	placebo	group,	2	patients	received	kidney	transplant	and	5	patients	withdrew	
consent	from	the	study.	4	patients	withdrew	consent	voluntarily	due	to	
personal	reasons	while	1	patient	withdrew	consent	due	to	gastro	intestinal	side	
effects.	All	39	patients	were	included	in	ITT	analysis	(Figure	11.1).		
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Figure	11.	1	Patient	allocation	during	study	
	
		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
																											
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Eligible	patients		
Consented	for	participation	
in	trial	n=84	
Withdrawn	consent	prior	to	
start,	n=10	
Reason	for	withdrawal	
Voluntarily	(personal)		n=10	
	
	
.	R	
	
	
	
	
Not	eligible	during	2	weeks	
run	in	period,	n=5	
Randomised	n=69	
Pentoxifylline	group	n=30	
Intention	to	
treat	analysis	
n=30	
Placebo	group	n=39	
Intention	to	
treat	n=39	
Per	protocol	
analysis	
n=23	
Deaths	n=2	
Transplant	n=2	
Withdrawn	
consent	
n=3	(reason	for	
withdrawal-	
Dyspepsia=1	
Voluntary=2)	
	
Per	protocol	
analysis	
n=32	
Transplant	n=2		
Withdrawal	of	
consent	n=5	
Reasons	for	
withdrawal:	
Diarrhoea	n=1	
Voluntarily	n=4	
	
		
Patients	screened	n=750	
	 71	
11.2	Baseline	characteristics	
	
The	baseline	characteristics	of	patients	in	Pentoxifylline	and	placebo	groups	did	
not	show	any	statistically	significant	difference	except	for	haemoglobin	and	
corrected	calcium	levels	(Tables	11.1	a	&	b).		All	patients	were	dialysing	using	
polysulfone	dialyser	membranes.	All	patients	had	urine	output	less	than	200mls	
in	24	hrs.	
	
Table	11.1	a			Baseline	characteristics-	demographics		
	
	 Pentoxyfylline		 Control	 p	value	
Age	(years)*	
	
56.21	(13.53)	 56.05	(14.06)	 0.96	
Gender	(male)	
	
24	(85%)	 29	(74%)	 0.29	
Ethinicity	
Asians	(Indian	subcontinent)	
Black	
White	
Others	
	
10	(35%)	
11	(39%)	
7	(25%)	
	
	
13	(33%)	
14	(35%)	
10	(25%)	
2	(5%)	
	
0.84	
0.77	
0.95	
Cause	of	CKD	
Diabetes	Mellitus	
Hypertension	
Chronic	Glomerulonephritis	
Adult	Polycystic	Kidney	disease	
Tubulo	interstitial	nephritis	
Congenital		
Others		
Unknown	
	
13	(46%)	
06	(21%)	
03	(10%)	
	
3	(10%)	
	
	
3	(10%)	
	
16	(41%)	
06	(15%)	
08	(20%)	
	
02	(05%)	
	
1	(2%)	
2	(5%)	
4	(10%)	
	
	
0.65	
0.63	
0.28	
	
0.38	
	
	
0.38	
Diabetes	Mellitus	 13	(46%)	 21	(53%)	
	
0.54	
Prescribed	ACE	inh	or	ARB		
	
12	(42%)	 14	(35%)	 0.56	
Dialysis	access	type-		
Arterio	venous	fistula	
17	(60%)	 25	(64%)	
	
0.77	
Dialysis	vintage	(months)	**	 22.5	(8-44.5)	 20	(12-60)	
	
0.49	
Prescribed	duration	of	dialysis	
per	week	(hours)*	
11.79	(0.88)		
	
11.88	(0.88)	 0.65	
Dialysis	adequacy	(kt/v)	*	 1.48	(0.24)	 1.60	(0.38)	
	
0.12	
	
The	categorical	values	are	given	as	numbers	(percentages)	while	continuous	
variables	are	given	as	mean	(standard	deviation)	*	or		
median	(interquartile	range)	**.		
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Table	11.1	b.	Baseline	characteristics	–	laboratory	parameters	
	
	 Pentoxifylline		 Control		 p	value	
	
ESA/Hb	ratio	(mean	of	2	
run-in	values)	**	
	
3.02	(2.51-5.30)	 3.92	(2.76-6.56)	
	
0.06	
ESA/Hb/weight	ratio	
(mean	of	2	run-in	values)	
**	
	
0.10	(0.06-0.13)	 0.12	(0.07-0.15)	 0.27	
Haemoglobin	(Hb)	g/dl	
(mean	of	2	run-in	values)	*	
	
11.34	(0.89)	 10.74	(0.92)	 0.01	
Haematocrit	*	 0.33	(0.03)	 0.32	(0.02)	
	
0.10	
Transferrin	saturation	**	
	
26	(22-34)	 24	(20-29)	 0.12	
Ferritin	mcg/L*	
	
415.8	(235.2)	 461.6	(174.7)	
	
0.51	
C	reactive	protein	mg/L		
(non-highly	sensitive)	**	
6	(5-14.7)	 7	(5-	16)	
	
0.72	
Parathyroid	hormone	
pmol/L	**	
	
33.05	(19.3-	56.6)	 25.6	(14.8	–	52.8)	 0.29	
Corrected	Calcium	
mmol/L	**	
	
2.23	(2.12-2.31)	 2.3	(2.24-2.44)	 0.02	
Phosphate	mmol/L*	
	
1.79	(0.54)	 1.74	(0.66)	 0.77	
Total	alkaline	
phosphatase	IU/L	*	
	
87.5	(62.25-128.3)	 91	(64-101)	 0.79	
Pre-dialysis	urea	mmol/L	
*	
	
20.72	(5.60)	 19.76	(4.82)	 0.45	
Pre-dialysis	creatinine	
μmol/L	** 
	
915	(695.8-1184)	 836	(698-979)	 0.30	
Pre-dialysis	potassium	
mmol/L	*	
	
5.02	(0.53)	 5.01	(0.72)	 0.93	
Albumin	g/L	
	
41.59	(3.60)	 41.1	(3.87)	 0.60	
	
The	categorical	values	are	given	as	numbers	(percentages)	while	continuous	
variables	are	given	as	mean	(standard	deviation)	*	or	median	(interquartile	
range)	**.		Abbreviation:	Erythropoiesis	stimulating	agent,	ESA.		
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11.3	Primary	and	associated	outcome	measures	
	
Per	protocol	analysis:		
The	primary	outcome	of	ESA	dose	in	relation	to	Hb	(ESA/Hb	ratio)	showed	
lower	mean	(SD)	ESA/Hb	ratio	4.08	(3.31)	in	Pentoxifylline	group	compared	to	
Placebo	group	4.67	(3.54)	but	it	failed	to	reach	statistical	significance	(p	value	=	
0.53).	
	
Intention	to	treat	(ITT)	analysis:		
The	primary	outcome	of	ESA	dose	in	relation	to	Hb	(ESA/Hb	ratio)	showed	
lower	ESA/Hb	ratio	in	Pentoxifylline	group	compared	to	Placebo	group	but	it	
also	failed	to	reach	statistical	significance	(p	value	=	0.12).	Comparison	within	
individual	groups	showed	an	improvement	in	Pentoxifylline	group	(mean	
difference=	-0.349,	p	value	=	0.62)	compared	to	placebo	(mean	difference	=	
0.25,	p	value=	0.68).		Associated	primary	outcomes	including	Hb,	ESA	dose	and	
ERI	also	did	not	show	any	statistically	significant	difference	between	the	groups.			
	
Intra	group	analysis	of	associated	outcomes	showed	an	improvement	in	ESA/Hb	
ratio	and	ESA	dose	in	Pentoxifylline	group	while	Haemoglobin	levels	showed	
improvement	in	placebo	group.	None	of	these	changes	were	of	any	statistical	
significance	(Table	11.2	&	Figures	11.2	a-d).	Comparison	of	mean	values	at	
every	study	visit	point	did	not	show	any	significant	difference	between	the	
groups	did	not	show	any	significant	difference	for	primary	or	any	of	the	
associated	outcomes	(Figures	11.3	a-d).	
	
The	results	remain	similar	to	previous	analysis.	No	statistically	significant	
different	outcomes	were	noted	even	after	change	in	data	analysis	end	point	
from	mean	of	results	from	two	follow	up	study	visits,	2	weeks	and	4	weeks	after	
the	end	of	IMP	intake	period	to	the	results	from	the	visit	immediately	after	the	
end	of	IMP	intake	period.		 	
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Table	11.2	Primary	and	associated	outcomes	(Intention	to	treat	analysis)	
	
	
ESA	–	erythropoietin	stimulating	agent	(Darbepoetin	dose	in	mcg),	Hb-	Haemoglobin	(gm/dl),	ERI-	erythropoietin	resistive	index	(ESA/	Hb	/	Weight)	
1. Means	of	first	two	ESA	/	Hb	values	during	run-in	period	(baseline)	and	ESA	/	Hb	values	at	the	start	of	follow	up	phase		
2. Mean	difference	=	baseline	value	–	follow	up	value	in	each	cohort.	
3. Results	displayed	as	Mean	(standard	deviation)	
Outcome		 Placebo	(n=39)	 Pentoxifylline	(n=30)	 p	value	
Baseline	
	
Follow	up	
	
Mean	
difference	
Baseline	
	
Follow	up	
	
Mean	
difference	
Follow	up	groups	
(placebo	&	
pentoxifylline)	
ESA	/Hb	
	
4.77	(2.37)	 5.03	(3.18)	 -0.25	 4.18	(2.30)	 3.83	(2.91)	 	0.34	 0.12	
Hb	
	
10.74	(.92)	 11.01	(1.30)	 -0.27	 11.34	(.89)	 11.14	(1.09)	 	0.19	 0.66	
ESA	 50.25	(23.94)	 52.95	(32.84)	 		-2.69	 44.29	(23.28)	 42.32	(28.59)	 1.96	 0.15	
ERI	 .061	(.02)	 .063	(.03)	 		0.001	 .053	(.02)	 .053	(.02)	 -0.0009	 0.25	
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Figures	11.2	(a-d).	Primary	and	associated	outcomes	(ITT	analysis)	
	
	
Figure	11.2	a.	ESA/Hb	ratio	in	placebo	and	Pentoxifylline	groups	
	
	
	
	
	
	
Figure	11.2	b.	Haemoglobin	in	placebo	and	Pentoxifylline	groups	
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Figure	11.2	c.	ESA	dose	in	placebo	and	Pentoxifylline	groups	
	
	
	
	
	
	
Figure	11.2	d.	ERI	in	placebo	and	Pentoxifylline	groups	
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11.3.1	Primary	and	associated	outcomes	measure	variability	during	
course	of	study	
	
Figures	11.3	(a-d)	Primary	and	associated	outcomes	measure	variability	during	
the	course	of	study	
	
Figure	11.3a	Variability	of	mean	ESA/	Hb	ratio	between	groups	during	the	
course	of	study		
	
	
	
	
Figure	11.3a		
Every	study	point	depicts	mean	with	standard	deviation	in	both	groups.	
Comparison	of	mean	ESA/Hb	between	placebo	and	pentoxifylline	group	at	
every	study	visit	along	the	course	of	study	did	not	show	any	significant	
statistical	difference.		
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Figure	11.3b	Variability	of	mean	ESA	dose	values	between	study	groups	during	
the	course	of	study		
	
	
	
	
	
Figure	11.3b		
	
Every	study	point	depicts	mean	with	standard	deviation	in	both	groups.	
Comparison	of	mean	ESA	dose	between	placebo	and	Pentoxifylline	group	at	
every	study	visit	along	the	course	of	study	did	not	show	any	significant	
statistical	difference.	
	
	
	
	
	
	
	
	
	
	
0
10
20
30
40
50
60
70
V1 V2 V3 V4 V5 V6 V7 V8 V9 V10 V11
ES
A	
do
se
	(m
cg
)
Pentoxifylline Placebo
	 79	
Figure	11.3c	Variability	of	mean	Haemoglobin	between	study	groups	during	the	
course	of	study	
	
	
	
	
	
	
Figure	11.3c		
Every	study	point	depicts	mean	with	standard	deviation	in	both	groups.	
Comparison	of	mean	Haemoglobin	between	Placebo	and	Pentoxifylline	group	at	
every	study	visit	along	the	course	of	study	did	not	show	any	significant	
statistical	difference	after	randomisation.		
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Figure	11.3d	Variability	of	mean	ERI	between	study	groups	during	the	course	of	
study	
	
	
	
	
	
	
Figure	11.3d	
Every	study	point	depicts	mean	with	standard	deviation	in	both	groups.	
Comparison	of	mean	ERI	between	Placebo	and	Pentoxifylline	group	at	every	
study	visit	along	the	course	of	study	did	not	show	any	significant	statistical	
difference.	
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11.4	Secondary	outcomes	
	
11.4.1	PET	CT	Scan	
	
Total	51	patients	were	able	to	attend	optional	baseline	and	follow	up	FDG	PET	
CT	scans.	Cross	sectional	data	analysis	of	SUV	max	and	TBR	across	the	whole	
cohort	(n=51)	at	baseline	showed	mean	(SD)	of	2.60	(0.60)	and	5.9	(2.93)	
respectively.	31	patients	were	in	placebo	group	while	20	patients	were	in	
Pentoxifylline	group.		At	baseline,	there	was	no	statistically	significant	
difference	in	TBR	or	SUV	max	in	Pentoxifylline	and	control	group	(Table	11.3a).		
On	the	follow	up	imaging	at	6	months,	there	was	no	statistically	significant	
difference	in	TBR	or	SUVmax	in	placebo	or	Pentoxifylline	group	(Figures	11.4	a	
&	b).		Similar	trend	was	noted	for	percentage	difference	in	TBR	and	SUV	max	
with	in	Pentoxifylline	group	(Table	11.3b).	
There	was	reduction	in	TBR	with	in	the	Pentoxifylline	group	but	it	failed	to	
achieve	statistical	significance	on	the	other	hand	there	was	a	rise	in	TBR	with	in	
the	placebo	group	at	the	end	of	study	follow	up	period.	There	was	reduction	of	
SUV	max	with	in	both	pentoxifylline	and	placebo	group	at	the	end	of	study	
follow	up	period	(Figure	11.4	c	&	d).		
	
	
Table	11.	3	a	FDG	PET	CT	Baseline	characteristics	
	
Outcome	 Placebo	(n=31)	 Pentoxifylline	(n=20)	 p	value	
	
SUV	max	 2.55	(0.65)	 2.68	(0.52)	 0.44	
TBR	 5.88	(3.24)	 5.82	(2.42)	 0.94	
	
Results	displayed	as	mean	(standard	deviation);	TBR-	target	to	background	ratio;	SUV	
max	–	standardised	uptake	value	maximum	
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Table	11.3	b	FDG	PET	CT	Results	(Follow	up	results)	
	
	
Results	displayed	as	mean	(standard	deviation)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Outcome	 Placebo	(n	=	31)	 Pentoxifylline	(n=20)	 p	value	
SUV	Max	 2.53	(.47)	 2.61	(.53)	 0.64	
TBR	 6.04	(3.41)	 5.27(1.94)	 0.36	
Difference	SUV	
max	(%)	
8.53	(62.64)	 -2.63	 0.45	
Difference	TBR	
(%)	
5.74	(22.95)	
	
-1.05	
	
	
0.39	
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Figures	11.4			18	FDG	PET	CT	results	
		
Figure	11.4	a.	Target	to	background	ratio	(TBR)	comparison	at	the	end	of	the		
																												study	period.		
	
	
	
	
	
	
	
Figure	11.4	b.	SUVmax	comparison	at	the	end	of	the	study	period		
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Figure	11.4	c.	Target	to	background	ratio	(TBR)	comparison	with	in	the	Placebo	
																											and	Pentoxifylline	groups	
	
	
	
	
	
	
Figure	11.4	d	SUVmax	comparison	with	in	the	Placebo	and	Pentoxifylline	groups	
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11.4.2	Cardiac	MRI	
	
In	total,	29	patients	in	the	study	agreed	to	undergo	the	optional	CMR	scans.	The	
baseline	CMR	results	are	shown	in	Table	11.4.	There	were	no	statistical	
differences	in	baseline	CMR	between	the	12	patients	who	were	randomised	to	
pentoxifylline	compared	to	the	17	patients	randomised	to	control.	After	6	
months	of	treatment	with	either	Pentoxifylline	or	Control,	there	were	no	
statistically	significant	changes	to	the	CMR	parameters	of	End-Diastolic	volume,	
End-Systolic	volume,	Stroke	volume,	Ejection	Fraction	or	Myocardial	Mass.	
There	were	also	no	inter-group	(Pentoxifylline	vs	control)	difference	in	the	
changes	of	these	parameters	that	was	statistically	significant	(Fig	11.5	a-e).	
However,	there	were	significant	reductions	in	aortic	compliance	in	both	groups.		
	
The	aortic	compliance	of	patients	that	received	6	months	of	Pentoxifylline	
decreased	by	-0.009	(95%	CI:	-0.005	to	-0.012)	units	whilst	the	reduction	for	
control	patients	was	-0.012	(95%	CI:	-0.010	to	-0.014)	units.	The	difference	in	
reduction	between	the	Pentoxifylline	vs	Control	patients	were	not	statistically	
significant	(Fig	11.5	f).		
	
Table	11.4	Cardiac	MR	Baseline	values	
	
	 Pentoxifylline	 Control	 P-value	
Number	 12	 17	 ns	
End	Diastolic	Volume	(mL)	 177	(83.03)	 150	(47.51)	 ns	
End	Systolic	Volume	(mL)	 78	(70.31)	 63	(28.93)	 ns	
Stroke	Volume	(mL)	 98	(33.69)	 87	(24.94)	 ns	
Ejection	Fraction	(%)	 59	(15.23)	 59	(9.09)	 ns	
Myocardial	Mass	(g)	 169	(77.74)	 133	(36.84)	 ns	
Aortic	Compliance	(mm/Hg)	 0.013	(0.003)	 0.014	(0.004)	 ns	
Results	displayed	as	mean	(standard	deviation);	ns	(p	value	not	significant)	
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11.5	Mechanistic	endpoint:	Cytokine	analysis	
					
Available	serum	samples	from	patients	who	had	consented	for	their	sample	to	
be	tested	for	experimental	outcomes	were	analysed	for	cytokine	profile	during	
the	course	of	trial.	Comparison	of	cytokine	titers	at	the	end	of	the	study	period	
showed	rise		IL-6	,	TGF	beta	and	TNF	titers	in	both	pentoxifylline	and	control	
group	except	for	statistically	significant	reduction	IFN	gamma	titers	when	
compared	to	placebo.	There	was	reduction	of	IFN	gamma	titers	with	in	the	
pentoxifylline	group	as	well.	(Table	11.5	and	figures11.6	a-d).		
	
On	comparison	of	variability	across	Pentoxifylline	and	placebo	groups	during	
overall	study	period	showed	improvement	in	IL-6	and	TNF	levels	in	
Pentoxifylline	group	with	IL-6	levels	achieving	statistical	significance.	While	the	
anti-inflammatory	cytokines,	TGF	beta	and	IFN	gamma	levels	were	significantly	
higher	in	Pentoxifylline	group	compared	to	placebo	group.		(Figures	11.7	a-h).			
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Table	11.5	Cytokine	analysis	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Means	of	first	two	readings	and	the	last	available	reading	during	intervention	phase	(visit	9)	were	used	for	calculating	baseline	and	follow					
up	parameters	respectively.	Mean	difference	=	baseline	value	–	follow	up	value	in	each	cohort.		
Results	displayed	as	Mean	(standard	deviation).	
Cytokine	titres	were	reported	as	picograms/millilitres	
	
	
	
Outcome		 Placebo	(n=39)	 Pentoxifylline	(n=30)	 p	value	
Baseline	
	
Follow	up	
	
Mean	
difference	
Baseline	
	
Follow	up	
	
Mean	
difference	
Follow	up	groups	
(placebo	&	
pentoxifylline)	
TNF	alfa	 24.81	(13.55)		
	
29.17	(16.76)	 -4.36	 19.79	(14.11)	 24.58	(17.05)	 -4.78	 .40	
IL	6	 9.28	(13.56)		
	
15.57	(22.00)	 -6.32	 5.64	(7.47)	 11.06	(11.06)	 -5.42	 .32	
TGF	 4.82	(4.95)	
	
6.4	(5.2)	 -1.64	 6.59	(7.11)	 7.61	(6.77)	 -1.020	 .34	
IFN	
gamma	
10.22	(17.27)	 13.75	(18.48)	 	-3.52	 5.68	(8.44)	 4.32	(4.98)	 1.35	 .04	
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Figure	11.6	a.	TNF	alfa	in	placebo	and	pentoxifylline	group	
	
	
	
	
	
	
	
	
Figure	11.6	b.			IL-6	in	placebo	and	pentoxifylline	group	
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Figure	11.6	c.			TGF	in	placebo	and	pentoxifylline	group	
	
	
	
	
	
	
Figure	11.6	d.		IFN	gamma	in	placebo	and	pentoxifylline	group	
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11.5.1	Cytokine	variability	during	the	course	of	study	
	
Figure	11.	7Cytokine	variability	during	the	study	
	
Figure	11.7	a	&	b	Interferon	gamma	(IFN	gamma)	variability	during	study	in	
Pentoxifylline	and	placebo	group	respectively	
	
Figure	11.7	a	
	
	
	
Figure	11.7	b	
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Figures	11.	7	(a	&	b)	Comparison	of	IFN	gamma	variability	across	Pentoxifylline	
and	Placebo	groups.	Grey	lines	show	case	variability	of	available	results	across	
11	visits	for	individual	patients	while	black	lines	show	variability	in	averaged	
gradient.	The	difference	in	averaged	scores	similar	to	the	area	under	the	curve	
represented	by	dark	black	lines	between	two	groups	was	statistically	significant	
(t	=	4.58,	p<.01)	with	Pentoxifylline	group	reporting	significantly	higher	mean	
averaged	score	(M	=	22.62,	SD	=	7.28)	as	compared	to	Placebo	group	(M	=	12.11,	
SD	=	2.25).	Hence,	Interferon	gamma	levels	were	significantly	higher	in	
Pentoxifylline	group.	
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Figure	11.7	c	&	d				Transforming	growth	factor		beta	variability	during	the	study	
in	Pentoxifylline	and	placebo	groups	respectively	
	
Figure	11.7	c	
	
	
	
	
Figure	11.7	d						
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Figures	11.7	(c	&	d)	Comparison	of	TGF	variability	across	Pentoxifylline	and	
placebo	groups.	Grey	lines	show	case	variability	of	available	TGF	levels	across	
11	study	visits	for	individual	patients	while	black	lines	show	variability	in	
averaged	gradient.	The	difference	in	averaged	scores	similar	to	the	area	under	
the	curve,	represented	by	dark	black	lines	between	two	groups	was	statistically	
significant	(t	=	2.38,	p<.05)	with	Pentoxifylline	group	reporting	significantly	
higher	mean	averaged	score	(M	=	6.68,	SD	=	1.50)	as	compared	to	placebo	group	
(M	=	5.33,	SD	=	1.14).	Hence	TGF	beta	was	significantly	higher	in	pentoxifylline	
group.		
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Figure	11.7	e	&	f			IL-6	variability	during	the	study	in	Pentoxifylline	and	placebo	
group	respectively	
	
Figure	11.7	e	
	
	
	
	
Figure	11.	7	f						
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Figures	11.7	(e	&	f)	
Comparison	of	IL-6	variability	across	Pentoxifylline	and	Placebo	groups.	Grey	
lines	show	case	variability	of	available	IL-6	levels	across	11	study	visits	for	
individual	patients	while	black	lines	show	variability	in	averaged	gradient.	The	
difference	in	averaged	scores	similar	to	the	area	under	the	curve,	represented	
by	dark	black	lines	between	two	groups	was	statistically	significant	(t	=	3.41,	
p<.01)	with	Placebo	group	reporting	significantly	higher	mean	averaged	score	
(M	=	12.11,	SD	=	2.69)	as	compared	to	Pentoxifylline	group	(M	=	8.31,	SD	=	
2.52).		
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Figure	11.	7	g	&	h				TNF	alfa	variability	during	the	study	in	Pentoxifylline	and		
																																						placebo	groups	respectively	
	
Figure	11.7	g	
	
	
	
	
Figure	11.7	h			
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Figures	11.7	(g	&	h)	Comparison	of	TNF	variability	across	Pentoxifylline	and	
Placebo	groups.	Grey	lines	show	case	variability	of	available	TNF	levels	across	
11	study	visits	for	individual	patients	while	black	lines	show	variability	in	
averaged	gradient.	The	difference	in	averaged	scores	similar	to	the	area	under	
the	curve,	represented	by	dark	black	lines	between	two	groups	was	statistically	
not	significant	(t	=	1.77,	p	=	.09)	with	placebo	group	reporting	mean	averaged	
score	(M	=	28.19,	SD	=	2.64)	as	compared	to	Pentoxifylline	group	(M	=	25.54,	SD	
=	4.22).	
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11.6	Safety	analysis		
	
Table	11.6				Adverse	event	description	
	
Adverse	event	category	 Pentoxifylline	
group	(n=28)	
Placebo	
group	
(n=39)	
p	value	
Others	 88	 124	 <0.05	
Cardio	vascular	system	except	
fluid	overload	
57	 85	 <0.05	
Fluid	overload	 29	 45	 <0.05	
Gastrointestinal	system	 9	 22	 0.05	
Access	related	-	non-infectious	 58	 63	 <0.05	
Access	-	infectious	 5	 11	 0.32	
Medication	change	 40	 65	 <0.05	
Respiratory	system	 11	 23	 0.11	
Musculoskeletal	including	–
Bone	metabolism	
9	 30	 <0.05	
Neurological	system	
(including	ophthalmology)	
13	 2	 <0.05	
Genitourinary	system	 4	 8	 0.5	
Endocrinology	 10	 8	 0.16	
Skin	 4	 1	 0.07	
Deaths	 2	 0	 0.09	
Serious	adverse	events	 8	 16	 0.14	
	
Pentoxifylline	group	had	overall	less	number	of	adverse	events	compared	to	
placebo	group.	Serious	adverse	events	(SAEs)	reported	in	the	table	are	also	
classified	into	sub	groups	except	for	deaths.	None	of	the	serious	adverse	events	
were	thought	to	be	secondary	to	IMP	during	the	course	of	the	study.		
	
In	Pentoxifylline	group,	1	patient	underwent	blood	transfusion	as	results	of	
complications	related	to	emergency	vascular	surgery	while	3	patients	
underwent	blood	transfusions	in	placebo	group.	There	were	14	incidents	of	loss	
of	haemodialysis	blood	circuit	among	9	patients	in	Pentoxifylline	group.	There	
were	7	such	incidents	among	6	patients	in	placebo	group	(p	value	=0.005).	
Haemodialysis	blood	circuit	clot	and	blood	transfusions	were	classed	under	
‘Others’	adverse	event	category	(Table	10.6).	
	
	 100	
	
12. Incidental	clinical	findings	on	FDG	PET	CT	scans		
	
Burden	of	comorbidities	is	high	among	haemodialysis	patient.	Underlying	
infective	focus	or	occult	malignancy	is	always	of	concern	when	patients	have	
Erythropoietin	stimulating	agent	(ESA)	hypo	responsiveness	but	otherwise	
clinically	stable.		Patients	with	similar	baseline	characteristics	underwent	whole	
body	15	Fluorodeoxyglucose	positron	emission	tomography	along	with	low	
dose	computerised	tomography	(FDG	PET	CT)	scan	to	assess	atherosclerotic	
plaque	inflammation	at	baseline	and	at	six	month	following	treatment	with	IMP	
(Pentoxifylline	400	mg	OD	or	Placebo).		Any	non-research	related	clinically	
significant	finding	was	reported	to	clinical	team	by	research	team	for	further	
action.		
62	patients	underwent	imaging	at	baseline.	Of	these	patients	20	(32%)	patients	
had	pathological	tracer	uptake,	8	(12%)	patients	had	suspected	malignancy	and	
2	(0.03%)	patients	had	confirmed	diagnosis	of	malignancy	(renal	cell	carcinoma	
in	the	upper	pole	&	moderately	active	thyroid	nodule	found	to	be	papillary	
carcinoma	of	thyroid).	
51	patients	subsequently	had	follow	up	imaging.	Of	these,	12	(24%)	patients	
had	new	evidence	of	pathological	tracer	uptake	of	which	1	(0.02%)	patient	had	
new	finding	suggestive	of	malignancy	requiring	interval	scan.	Only	3	patients	
still	had	on	going	findings	noticed	on	initial	imaging.	There	was	no	association	
between	elevated	non-highly	sensitive	(hs)	c	reactive	protein	(CRP)	around	
time	of	scan	and	pathological	tracer	uptake	(P=0.468).		
In	total	31%	scans	showed	pathological	tracer	uptake.		7	(6.4%)	patients	
underwent	invasive	investigations	to	rule	out	malignancy.	2	patients	had	
confirmed	malignancy,	1	was	started	on	anti	-tubercular	therapy,	4	patients	
needed	antibiotics	and	1	patient	underwent	colonoscopy	for	polypectomy.		2	
patients	who	had	confirmed	malignancy	had	to	be	suspended	from	ongoing	
living	donor	renal	transplant	workup	(Table	7).	This	observation	is	reflective	of	
disease	burden	among	clinically	asymptomatic	haemodialysis	patients.		
	
	
	
	 101	
	
Table	12.1.	Incidental	findings	on	FDG	PET	CT	scan	
	
Timing	of	Imaging		 Initial	 Follow	up	
Number	of	scans	 62	 49	
Pathological	tracer	uptake	 20	 15	
Suspected	malignancy	 9	 1	(new)	
Lung	nodule	 0	 1	
Inflammatory	/	infective	lymphadenopathy	 4	 1	(old)	
Colonic	polyp	(non-malignant)	 1	 	
Infected	renal	cyst	 1	 	
Infected	sebaceous	cyst	 1	 	
Renal	cell	carcinoma	 1	 	
Papillary	carcinoma	of	thyroid	 1	 	
Confirmed	malignancy	(new)	 2	 2	(old)	
Pathological	uptake	(other)	 11	 11	
Arthropathy	 2	 2	
Sialadenitis	 2	 1	
Access	related	infection	 1	 1	
Gastric	mucosal	uptake	 2	 3	
Lung	changes	 3	 2	
Lymphadenopathy	 0	 1	
Other	 1	 1	
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13. Conclusion	and	discussion	
	
Anaemia	management,	particularly	in	a	patient	with	high	ESA	requirement	
poses	a	challenge	to	clinicians.	High	ESA	requirement	is	also	associated	with	
adverse	cardiovascular	outcomes	resulting	in	significant	morbidity	and	
mortality	in	this	cohort	of	patients.	Inflammation	is		one	of	the	major	factors	
contributing	to	high	ESA	requirement	as	well	as	adverse	cardiovascular	
outcomes.	
	
Pentoxifylline	by	its	effect	on	inhibition	of	cytokine	production	through	cAMP	
pathway	may	result	in	the	reduction	of	inflammation.	Pentoxifylline	has	been	
shown	to	improve	Hb	or	reduce	ESA	requirement	in	a	few	uncontrolled	studies	
and	one	double-blind	placebo-controlled	RCT.		
	
This	thesis	aimed	to	assess	the	effects	of	Pentoxifylline	on	ESA	resistance	and	
associated	outcomes.		We	also	explored	the	effect	of	pentoxifylline	on	surrogate	
markers	of	adverse	cardiovascular	events	such	as	aortic	distensibility	and	
vascular	plaque	inflammation	measured	by	cardiac	MRI	and	FDG	PET	CT	scan	
respectively.	Effect	of	pentoxifylline	on	inflammatory	status	was	also	assessed.		
13.1	Effect	of	Pentoxifylline	on	ESA	requirement		
	
This	double-blind	placebo	controlled	randomised	study	did	not	show	any	
statistically	significant	beneficial	effect	of	pentoxifylline	compared	to	placebo	in	
reducing	ESA	requirement	(reflected	by	ESA/Hb	ratio,	ESA	dose,	Hb	levels	and	
ERI)	in	ESA	resistant	haemodialysis	patients.	Baseline	characteristics	were	
similar	in	both	groups	except	for	higher	haemoglobin	levels	in	Pentoxifylline	
group	(p	value	=	0.01)	and	corrected	calcium	levels	(p	value	=	0.02)	in	the	
placebo	group.	The	impact	of	higher	haemoglobin	level	may	have	been	
significant	if	the	study	results	were	positive.		The	Patient	cohort	was	ethnically	
diverse,	and	a	majority	of	patients	were	male,	reflecting	patient	distribution	at	
our	centre.		
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There	was	an	improvement	in	the	primary	outcome	measure	of	ESA	/	Hb	ratio	
in	the	Pentoxifylline	group	compared	to	the	placebo	group,	but	it	failed	to	reach	
statistical	significance.	A	similar	trend	was	noted	within	the	Pentoxifylline	
group	when	baseline	ESA/Hb	ratio	was	compared	with	follow	up	results.	
	
One	patient	underwent	blood	transfusion	in	pentoxifylline	group	while	three	
patients	received	blood	transfusion	in	the	placebo	group.	There	was	a	
significantly	higher	incidence	of	haemodialysis	blood	circuit	loss	due	to	clotting	
in	the	Pentoxifylline	group	compared	to	the	placebo	group	(p	value	=0.005).	
Dialysis	circuit	was	discarded	by	the	clinical	team	for	one	patient	each	in	both	
groups	to	prevent	haemodialysis	access	from	getting	thrombosed	due	to	Hb	
greater	than	13gm/dl	(off	protocol).	Each	episode	of	dialysis	circuit	loss	results	
in	200-300	ml	of	blood	loss	leading	to	drop	in	Hb	levels.		This	factor	could	have	
also	contributed	to	the	lack	of	statistically	significant	outcomes.	
	
Despite	a	robust	study	design,	this	study	was	limited	by	less	than	expected	
recruitment	of	patients.	Investigators	felt	that	there	were	many	barriers	to	
recruitment	in	a	trial	with	an	investigational	medicinal	product.	Already	high	
pill	burden,	known	poor	compliance	to	treatment	as	a	result	of	various	
psychosocial	aspects	of	chronic	illness	were	some	of	the	main	reasons	behind	
the	lack	of	acceptance	among	patients.	Cultural	and	language	barriers	also	play	
a	role	in	relatively	poor	research	study	acceptance	among	our	cohort.			
	
After	the	completion	of	the	current	study,	there	has	been	a	drive	by	various	
agencies	at	the	national	and	local	level	to	enhance	research	awareness	among	
CKD	patients.	Higher	patient	recruitment	rates	to	other	trials	were	noted	after	
these	interventions.		
	
The	 results	 of	 our	 study	 are	 in	 contrast	 to	 another	 double-blind	 placebo	
controlled	 RCT	 published	 after	 the	 commencement	 of	 our	 study.	 In	 this	
multicentre	 trial,	53	patients	with	CKD	4	or	5D	with	ESA	hyporesponsiveness	
defined	 by	 ESA	 resistance	 index	 of	 ≥10.0	 I.U./Kilograms	 (kg)/wk/gm/dL	 for	
erythropoietin-treated	patients	and	≥	0.05	mg/kg/wk/gm/dL	(for	darbepoetin	
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alpha-treated	patients)	were	given	pentoxifylline	400mg	once	a	day	(OD)	for	four	
months.	There	was	no	significant	improvement	in	ERI	between	the	pentoxifylline	
and	 control	 group	 (p=0.1).	 However,	 pentoxifylline	 significantly	 improved	 Hb	
concentration	 relative	 to	 the	 control	 group	 (p=0.01).	No	difference	 in	adverse	
events	was	noted	in	either	group.	This	trial	was	limited	by		a	smaller	sample	size	
than	planned	due	to	slow	recruitment.	This	study	also	included	patients	with	CKD	
stage	4	[123].		
	
A	randomised	study	from	Isfahan,	Iran,	Mortazavi	et	al.	compared	the	effect	of	
pentoxifylline	on	haemoglobin	and	ESA	required	compared	to	placebo.	50	
patients	undergoing	chronic	haemodialysis	enrolled	in	the	study	were	divided	
into	two	groups	taking	pentoxifylline	and	placebo	over	a	period	of	six	months.	
The	Study	did	not	show	any	significant	change	in	haemoglobin	(10.6+1.4	vs	
10.1+1.7)	or	ESA	requirement	(7.5+4.4	vs	8.3+3.4)	between	pentoxifylline	and	
placebo	group	respectively.	Unfortunately,	this	study	publication	was	marred	by	
lack	of	details	on	study	methodology	and	baseline	characteristics.	The	baseline	
characteristics	were	only	compared	for	age,	sex	and	cause	of	renal	failure.	The	
study	did	not	enrol	patients	with	ESA	resistance.	Study	methodology	such	as	
randomisation	or	any	blinding	protocol	was	also	not	mentioned.	There	is	a	
possibility	that	there	were	many	confounding	factors	that	could	have	resulted	in	
the	published	negative	results.	Therefore	drawing	any	valuable	conclusion	from	
this	study	may	be	inappropriate	[126].		
	
In	a	non-blinded	study	published	by	Shahbazian	et	al	demonstrated	a	
statistically	significant	improvement	in	haemoglobin	in	ESA	resistant	
hemodialysis	patients	treated	with	pentoxifylline	compared	to	controls.	Hb	was	
reported	to	be	11.22	+/-	1.26	in	treatment	group	(n=19)	compared	to	9.77	+/-	
1.08	in	control	group	(n=20)	with	a	p	value	of	0.	001.Within	the	groups	there	
was	a	statically	significant	improvement	in	CRP	in	treatment	group.	
Unfortunately,	ESA	dosage	comparison	between	the	groups	at	baseline	or	at	the	
end	of	treatment	was	not	published.	Although	results	of	this	study	were	in	line	
of	available	data	on	pentoxifylline	yet	it	will	be	difficult	to	interpret	the	results	
in	the	absence	of	ESA	dosage[127].	
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On	 the	other	hand,	 smaller	uncontrolled	 studies	discussed	 in	 the	 introduction	
section,	 have	 demonstrated	 improvement	 of	 ESA	 requirement	 and	 or	
haemoglobin.	Studies	 including	a	double-blind	placebo-controlled	studies	have	
demonstrated	pentoxifylline	associated	reduction	in	inflammation	status	in	CKD	
patients	by	reduction	in	cytokines	and	highly	sensitive	CRP	levels[8,	112,	113].	
This	 is	 in	 keeping	 with	 the	 hypothesis	 of	 inflammation-driven	 ESA	
hyporesponsiveness	 through	direct	 inhibition	of	 erythropoiesis	 and	 functional	
iron	deficiency	through	the	hepcidin	pathway.		
	
Randomised	controlled	studies	are	not	able	to	demonstrate	the	effectiveness	of	
pentoxifylline	 in	 ESA	 resistance.	 This	 could	 be	 attributed	 to	 comorbidities	
associated	 with	 advanced	 CKD	 patients	 on	 haemodialysis	 who	 subsequently	
suffer	from	ESA	resistance.	This	high-risk	cohort	of	patients	suffers	from	frequent	
spells	 of	 illnesses	 usually	 associated	with	 cardiovascular	 events	 and	 infective	
complications	which	could	mask	the	potential	beneficial	effect	of	Pentoxifylline	
resulting	 from	 its	 effect	 on	 pro-inflammatory	 cytokines	 demonstrated	 in	 our	
study.		Pentoxifylline	was	consistently	found	to	be	safe	in	haemodialysis	patients.		
	
Recently,	 the	 effect	 of	 pentoxifylline	 was	 studied	 in	 another	 inflammatory	
condition.	 A	 large	 multicentre,	 double	 blind	 study	 involving	 1103	 patients	
evaluated	 the	effect	of	pentoxifylline	on	acute	 alcoholic	hepatitis	 compared	 to	
prednisolone.	The	dose	of	Pentoxifylline	used	was	also	400	mg	OD.	This	study	did	
not	 show	 any	 beneficial	 effect	 of	 pentoxifylline	 compared	 to	 Prednisolone.	
Prednisolone	 was	 shown	 to	 improve	 short-term	 outcome	 in	 acute	 alcoholic	
hepatitis	[128].	
	
There	 is	 growing	 evidence	 that	 Diabetic	 nephropathy	 is	 an	 inflammatory	
condition.	Therefore,	newer	anti-inflammatory	agents	have	been	studied	to	halt	
the	progression	of	 the	disease.	 	The	PREDIAN	trial	 studied	 the	 impact	of	 anti-
inflammatory	and	anti-fibrotic	effect	of	Pentoxifylline	in	patients	with	Diabetic	
nephropathy	who	were	on	renin-angiotensin	system	(RAS)	inhibition	therapy.	In	
this	open	label	randomised	study,	82	patients	received	Pentoxifylline	1200	mg	
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once	a	day	while	87	patients	were	assigned	to	the	placebo	group	for	a	period	of	2	
years.	 There	 was	 a	 statistically	 significant	 lesser	 reduction	 of	 GFR	 in	 the	
Pentoxifylline	group	compared	to	placebo	at	the	end	of	the	two	year	study	period.	
Urinary	TNF	alfa	also	improved	significantly	in	Pentoxifylline	group.	The	authors	
mention	that	improving	trend	of	GFR	was	apparent	at	six	months	and	reached	a	
level	of	statistical	significance	only	after	one	year	of	therapy.	Pentoxifylline	at	the	
given	 dose	 was	 tolerated	 well	 except	 for	 higher	 incidence	 of	 gastrointestinal	
symptoms	which	resolved	spontaneously	 in	 the	majority	of	patients.	 	Hence,	a	
higher	 dose	 of	 Pentoxifylline	 given	 for	 longer	 duration	 has	 shown	 significant	
benefits	 in	 diabetic	 nephropathy	 including	 a	 reduction	 in	 urinary	 cytokines	
levels[129].	
	
On	face	value	PEAR	study	may	appear	negative	albeit	dose	used	was	400	mg	and	
duration	of	the	study	was	six	months	which	may	have	been	too	short	to	show	any	
improvement	 in	 ESA	 requirement	 despite	 some	 beneficial	 effects	 on	 overall	
cytokine	 exposure.	 The	 effect	 of	 Pentoxifylline	 was	 not	 translated	 into	 its	
beneficial	 effect	 on	 ESA	 requirement.	 Improving	 trends	 were	 also	 visible	 in	
atherosclerotic	plaque	inflammation	quantified	by	FDG	PET	CT	analysis.	There	is	
a	possibility	that	a	longer	duration	of	study	and	or	higher	dose	of	Pentoxifylline,	
could	have	shown	a	beneficial	effect	on	the	primary	outcome.	Unfortunately,	the	
quality	of	life	assessment	was	not	done	during	this	study.	
	
PEAR	study	outcomes	make	a	strong	argument	for	a	large	outcome	based	study	
conducted	 in	 a	 setting	 of	 a	 pragmatic,	 large	 cluster	 randomised	 trial.	 Higher	
dosing	of	pentoxifylline	could	be	considered	in	haemodialysis	patients	following	
an	appropriate	pilot	study.	Chronic	haemodialysis	setting	is	an	ideal	situation	for	
conducting	pragmatic	 clinical	 trials.	 	 	While	undergoing	haemodialysis,	patient	
encounters	are	regular	and	predictable.	A	significant	amount	of	clinical	data	 is	
already	collected	 for	routine	 clinical	 care.	National	 renal	registries	also	 collect	
various	aspects	of	this	dataset	in	the	majority	of	the	developed	world	[130].	
	
In	 conclusion,	 further	 studies	 are	 required	 with	 larger	 patient	 numbers	 to	
establish	 effect	 pentoxifylline	 for	 ESA	 hyporesponsiveness	 in	 haemodialysis	
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patients.	 Two-	 well	 designed	 RCTs	 have	 failed	 to	 recruit	 adequate	 numbers.	
There	 is	 a	 scope	 to	 consider	 to	 large	 pragmatic	 trial	 with	 randomisation	 by	
‘cluster’	rather	than	individual	patient-based	randomisation.		
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13.2	Effect	of	pentoxifylline	on	surrogate	markers	of	cardiovascular	risks	
and	inflammation	status	
	
The	incidence	of	Chronic	kidney	disease	is	on	the	rise	across	the	world.	In	2010,	
CKD	was	the	third	biggest	cause	of	overall	loss	of	years	of	life	(82%)	behind	HIV	
&	AIDS	(396%)	and	diabetes	mellitus	(93%)	[131].		Studies	have	shown	the	
association	of	a	reduction	in	GFR	with	the	rise	in	cardiovascular	disease	risk.	
This	risk	is	even	higher	in	patients	undergoing	haemodialysis	[132].		In	addition	
to	traditional	risk	factors,	an	inflammatory	state	in	CKD	is	associated	with	
adverse	cardiovascular	outcomes.		
	
13.2.1	Atherosclerotic	plaque	inflammation	
	
The	impact	of	arterial	wall	inflammation	on	increased	cardiovascular	disease	risk	
in	CKD	patients	is	coming	into	the	spotlight	over	the	past	few	years.	The	focus	of	
intervention	studies	has	shifted	to	metabolically	active	inflamed	unstable	plaque	
rather	than	calcified,	stable	but	anatomically	significant	atherosclerotic	plaque.	
	
Interventions	such	as	 the	statins,	which	cause	the	reduction	 in	atherosclerotic	
plaque	inflammation	have	resulted	in	improvement	in	cardiovascular	outcomes	
in	non-dialysis	patients.	The	method	of	analysing	the	anti-inflammatory	effect	of	
an	intervention	on	atherosclerotic	plaque	inflammation	with	18	FDG	PET	CT	scan	
has	been	well	established	with	statin	trials.		
	
A	multicentre	randomised	placebo-controlled	double	blind	study	by	Tawakol	et	
al.	 demonstrated	 the	 effect	 of	 intensifying	 statin	 therapy	 on	 atherosclerotic	
plaque	 inflammation	 along	 the	 major	 blood	 vessels.	 83	 patients	 with	
cardiovascular	 disease	 risk	 factors	 or	 known	 to	 have	 atherosclerosis,	 were	
randomised	to	atorvastatin	10	mg	versus	80	mg	OD	dosing.	FDG	PET	CT	imaging	
analysed	atherosclerotic	plaque	inflammation	in	carotid	arteries	and	ascending	
aorta	by	measuring	TBR	of	FDG	uptake	in	the	plaques	at	baseline,	four	weeks	and	
twelve	weeks	interval.	Statins	produced	a	dose-dependent	significant	reduction	
in	plaque	 inflammation	noted	as	early	as	 four	weeks	 scan	which	 continued	 to	
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improve	at	12	weeks	scans.	There	was	no	association	of	highly	sensitive	CRP	or	
lipid	profile	with	these	changes	[97].		
	
In	haemodialysis	patients,	statins	have	not	been	found	to	be	effective	in	reducing	
cardiovascular	events	in	multiple	well	designed	trials[133-136].		This	is	probably	
due	 to	 the	 complex	 mechanism	 and	 a	 higher	 degree	 of	 inflammation	 in	
haemodialysis	patients.			
	
	Due	 to	 its	 anti-inflammatory	 action	 in	 dialysis	 patients,	 the	 effect	 of	
pentoxifylline	 on	 atherosclerotic	 plaque	 inflammation	was	 also	 studied.	 PEAR	
study	 was	 the	 first	 study	 to	 quantify	 atherosclerotic	 plaque	 inflammation	 in	
chronic	 haemodialysis	 patients.	 The	 analysis	 of	 baseline	 scans	 (before	
intervention)	 of	 all	 patients	 showed	 a	 significantly	 elevated	 arterial	 wall	 FDG	
uptake	with	a	mean	(SD)	TBR	value	of	5.9	(2.93).		To	put	this	observation	of	high	
mean	TBR	into	perspective,	as	also	mentioned	in	the	introduction	section,	a	study	
of	non-CKD	patients	undergoing	FDG	PET	CT	scan,	mean	(SD)	TBR	value	of	2.27	
(0.34)	was	associated	with	risk	of	developing	cardiovascular	disease	in	6	months	
[95].		
	
The	improvement	of	atherosclerotic	plaque	inflammation	depicted	by	TBR	in	the	
Pentoxifylline	 group	 failed	 to	 reach	 statistical	 significance	 compared	 to	 the	
placebo	group	after	six	months	of	treatment.	There	was	no	statistically	significant	
difference	 between	 the	 two	 groups	 for	 SUV	max	 as	well.	 In	 the	 Pentoxifylline	
group,	 there	was	 an	 improvement	 of	 TBR	 at	 the	 time	of	 follow	up	 scan	when	
compared	 with	 baseline	 scans.	 While	 in	 the	 placebo	 group,	 there	 was	
deterioration	 of	 TBR	 in	 follow	 up	 scans	 when	 compared	 to	 baseline	 scans.	
Therefore,	 even	 though	 statistically	 nonsignificant,	 the	 positive	 impact	 of	
Pentoxifylline	 demonstrated	 by	 PEAR	 study,	 in	 reducing	 or	 halting	
atherosclerotic	 plaque	 inflammation	 in	 haemodialysis	 patients	 could	 still	 be	
inferred.		
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13.2.2	Cardiac	MRI		
	
This	study	did	not	show	any	statistically	significant	change	in	Aortic	compliance	
between	pentoxifylline	and	placebo	group.	There	were	no	significant	changes	in		
parameters	of	cardiac	function	such	as	end-diastolic	volume,	end	systolic	volume,	
stroke	volume,	ejection	fraction,	myocardial	mass	when	compared	between	two	
groups	at	the	end	of	6-month	treatment	period.		
	
The	 cardiac	 MRI	 analysis	 was	 limited	 by	 a	 very	 small	 number	 of	 patients	
undergoing	 imaging.	 Major	 barriers	 to	 patient	 participation	 were	 a)	 new	
diagnosis	of	claustrophobia	while	undergoing	scans	b)	patients	unable	to	fit	into	
cardiac	MRI	scanner	as	a	result	of	obesity.	Some	patients	did	not	attend	imaging	
due	to	lack	of	available	time.	Haemodialysis	patients	undergo	dialysis	treatment	
three	times	per	week	and	remaining	two	working	days	of	the	week	are	usually	
taken	up	with	tasks	such	as	GP	visits,	other	hospital	appointments	or	personal	
work.		
	
In	haemodialysis	patients,	increased	aortic	stiffness	is	a	strong	independent	risk	
factor	for	cardiovascular	and	all-cause	mortality	[108,	109].	Study	by	Briet	et	al.	
demonstrated	 that	 GFR	 was	 strongly	 correlated	 with	 arterial	 stiffness	 [136].	
Another	study	demonstrated	that	24	patients	on	chronic	haemodialysis	with	no	
history	 of	 coronary	 heart	 disease	 had	 significantly	 reduced	 aortic	 compliance	
similar	to	non-CKD	patients	with	advanced	coronary	artery	disease	[137].			
	
As	 previously	 discussed	 in	 the	 introduction	 section,	 arterial	 stiffness	 is	 the	
outcome	of	a	complex	process	of	alteration	in	the	intrinsic	elastic	properties	as	
result	of	calcification,	increased	collagen	content,	elastinolysis,	reduced	density	
of	vascular	smooth	muscle	cells	and	inflammation.	In	ESRD,	calcification	of	blood	
vessels	plays	a	significant	role	in	the	pathogenesis	of	arterial	sclerosis.	Hence	the	
interventions	which	are	proven	to	be	effective	in	improving	arterial	stiffness	in	
non-CKD	 population	 may	 not	 be	 beneficial	 in	 advanced	 CKD	 patient	 cohort.		
Atherosclerosis	 is	not	considered	to	be	the	major	contributor	towards	arterial	
stiffness.	
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Blood	 pressure	 has	 been	 considered	 as	 a	 modifiable	 risk	 factor	 in	 the	
pathogenesis	of	arterial	stiffness,	but	its	role	in	ESRD	patients	remains	uncertain.	
A	study	of	150	patients	with	ESRD	demonstrated	that	pulse	wave	velocity	which	
was	 not	 sensitive	 to	 changes	 in	 BP	 control	 was	 an	 independent	 predictor	 of	
mortality.	In	this	study,	BP	control	was	optimised	by	adjusting	dry	weight	and	
pharmacological	treatment	such	as	ACE	inhibitor,	calcium	antagonists	and	beta	
blockers.	Patients	were	 followed	up	for	mean	58	months.	Lack	of	reduction	 in	
pulse	wave	velocity	 in	response	to	an	improvement	 in	BP	was	associated	with	
cardiovascular	and	all-cause	mortality.	Adjusted	RR	for	a	PWV	decrease	of	1	m/s	
was	0.79	(95%	CI	0.69	to	0.93)	 for	cardiovascular	mortality	and	0.71	(95%	CI	
0.60	 to	0.86)	 for	all-cause	mortality.	Use	of	 an	ACE	 inhibitor	had	a	 favourable	
response	on	all	cause	and	cardiovascular	mortality	[138].		
	
A	recent	study	published	by	Sarafidis	et	al	analysed	the	significance	of	
ambulatory	BP,	central	pulse	pressure,	pulse	wave	velocity	and	heart	rate	
adjusted	augmented	index		in	170	haemodialysis	patients.		At	the	end	of	average	
follow	up	of	28	months,	ambulatory	pulse	wave	velocity	was	the	only	parameter	
associated	with	the	primary	end	point	of	all-cause	mortality	and	non-fatal	
cardiovascular	events	(hazard	ratios,	1.579;	95%	confidence	intervals,	1.187-
2.102)	[139].	
	
Inflammation	plays	a	significant	role	in	the	pathogenesis	of	arterial	stiffness.	
Inflammation	measured	by	hs	CRP	and	cytokine	levels	have	been	shown	to	be	
associated	with	arterial	stiffness	in	non-CKD	patients.	[140,	141].	In	
inflammatory	conditions	secondary	to	rheumatological	problems,	interventions	
targeted	towards	reducing	inflammation	status	have	resulted	in	improvement	
of	arterial	wall	stiffness	[105].		
		
Similar	to	hepcidin	in	iron	regulation,	the	role	of	Fetuin	in	arterial	stiffness	is	
worth	mentioning.	Fetuin	is	a	negative	acute	phase	protein	synthesised	in	the	
liver.	It	inhibits	calcification	of	blood	vessels	by	maintaining	solubility	of	serum	
calcium	phosphate.	Fetuin	leads	to	formation	of	calciprotein	particles	which	in	
turn	result	in	inhibition	of	calcium	phosphate	aggregate	formation	[142].			
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A	study	of	222	prevalent	haemodialysis	patients		by		Metry	et	al	,	demonstrated	
increased	mortality	risk		(HR	2.3;	CI	1.2-4.5,	P	=	0.01)	in	inflamed	haemodialysis	
patients	in	with	low	Fetuin-A	protein	levels	compared	to	non-inflamed	dialysis	
patients	with	high	Fetuin-A	protein	levels	after	adjustment	for	comorbidities	
score,	age,	gender,	dialysis	vintage	and	inflammation	[143].		Multiple	
comorbidities	such	as	diabetes	mellitus,	hypertension	and	pre-existing	
inflammatory	illnesses	in	the	presence	of	conditions	associated	with	
haemodialysis	such	as	inflammation,	oxidative	stress	and	deranged	bone	
mineral	metabolism	provide	a	perfect	stage	for	the	pathogenesis	of	arterial	
stiffness.		
	
In	PEAR	study,	we	were	limited	by	the	number	of	patients	undergoing	the	gold	
standard	test	for	measurement	of	Pulse	wave	analysis.	Therefore,	we	were	we	
were	unable	to	establish	any	trends	for	changes	in	various	cardiovascular	
parameters.	However,	there	is	scope	for	further	studies	focussed	on	the	impact	
of	reducing	inflammation	load	in	dialysis	patients	on	arterial	stiffness	by	
conducting	longer	duration	of	studies	as	alluded	to	earlier.	Interventions	to	
reduce	inflammation	in	advanced	CKD		remains	a	relatively	unexplored	area	in	
CKD	research.		
	
13.2	Effect	of	pentoxifylline	on	cytokines	
	
Treatment	of	ESA	resistant	haemodialysis	patients	with	pentoxifylline	did	not	
show	any	statistically	significant	reduction	in	cytokine	titres,	compared	to	
placebo	when	analysed	based	on	primary	outcome	analysis	criteria.	There	was	
an	improving	trend	of		IFN	gamma		in	the	Pentoxifylline	group	when	values	at	
the	start	and	the	end	of	study	were	compared.		
	
Our	cohort	of	patients	had	a	very	high	incidence	of	infective	or	inflammatory	
origin	adverse	events.	These	adverse	events	would	in-turn	affect	the	cytokine	
titres	leading	to	high	variability	in	results.	Therefore	comparing	overall	trends	
with	averaged	scores	would	provide	a	better	picture	of	cytokine	levels	during	
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the	course	of	the	study.		On	comparing	the	variability	during	the	overall	study	
period,	IL-6	and	TNF	alfa	titres	showed	an	improvement	in	the	Pentoxifylline	
group.	The	difference	of	averaged	score	of	IL	-6	levels	achieved	statistical	
significance	when	compared	to	placebo	was	suggestive	of	reduced	
inflammatory	burden	in	the	Pentoxifylline	group.	The	anti-inflammatory	
cytokines,	TGF	beta	and	IFN	gamma	titres,	on	the	other	hand,	were	higher	in	
pentoxifylline	compared	to	placebo	group	when	comparing	the	overall	
variability	between	the	groups.	These	results	are	in	line	with	general	anti-
inflammatory	properties	of	Pentoxifylline.		
	
In	PEAR	study,	Pentoxifylline	has	been	shown	to	reduced	exposure	of	IL-6	and	
TNF	levels	for	a	period	of	six	months.	While	exposure	of	anti-inflammatory	
cytokines	such	as	TGF	beta	and	interferon	gamma	was	higher	in	Pentoxifylline	
during	the	study	period.		These	results	suggest	an	overall	reduction	in	the	
inflammatory	milieu	in	Pentoxifylline	patients.	
	
An	excellent	meta-analysis	by	Brie	et	al.	reviewed	the	effect	of	pentoxifylline	on	
inflammatory	markers	and	blood	pressure.	15	randomised	controlled	trial	
studies	with	16	treatment	arms	were	included	in	the	analysis.	Only	one	study	
included	patients	with	chronic	kidney	disease	[144]	while	the	rest	of	the	studies	
included	patients	with	known	cardiovascular	disease	and	associated	risk	factors	
such	as	diabetes	mellitus	and	associated	proteinuria.	There	was	conclusive	
evidence	on	the	effect	of	pentoxifylline	in	reducing	TNF	alfa	(Weighted	mean	
difference	(WMD):	-1.03	pg/ml,	95%	CI:	-1.54,	-0.51;	P<0.001	in	11	treatment	
arms)	and	hs	CRP	(WMD:	-1.39mg/l,	95%	CI:	-2.68,	-0.10;	P=0.034	in	5	
treatment	arms).	The	meta-analysis	could	not	demonstrate	any	significant	
reduction	in	IL-	6	titres	or	blood	pressure.			
	
However,	the	role	of	pentoxifylline	on	inflammatory	status	measured	by	
cytokines	in	advanced	CKD	patients	has	not	been	consistent.	Two	small	non	
randomised	studies	by	Cooper	et	al.	(3)	and	Ferrari	et	al.	(104)	demonstrated	a	
reduction	in	TNF-α,	interferon	gamma	and	IL-6	respectively.	Another	
uncontrolled	study	involving	15	ESA	resistant	stable	haemodialysis	patients	
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showed	pentoxifylline	associated	improvement	in	HB	levels	with	no	significant	
impact	on	TNF-α	titres	over	a	period	of	3	months	[145].		As	previously	
discussed,	double-blind	RCT	by	Gonzalez-Espinoza	et	al.	demonstrated	a	
statistically	significant	reduction	in	TNF-α,	IL-6	and	C	reactive	protein	18	
haemodialysis	patients	with	the	matched	controls.	Unfortunately,	the	outcome	
did	not	include	Hb	concentration	or	ESA	dose	follow	up.		Reduction	of	specific	
inflammatory	markers	may	not	necessarily	correlate	with	improvement	of	
overall	multifactorial	inflammation	unless	there	is	an	improvement	in	
associated	outcomes	such	as	improvement	in	ESA	resistance	or	cardiovascular	
risk	(or	surrogate	markers).	
	
The	PEAR	study	is	the	only	double-blind	placebo	controlled	study	to	investigate	
the	effect	of	Pentoxifylline	on	ESA	resistance,	surrogate	markers	of	
cardiovascular	risks	and	inflammation	status.	Once	again	similar	to	PET	CT	
imaging	studies	the	improving	trend	of	pro	and	anti-inflammatory	cytokines	is	
promising.		
	
13.3	Effect	of	pentoxifylline	on	CKD	progression	and	proteinuria:	a	review	
of	available	evidence	
	
The	effect	of	pentoxifylline	on	the	progression	of	CKD	and	proteinuria	has	
investigated	in	multiple	studies	over	past	2	decades.		The	beneficial	effect	of	
pentoxifylline	on	CKD	is	through	its	anti-inflammatory	activity	described	earlier	
in	the	thesis.	Pentoxifylline	has	been	shown	to	reduce	urinary	TNF	alfa	in	
proteinuric	diabetic	kidney	disease	[146]	and	suppresses	Monocyte	
chemoattractant	protein-1	in	non-diabetic	chronic	kidney	disease	[147].	In	in-
vitro	studies	by	Lin	et	al,	Pentoxifylline	has	also	been	shown	to	attenuate	renal	
progression	in	rats	with	remnant	kidneys	[148]and	reduce	renal	fibrosis	by	
blocking	SMAD	3/4	activated	transcription	of	connective	tissues	growth	factor	
[149].	
			
In	a	post	hoc	analysis	of	PREDIAN	trial	pentoxifylline	was	shown	to	be	
associated	with	decreased	serum	and	urinary	TNF	alfa	while	there	was	a	
significant	increase	in	serum	and	urinary	Klotho	after	1	year	of	therapy.	Kidney	
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is	the	main	source	of	klotho	and	its	level	is	significantly	decreased	in	CKD.	
Klotho	by	its	actions	as	a	humoral	factor	regulates	various	signalling	pathways	
with	beneficial	effects	towards	reducing	progression	of	CKD[150].		
	
Metanalysis	published	by	Jiang	et	al	showed	that	Pentoxifylline	significantly	
decreased	proteinuria	[weighted	mean	difference	(WMD)	-0.60	g/day	(95	%	CI	-
0.84	to	-0.36);	p	<	0.001]	compared	to	placebo	or	no-treatment	groups,	but	the	
reduction	in	proteinuria	was	not	statistically	significant	when	compared	to	ACE	
inhibitor	(captopril)	treatment.	The	decrease	of	glomerular	filtration	rate	was	
significantly	less	[WMD:	3.67	ml/min	(2.71-4.62);	p	<	0.001]	in	the	
pentoxifylline	group	than	in	the	controls.	This	study	included	12	trials	with	613	
participants.	Inclusion	criteria	was	prospective	randomised	and	non-
randomised	control	trials	including	patients	with	CKD	and	proteinuria.	
Minimum	follow	up	duration	was	2	months.	This	metanalysis	was	limited	by	
studies	with	high	degree	of	heterogeneity	with	respect	to	dose	and	duration	of	
pentoxifylline	administration,	staging	and	cause	of	CKD,	degree	of	proteinuria,	
usage	of	ACEI	and	ARBs.	Cause	of	CKD	in	majority	of	the	studies	was	diabetic	
nephropathy.	Majority	of	studies	were	classed	as	low	methodological	quality	
and	short	follow	up	duration[151].				
	
In	a	metanalysis	published	in	2016	by	Leporini	et	al,	pentoxifylline	was	shown	
to	improve	renal	function,	particularly	in	advanced	stages	of	CKD	in	studies	
with	long	follow	up	period.	The	improvement	in	proteinuria	was	more	evident	
in	patients	with	type	1	diabetes	and	with	high	degree	of	proteinuria.	This	
metanalysis	included	26	studies	with	1518	participants.	All	the	studies	analysed	
by	Jiang	et	al	were	also	included	in	this	metanalysis.		The	inclusion	criteria	were	
RCTs	and	quasi	RCTs	providing	information	on	the	effects	of	Pentoxifylline	on	
renal	endpoints	in	CKD	patients.	The	follow	up	period	in	the	studies	analysed,	
ranged	from	21	days	to	12	months	except	for	the	PREDIAN	study	which	had	
follow	up	period	of	24	months.	Rest	of	the	limitations	encountered	were	similar	
to	limitations	described	by	Jiang	et	al.	Pentoxifylline	was	shown	to	be	well	
tolerated	in	patients	with	CKD	[152].				
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RAAS	inhibition	with	ACE	inhibitor	or	an	ARB	has	been	proven	as	gold	standard	
treatment	for	delaying	the	progression	of	both	diabetic	and	non-diabetic	CKD	
for	many	years[153-155].	A	large	prospective	cohort	study	from	a	national	
insurance	registry-based	data	has	shown	beneficial	effect	of	pentoxifylline	in	
reducing	risk	for	composite	outcome	of	maintenance	dialysis	initiation	or	death	
in	patients	already	on	ACE	inhibitor	(HR,	0.94;	95%	CI	0.90-0.99)	or	ARB	
treatment	(HR,	0.91;	95%	CI,	0.85-0.97),	after	propensity	score	matching.	The	
study	enrolled	14,117	with	CKD	stage	5	(not	on	dialysis)	with	creatinine	>6	
mg/dl	and	hematocrit	<28%	and	on	pentoxifylline	treatment[156].		Another	
similar	national	insurance	cohort	study	published	by	Wu	et	al	demonstrated	
that	pentoxifylline	provided	comparable	beneficial	effect	when	combined	with	
ACE	inhibitor	or	ARB	therapy.	Pentoxifylline	was	also	shown	provide	greater	
benefit	in	slowing	down	progression	of	CKD	in	patients	with	chronic	kidney	
disease	stage	5	who	were	not	on	dialysis[157].		
	
A	metanalysis	published	in	2017	on	the	effect	of	pentoxifylline	therapy	
combined	with	ACE	inhibitor	or	ARB	on	CKD	progression	and	proteinuria	
demonstrated	protective	effect	of	pentoxifylline	in	patients	with	CKD	stage	(3-
5)	and	proteinuria	when	compared	to	ACE	inhibitor	or	ARB	therapy	alone.	
Combined	therapy	showed	significant	improvement	in	proteinuria	(SMD	-0.52;	
95%	CI	-0.90	to	0.15;	I2 = 68%)	and	significant	improvement	in	rate	of	CKD	
progression	(SMD	0.30;	confidence	limit	[Cl]	95%	CI	0.06	to	0.54;	I2 = 0%)	at	6	
months	of	therapy.	The	beneficial	effect	was	also	noted	at	9	to	12	months.		This	
metanalysis	included	11	randomised	controlled	studies	with	705	enrolled	
patients[158].	 
	
The	role	of	pentoxifylline	is	promising	in	CKD	progression.	However,	none	of	
the	studies	reported	hard	outcomes	such	doubling	of	serum	creatinine,	need	for	
renal	replacement	therapy,	cardiovascular	outcomes	and	mortality	as	primary	
outcome	measure.	Therefore,	well	planned	multi	centre	trials	are	needed	before	
pentoxifylline	could	be	recommended	to	be	used	in	CKD	patients.		
13.4	Safety	analysis		
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In	keeping	with	available	data	on	pentoxifylline	usage	in	haemodialysis	patients,	
drug	was	noted	to	be	safe.	None	of	the	adverse	events	in	the	pentoxifylline	
group	were	attributed	to	pentoxifylline.	As	predicted	in	this	patient	cohort,	
most	of	the	hospital	admissions	leading	to	SAEs	were	related	to	cardiovascular	
events.	
	
One	patient	each	in	both	groups	had	an	episode	of	gastrointestinal	bleeding.	The	
patient	in	the	pentoxifylline	group	was	thought	to	have	Mallory	Weiss	
syndrome	while	patient	in	the	placebo	group	had	not	taken	any	dose	IMP	
voluntarily	prior	to	episode	of	GI	bleed.	
	
There	was	a	significantly	higher	incidence	of	haemodialysis	blood	circuit	
clotting	leading	to	approximately	180	to	300	ml	blood	per	episode.	
Haemodialysis	blood	circuit	clotting	is	a	multifactorial	phenomenon.	Hence,	
pentoxifylline	therapy	cannot	be	directly	implicated	until	there	is	further	
evidence.	This	adverse	event	has	not	been	reported	in	prior	studies.		
	
There	was	a	statistically	significant	incidence	of	adverse	events	under	a	broad	
subgroup	of	neurological	system	(including	ophthalmology)	in	the	
pentoxifylline	group.	Out	of	a	total	15	reported	adverse	events,	5	adverse	events	
were	related	to	a	patient	undergoing	glaucoma	surgery,	2	adverse	events	were	
due	post	dialysis	headache,	1	due	to	presumed	transient	ischaemic	event,	2	due	
to	delirium	secondary	to	sepsis,	2	due	to	a	patient	diagnosed	with	carpal	tunnel	
syndrome,	1	patient	required	psychological	support,	1	patient	suffered	from	
cerebrovascular	accident	(CVA)	and	one	patient	was	diagnosed	with	length	
dependent	axonal	sensory	motor	polyneuropathy.		
	
The	haemodialysis	patient	cohort	with	ESA	hyporesponsiveness	has	a	
significantly	higher	comorbidities	leading	frequent	change	in	medications.	
The	majority	changes	in	medications	among	study	patients	included	phosphate	
binders,	activated	vitamin	D,	anti-anginals	and	antibiotics.	The	higher	degree	of	
adverse	events	in	the	control	group	Paragraph	4would	explain	greater	number	
of	medication	changes	in	this	group.	Relatively	less	number	of	adverse	event	in	
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pentoxifylline	group	could	be	explained	by	its	anti-inflammatory	and	
hemorheological	properties.		
	
There	were	two	deaths	in	the	pentoxifylline	group.	One	patient	had	sudden	
death	at	home	post	dialysis	session.	Cause	for	death	was	presumed	to	be	sudden	
cardiac	death	which	is	unfortunately	the	commonest	cause	of	sudden	death	
among	haemodialysis	patients	[159].	While	the	second	death	was	due	to	lower	
respiratory	tract	infection	as	a	complication	of	CVA.		
13.5	Conclusion	
	
Inflammation	is	increasingly	implicated	to	be	the	common	pathway	of	most	of	
the	cardiovascular	risk	factors.	Pentoxifylline	through	its	properties	of	
improving	blood	rheology	and	anti-inflammatory	activity	has	been	studied	in	a	
variety	of	conditions	associated	with	inflammation	and	blood	circulation.	A	
review	article	by	McCarty	et	al.	summarises	the	ongoing	research	and	benefits	
of	Pentoxifylline	on	a	variety	of	conditions	such	as	prevention	of	cardiovascular	
events	including	control	of	stable	angina,	prevention	of	stroke	and	transient	
ischaemic	attacks.	Similarly	there	is	growing	evidence	of	beneficial	effects	of	
Pentoxifylline	on	the	progression	of		chronic	kidney.	Perioperative	
administration	of	Pentoxifylline	administration	has	also	been	shown	decrease	
systemic	inflammatory	response	after	cardiopulmonary	bypass	surgery	as	
demonstrated	by	reduced	neutrophil	activation	and	pro-inflammatory	cytokine	
response.	Unfortunately,	most	of	the	trials	on	Pentoxifylline	are	relatively	small	
and	have	not	contributed	to	any	significant	change	in	clinical	practice.	
Pentoxifylline,	being	a	safe,	cheap	and	widely	available	non-specific	anti-
inflammatory	agent	is	likely	to	continue	as	a	compound	of	immense	interest	for	
future	research	[160].		
	
In	 the	 current	 scenario,	 there	 is	 no	 proven	 specific	 intervention	 available	 to	
improve	 Cardiovascular	 outcomes	 in	 haemodialysis	 patients.	 The	 available	
evidence	 which	 is	 driven	 from	 small,	 short-term	 studies	 has	 not	 led	 to	 any	
significant	change	in	practice	in	the	CKD	population.	Therefore,	targeting	arterial	
wall	 inflammation	 in	 long-term	event	driven	 studies	may	 result	 in	 substantial	
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evidence	and	greater	generalizability	of	findings.		
	
Although	outcomes	are	statistically	 insignificant	yet	 the	data	 from	PEAR	study	
provides	 an	 insight	 into	 the	 severity	 of	 incidental	 atherosclerotic	 plaque	
inflammation	and	impact	of	non-specific	anti-inflammatory	drug	intervention	in	
high-risk	haemodialysis	patients	for	the	first	time.	
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STUDY SUMMARY/SYNOPSIS 
 
TITLE A Single-Centre randomized placebo controlled, double 
blinded study of Pentoxifylline in End-Stage Renal 
Disease Patients with Erythropoeitin resistance 
SHORT TITLE PEntoxifylline in Anaemia Resistant to erythropoietin 
(PEAR) 
Protocol Version 
Number and Date 
 
Protocol PEAR_29th Oct.2013_v 10-1 
Methodology 
 
A Single-Centre randomized placebo controlled, double 
blinded study  
Study Duration 
 
24 months 
 
Study Centre 
 
Barts Health NHS Trust 
Rationale Unfortunately, a considerable proportion of ESRD patients 
exhibit a suboptimal haematologic response to ESA. In 
some patients, this has been attributed to elevated levels of 
inflammatory cytokines including TNF-a and IFN-g. 
Pentoxifylline specifically inhibits T-cell production of 
TNF-a and IFN-g and in a small uncontrolled study 
suggested this drug was a useful adjunct for patients with 
ESA resistance. 
 
Objectives 
 
To study the effects Pentoxifylline in ESA resistant ESRD 
patients on haemodialysis  
 
Endpoints:  
The primary study end point is the ESA requirement 
relative to the Hb level. 
 
Secondary endpoints include: 
• Safety analysis  
• Hb values and ESA doses after 6 months of 
treatment. 
• Blood sampling will be performed at the start of 
each hemodialysis session every month.   
• Cardiovascular imaging will be performed at 
baseline and at 6 months. The effect IMP has on 
the following cardiovascular parameters will be 
examined: 
o mean target-to-background ratio across a 
substantial portion of artery (typically 
aorta, supraaortic vessels and femoral 
arteries) using 18-FDG-PET (time-of-
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flight). This will allow us to assess whether 
IMP has an anti-inflamatory effect on the 
blood vessels 
o vascular stiffness measures (e.g. aortic 
distensibility at three levels of aorta 
(mmHg-1), pulse wave velocity (m/s) and 
carotid distensibility (mmHg-1))using 
magnetic resonance (MR) imaging.  
o Measures of systolic and diastolic function, 
using cardiac MR (CMR) tagging 
techniques (strain (%) and strain-rate (s-1)) 
 
 
Phase of the Trial 
 
II 
Number of 
Subjects/Patients 
100.  
 
Main Inclusion Criteria 
 
Inclusion Criteria 
• Be able to read and understand the written consent 
form, complete study-related procedures, and 
communicate with the study staff; 
• Willing to comply with study restrictions; 
• Between 18 and 85 years of age (inclusive). 
• Diagnosis of clinically stable ESRD, as determined 
by the investigator; 
• Requiring regular dialysis therapy for at least 12 
weeks prior to first administration of study agent; 
 
• Receiving treatment with IV or SC erythropoietin 
receptor agonist at least weekly (ie exclude Micera 
or other ESAs given fortnightly or monthly) for a 
minimum of 8 weeks prior to administration of 
study agent, requiring doses to remedy EPO-
resistance (requiring greater than or equal to 
6000iu equivalent of EPO per week or if ESA 
resistance index is greater than or equal to 6.5iu 
/kg/wk/g Hb for equivalent EPO dose), with 
evidence of stable hemoglobin levels 
 
• Baseline hemoglobin values between 9.0 and 12.0 
g/dL before entering the study; 
• CRP levels of ≥5 mg/L 
Statistical 
Methodology and 
Analysis 
 
We expect that the mean of the run-in and last 2 valid 
visits will be used for primary end-point analyses.  
 
Primary Endpoint Analysis: We shall be compare 
dEPO/kg requirement between the 2 groups using 
unpaired student t-test. 
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Glossary of Terms and Abbreviations 
 
° C Degree Celsius  
μg  Microgram  
AE Adverse Event  
ALT  Alanine aminotransferase  
AP Alkaline phosphatase  
AR Adverse Reaction 
AST  Aspartate aminotransferase  
BHT Barts Health Trust 
BUN Blood nitrogen urea 
CK Creatine kinase 
CKD Chronic Kidney Disease 
CMR Cardiac Magnetic Resonance Imaging 
CRF  Case Report Form  
(hs-)CRP (high sensitive) C- reactive protein 
CRF Clinical Research Form 
CSR  Clinical Study Report  
CV Cardiovascular 
DM Diabetes Mellitus 
DNA Deoxyribonucleic acid 
EC  European Community  
ECG  Electrocardiogram  
EMEA  European Medicines Agency  
EOT  End of Trial  
EPO Erythropoietin  
ESA Erythropoietin Stimulating Agents 
ESRD End Stage Renal Disease 
FBC Full blood count 
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
Glc glucose 
Hb Haemoglobin 
HD Haemodialysis (inclhaemodiafiltration or haemofiltration) 
hr(s) Hour(s) 
ICF Informed Consent Form  
ICH  International Conference on Harmonization  
IEC  Independent Ethics Committee  
IMP  Investigational Medicinal Product  
INF-g Interferon-g 
IP Investigational Product  
IRB  Institutional Review Board  
ITT Intention to Treat 
iu International units 
iv intravenous 
kg  Kilogram  
L Litres 
LFT Liver Function Tests 
MCH(C)  Mean Corpuscular Hemoglobin (Concentration)  
MCV  Mean Corpuscular Volume  
MedDRA Medical Dictionary for Regulatory Activities  
mg milligrams 
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MHRA Medicine Health Regulatory Authority 
mL Milliliter  
NA Not applicable  
NCS  Not clinically significant  
OTC  Over the counter (non-prescription medication)  
PET-CT Positron emission tomography – computed tomography 
PIS Patient Information Sheet 
PTH Parathyroid hormone 
RBC  
R&D 
Red Blood Cell  
Research and Development Department 
RLH Royal London Hospital 
SAE  Serious Adverse Event  
sc Subcutaneously 
SPC Summary of Product Characteristic 
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TNF-a Tumour Necrosis Factor-a 
TMF  Trial Master file  
Tsats Transferrin saturation 
U&E Urea & Electrolytes 
VS Vital signs  
WBC  White Blood Cell  
WHO  World Health Organization  
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1 Introduction 
 
 
1.1 Background  
Pentoxifylline (used for twenty years in the treatment of peripheral and cerebral vascular diseases),  
has potent haemorrheological and anti-inflammatory properties (secondary to inhibition of 
phosphodiesterases)  and (in 2  small, prospective, non-randomized phase 2a studies)improved 
haemoglobin levels in CKD patients with ESA-resistant anaemia.  
 
The use of ESA in resistant patients is very expensive: Twenty % of the patients on dialysis have 
ESA-resistance, which is a surrogate marker for excessive, all-cause and CV mortality. There are no 
specific therapeutic strategies available to these patients. Moreover, the health economic 
consideration for the treatment of ESA-resistant patients with ever increasing amounts of ESAis 
very significant. In BLT, the cost for ESA alone for 250 ESA-resistant patients amounts to £ 2.5 
Million per year which is the same cost as for the remaining 950 ESA-sensitive patients.  
 
If the proposed strategy is successful in ESA-resistant dialysis patients, then it may also be 
employed  in so-called ESA-sensitive’ patients in order to lower their ESA-requirements (and to 
make them ‘more sensitive’). 
 
1.2 Investigational Medicinal Product  
Pentoxifylline may also have other pleiotropic effects that may be due to direct action or mediated 
by enhanced tissue-protective effects of ESA that has been well documented. We are particularly 
interested in any possible synergistic actions of the direct anti-inflammatory action of pentoxifylline 
and ESA that may be beneficial to the vascular abnormalities that are found in ESRD patients.  
 
In fact, sudden cardiac and other cardiovascular events are the most common causes of death in 
ESRD patients. Surrogate markers of vascular abnormalities that have been found to correlate 
closely to morbidity and mortality include vascular calcification, pulse wave velocity and impaired 
vasodilation. 
 
We therefore wish to examine if Pentoxifylline is beneficial in ESRD patients with evidence of 
ESA-resistance. We wish to examine if the treatment improves ESA response and if we can detect 
any improvements in biochemical &radiological surrogate markers of vascular health. 
 
1.3 Preclinical Data  
SmPC for Pentoxifylline states, “Nothing of clinical relevance” for pre-clinical safety data. 
 
1.4 Clinical Data  
Pentoxifyllineis a licenced treatment for peripheral vascular disease because of its potent 
hemorrheological properties. It also has anti-inflammatory properties, mediated viainhibition of 
phosphodiesterase. 
 
Beneficial effects have been reported in idiopathic dilated cardiomyopathy, childhood type 1 
diabetes, and systemic vasculitis. Modest clinical effects have also been observed in rheumatoid 
arthritis. 
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Two small, prospective, non-randomised studies have demonstrated that: 
• Pentoxifyllinemay significantly improve haemoglobin levels in chronic kidney disease 
patients with ESA-resistant anaemia. Navarro et al treated 7 anaemic patients not on dialysis 
with oxpentifylline (oral 400 mg daily) for 6 months.  
• Haemoglobin levels significantly increased from 9.9 ± 0.5 to 10.6 ± 0.6 g/dL (p < 0.01). 
Similarly, Cooper et al used the same dose for 4 months in 16 EPO-resistant anaemic 
dialysis patients. Among the 12 patients who completed the study, mean haemoglobin 
concentration increased from 9.5 ± 0.9 to 11.7 ± 1.0 g/L (p = 0.0001). 
 
1.5 Rationale and Risks/Benefits  
The following are side-effects listed in the SmPC for Pentoxifylline: 
These adverse reactions have been reported in clinical trials or post-marketing. Frequencies are 
unknown.  
System Organ Class Adverse Reaction 
Investigations  Transaminases increased  
Cardiac disorders  Arrhythmia, Tachycardia, Angina Pectoris  
Blood and lymphatic system disorders  Thrombocytopenia  
Nervous system disorders  Dizziness, headache, meningitis aseptic*  
Gastrointestinal disorders  Gastrointestinal disorder, Epigastric discomfort, 
Abdominal distension, Nausea, Vomiting, 
Diarrhoea  
Skin and subcutaneous tissue disorders  Pruritus, Erythema, Urticaria, Hot flush  
Vascular disorders  Haemorrhage**, Hypotension  
Immune system disorders  Anaphylactic reactions, Anaphylactoid reaction, 
Angioedema  
Hepatobiliary disorders  Cholestasis  
Psychiatric disorders  Agitation, Sleep disorder  
Respiratory disorders  Bronchospasm  
Description of selected adverse reactions 
* Reports of aseptic meningitis were predominantly in patients with underlying connective tissue 
disorders  
** A few very rare events of bleeding (e.g. skin, mucosa) have been reported in patients treated 
with Trental with and without anticoagulants or platelet aggregation inhibitors. The serious cases 
are predominantly concentrated in the gastrointestinal, genitourinary, multiple site and surgical 
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wound areas and are associated with bleeding risk factors. A causal relationship between Trental 
therapy and bleeding has not been established. Thrombocytopenia has occurred in isolated cases. 
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2 Trial Objectives and Design 
2.1 Trial Objectives  
To study the effects Pentoxifylline in ESA resistant ESRD patients on haemodialysis 
 
Endpoints:  
Primary study endpointis the ESA requirement relative to the Hb level. 
 
Secondary endpoints include: 
• Safety analysis  
• Hb values and ESA doses after 6 months of treatment. 
• Cardiovascular imaging will be performed at baseline and at 6 months. The effect IMP has 
on the following cardiovascular parameters will be examined: 
o mean target-to-background ratio across a substantial portion of artery (typically 
aorta, supraaortic vessels and femoral arteries) using 18-FDG-PET (time-of-flight). 
This will allow us to assess whether IMP has an anti-inflamatory effect on the blood 
vessels 
o vascular stiffness measures (e.g. aortic distensibility at three levels of aorta (mmHg-
1), pulse wave velocity (m/s) and carotid distensibility (mmHg-1))using magnetic 
resonance (MR) imagin 
o Measures of systolic and diastolic function, using cardiac MR (CMR) tagging 
techniques (strain (%) and strain-rate (s-1)) 
 
 
2.2 Trial Design  
Study Design: This is a single-centre, randomised double blinded placebo controlled trial of100 
patients with ESRD on dialysis. Patients will receive either Pentoxifylline 400mg once a day or 
placebo for 6 months with a further 2 month follow-up after therapy is stopped. Randomisation will 
be stratified for diabetes mellitus status and ESA requirement (adjusted for Hb). 
 
Run-in Period: All subjects will undergo a run-in period of 2 weeks so that baseline haemoglobin 
levels can be measured once every week (+/- 3 days) so that we will have 3 values prior to starting 
IMP or placebo. 
 
Drugs and Dosages: Study drug will be given orally and at a dose of 400mg once a day. This dose 
was previously shown to be well-tolerated in ESRD patients and could suppress ex-vivo T-cell 
generation of TNF-a and IFN-g. 
 
The dose of ESA for each patient will remain unchanged unless consecutive Hb values are <10.0 or 
>12g/dl (or for clinical indications). This reflects the Local Barts Health NHS Trust Renal Protocol 
for managing Hb / ESA dose. Intravenous iron supplementation will be given in accordance with 
the Local Barts Health NHS Trust Renal  protocol. These protocols are listed in section 5.  
 
2.3 Study Scheme Diagram  
 
 
 
PEAR 
Protocol: PEAR_14Oct2015_v11-1  Page 16 of 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 week Run-In Period 
6 month Treatment Period 
Safety/Response Assessment Safety/Response Assessment 
Patient Written 
Informed Consent 
Patient 
Screening/Enrollment 
Procedures 
Randomisation Arm A 
Arm B 
2 week Run-In Period 
6 month Treatment Period 
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3 Subject Selection 
3.1 Number of Subjects and Subject Selection  
We shall aim to recruit and treat a maximum of 100 patients (in each group) with end-stage renal 
disease established on dialysis. Although the power calculation below suggests we only require 30 
patients (in each group) to reach the end of the 6 month treatment to achieve the statistical power 
detailed below, there is a very high drop out rate because of death and transplantation. We therefore 
do not expect to recruit more than 100 patients/group and it is possible that 30/group patients will 
be sufficient if drop-out rates are lower than expected. 
 
Patients with ESA resistance defined as receiving treatment with IV or SC erythropoietin receptor 
agonist at least weekly (ie exclude Micera or other ESAs given fortnightly or monthly)for a 
minimum of 8 weeks prior to enrolment, requiring greater or equal to 6000 IU equivalent of EPO 
per week to achieve stable hemoglobin levels 
 
 
All subjects will be screened for eligibility within 28 days before enrollment, based upon data 
obtained from the most recent clinical visit(s). The population will consist of patients of either 
gender, aged 18-85 years (inclusive). 
 
3.1.1 Power calculation 
From internal audit data on ESA usage, we assume the average dose of ESA will be 12000iu/week 
(with SD=500) 
If the placebo group have Hb=10g/dl, the ESA/Hb ratio = 1200 
 
The study by Cooper et al showed that 4 months treatment increased Hb levels by 25%. 
We wish to power this study to demonstrate that IMP will increase ESA response by 5% 
 
If we assumed the SD for ESA/Hb = 100, this will mean that for an alpha level of 5% (95%CI) and 
a beta level of 5% (statistical power of 95%) we shall need 30 patients in each group. We assume 
that there will be a 50% drop out (transplantation and patient withdrawal) so we plan to recruit no 
more than 100 patients/group 
 
3.2 Inclusion Criteria  
Eligibility for study participation will be based upon data obtained from the most recent clinical 
visit(s). In addition, recent medical history will be obtained prior to enrolment. To be eligible for 
study participation, subjects must meet all of the following criteria: 
 
• Be able to read and understand the written consent form (with the help of a translator if 
necessary), complete study-related procedures, and communicate with the study staff; 
• Willing to comply with study restrictions; 
• Between 18 and 85 years of age (inclusive). 
• Diagnosis of clinically stable ESRD, as determined by the investigator; 
• Requiring regular dialysis therapy for at least 12 weeks prior to first administration of study 
agent; 
• Last hemoglobin value at time of consent between 9.0 and 12.0 g/dL before entering the 
study; 
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• Receiving treatment with IV or SC erythropoietin receptor agonist at least weekly (ie 
exclude Micera or other ESAs given fortnightly or monthly) for a minimum of 8 weeks prior 
to administration of study agent, requiring doses to remedy EPO-resistance (requiring 
greater than or equal to 6000iu equivalent of EPO per week or if ESA resistance index is 
greater than or equal to 6.5iu /kg/wk/g Hb for equivalent EPO dose), with evidence of stable 
hemoglobin levels 
 
• Serum folate and vitamin B12 levels are normal and T-sats>25% and / or ferritin > 200 
mcg/l  (last result prior to consent). 
 
 
3.3 Exclusion Criteria  
Eligibility for study participation will be based upon data obtained from the most recent clinical 
visit(s). In addition, recent medical history will be obtained prior to enrollment. If a subject displays 
any of the following criteria, he or she may not be enrolled in the study: 
 
• Clinically relevant abnormal history of physical and mental health other than conditions 
related to chronic kidney disease of patient, as determined by medical history taking (as 
judged by the investigator); 
• Clinically relevant abnormal laboratory results, ECG, vital signs, or physical findings other 
than conditions related to chronic kidney disease of patient (as judged by the investigator); 
• Subject has uncontrolled hypertension (in the opinion of the clinician); 
• Subject is unable to refrain from the use of disallowed concomitant medication from one 
week prior to the first study drug administration until follow-up assessments (see section 
3.3); 
• Participation in an investigational drug trial in the 3 months prior to administration of the 
initial dose of study drug  
• Subject has undergone major surgery within 3 months prior to screening; 
• Any other condition that in the opinion of the investigator would complicate or compromise 
the study (e.g. known haemoglobinopathy), or the well being of the subject. 
• Females of child-bearing potential who are not willing to use contraception for the duration 
of the study. 
• Females who are breast feeding. 
• Subject is known hypersensitivity to the active constituent, pentoxifylline other methyl 
xanthines or any of the excipients.  
• Subjects with recent cerebral haemorrhage, extensive retinal haemorrhage, acute myocardial 
infarction and severe cardiac arrhythmias 
• Contraindications to magnetic resonance imaging (e.g. severe claustrophobia, pacemaker, 
defibrillators, etc.) 
• Subjects who are on (or are due to start) immunosuppressive and anti-inflammatory drugs 
except Asprin at a dose of ≤ 300mg/d. 
 
3.4 Criteria for Premature Withdrawal  
Systematic noncompliance may culminate in a patient’s withdrawal from the study.  
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We would perform the end-point tests (blood and radiology) if the patient agrees prior to formal 
withdrawal from the study. 
 
The 1 month safety follow-up period (including blood tests) will also be performed if the patient 
agrees. 
 
4 Investigational Medicinal Products (IMPs) 
IMP: Overencapsulated Pentoxifylline,  
Placebo: matching overencapsulated cellulose 
 
4.1 Formulation of IMP 
Capsules 
 
4.2 IMP Supply  
IMP and placebo are manufactured and supplied by Mawdsleys.  
 
 
4.3 Prescription of IMP  
A specifically designed Clinical trial prescription will be used for this study.  
4.4 Preparation and Administration of IMP  
The IMP will be given orally at a dose of Pentoxifyline 400mg once a day. 
 
4.5 Packaging and Labelling of IMPs  
A specifically designed Clinical trial label will be used for this study  
4.6 Accountability/Receipt /Storage and Handling of IMP  
The supply of IMP and Placebo will be shipped to Pharmacy at BHT. 
Pharmacy will store and dispense study drugs for patients. 
Drugs will be collected by Research Nurse or delegated investigator and handed to patients in 
study. 
Drug accountability: All treatments for the study will be stored in the Department of Pharmacy of 
BHT until dispensing when it is required.  
 
 
4.7 Dispensing of IMP  
Pharmacy at BHT will dispense IMP 
 
4.8 Prior and Concomitant Therapies  
During the study the patients will continue all their regular therapy. Initiating a drug with known 
anti-inflammatory properties will be avoided. If this has to be done because of the clinical condition 
of the patient, study drug administration will be discontinued, and replacement of the patient may 
be considered. Concomitant medications that are to be expected includeing iron therapy on a regular 
basis to maintain Tsats>25% and/or ferritin >200, phosphate binders, statins, medication to treat 
hyperparathyroidism, antihypertensive agents and other drugs to treat known complications of renal 
failure. 
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In general, concomitant medication resulting in non-eligibility includes all medication that in the 
opinion of the investigator would complicate or compromise the study or interfere with the study 
objectives. 
 
 
4.9 Return/Recall or Destruction of IMP   
Unused drugs will be collected from patients. Accountability by pill counting will be performed  by 
the reseach team and drugs then returned to pharmacy for destruction. 
 
The IMP is provided by Mawdsley who have a standard recall procedure. 
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5 Study Procedures 
5.1 Informed Consent Procedures 
Patient information sheet and consent form are separate to this protocol. 
 
A member of the clinical team looking after the patient will approach the potential subject. This will 
usually be done whilst they are undergoing their regular dialysis or waiting for their dialysis. 
Patients attend x3/wk for their dialysis, so we would expect them to consider the proposal and if 
they agree to sign the informed consent (this may be performed either by the clinical team member 
or a member of the research team). Consent will be countersigned by PI or Local Collaborator 
delegated by the PI on the delegation log prior to any treatment being given. And that any Nurse 
undertaking this role will be trained to do so and evidence of this will be in the TMF 
 
Patients attend hemodialysis x3/week indefinitely so it is possible for patients to take days or even 
weeks to decide. 
 
Use of independent  translators will be permitted. 
 
Patients generally attend hemodialysis x3/week until they die, get transplanted or move away (but 
the last of these is relatively rare). We therefore believe there is opportunity and it will be easy for 
the research team to feedback information to patients. 
 
5.1 Screening Procedures  
A member of the clinical  care team will use the electronic Renal Database to identify potential 
subjects. 
 
The screening/identification will be performed by a member of staff who has clinical 
responsibilities for renal patients, particularly hemodialysis patients 
 
5.2 Randomisation Procedures (if applicable)  
Allocation ratio and any stratification factors (with levels): 1:1 randomisation stratified for 
Diabetes status and and ESA requirement (adjusted for Hb). 
 
Generation of randomisation codes (manual or automated process): Patients will be allocated 
to study drug according to recruitment sequence. The drugs sequence will be been randomized by 
the IMP supplier. Method of randomisation by IMP supplier will be described in a separate  
randomisation procedure document. 
 
Individual responsible for randomisation and documentation: Study CI or delegated research 
person will record the recruitment number during the consent procedure. 
 
Access to code break in an emergency: Code Break envelopes will be kept in  a locked  Office , 
that can be accessed after contacting nominated Research Persons. 
 
5.3 Schedule of Treatment for each visit  
IMP: Oral Pentoxiphylline 400mg once a day  
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Placebo: Equivalent capsule once a day 
 
5.4    Schedule of Assessment  
Subjects will attend their Dialysis Unit (run by BHT )for their standard hemodialysis on Day 1 
(visit 1).Subjects will be entered in a run-in period for 2 weeks where biochemistry and 
haematology will be measure weekly (+/-3 days) to establish baseline. All blood tests will be taken 
prior to a dialysis session and preferably after an inter-dialytic gap of 48hrs. If the ESA dose 
changes in the run-in period, the patients will be withdrawn.  
 
Patients will be randomized if the subject meets the inclusion criteria: Subjects will return to the 
dialysis unit,according to their normal dialysis schedule.During weeks 3-29,subjects will be treated 
with either IMP or placebo. These will be provided to the patients during the monthly visits. 
Subjects will be asked to return unused medication for compliance check. 
 
Haematology and Chemistry will be checked every month (+/- 7 days) – see schedule of blood tests. 
All blood tests will be taken prior to a dialysis session and preferably after an inter-dialytic gap of 
48hrs. These tests will include: Hb, Hct, CRP. These monthly blood tests will be taken as part of the 
patients’ standard care and performed in the same local lab as the “additional” “Run-in” (weekly) or 
“Off-Treatment” (fortnightly) blood tests (that are restricted to Hb, Hct and CRP). 
 
After week 29, treatment (IMP or placebo) will be stopped. Subjects will be asked to return any 
remaining unused medication. Haematology and Chemistry will be checked every fortnight (+/- 3 
days) – see schedule of blood tests. All blood tests will be taken prior to a dialysis session and 
preferably after an inter-dialytic gap of 48hrs. This “Off-Treatment Follow-up Period” will last for 
1 month. 
 
5.4.1 Screening 
The investigator or study physician will thoroughly explain the nature and purpose of the study to 
each subject, as well as the associated procedures and any expected effects and adverse reactions 
before any study-specific screening procedures are conducted. The subject will be provided with a 
Subject Information Sheet and given sufficient time and opportunity to inquire about the details of 
the study and to decide whether to participate. If he or she wishes to participate in the study, the 
subject will be asked to sign and date an Informed Consent Form (ICF). Study eligibility will be 
based on investigation of the subject status, after inspection of the following parameters: 
 
§ Check of inclusion and exclusion criteria (as described in this protocol); 
§ Demographics, including gender, race; 
§ Complete medical history from 30 days before screening; 
§ Hematology, coagulation, clinical chemistry of most recent clinical visit will be recorded; 
§ Plasma CRP level. 
§ ESA dose 
 
Selected subjects who proved to be eligible candidates after investigation of subject status will be 
enrolled in the study. 
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5.4.2 Study scheme 
 
Procedure  
 
Week: 
Run-in: weeks 
(weekly visits) 
Treatment Period 
(monthly visits) 
Non-Treatment Period 
(Fortnightly visits 
including end of study 
visit) 
-2 -1 1 - 26 26-30 
24hr Urine collection  x  x 
Hematology, Clinical 
Chemistry 1 
X X  X 
Blood to be taken for storage 
if separate consent obtained 
X X X X 
Drug Administration    X  
Vital signs 2 X X X X 
Adverse Events 3   ß--------------------------------------à 
Concomitant medication 3   ß--------------------------------------à 
1Hematology and clinical chemistry assessments before dialysis. 
2Including pulse rate and supine BP pre-dialysis. 
3Adverse events and concomitant medication (including the dose of ESA) will be collected from signing the ICF at 
screening until last visit. 
 
Consent will be obtained prior to the start of Visit 1 dialysis. 
 
 
Visit 1 (week -2) 
• Arrival at Barts Health Trust (time of day dependent on hemodialysis scheme) 
• Vital signs 
• Signs and symptoms recording (pre-dialysis, pre-study medication); 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs. 
• Hematology, clinical chemistry and hs-CRP; 
• Haemodialysis; 
 
Visit 2 (on week -1) 
• Arrival at BHT (time of day dependent on hemodialysis scheme) 
• Vital signs; 
• Signs and symptoms recording (pre-dialysis, pre-study medication); 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs.  
• Hematology, clinical chemistry and hs-CRP, serum for -70C and DNA; 
• Haemodialysis; 
• Give bottle for patient to collect 24hr urine output (to be collected at next dialysis) 
 
RANDOMISATION will be performed prior to visit 3 
 
Visits 3-8; monthly i.e. weeks 1-26 
• Arrival at BHT (time of day dependent on hemodialysis scheme) 
• Vital signs; 
• Signs and symptoms recording (pre-dialysis, medication); 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs. 
• Hematology, clinical chemistry and hs-CRP, serum for -70C and DNA(monthly) 
• Haemodialysis; 
• Collect unused medication and give IMP/placebo for another month. 
• Additional visits may be made by the investigators particularly during the first month to ensure 
patient compliance and to record any AR. These visits will be recorded in the CRF by the most 
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recent visit number followed by a letter suffix (e.g. visit 3-A or 3-B). 
 
Visit 9 
• Arrival at BHT (time of day dependent on hemodialysis scheme) 
• Vital signs;12-lead ECG (pre-dialysis); 
• Signs and symptoms recording (pre-dialysis, medication); 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs.  
• Hematology, clinical chemistry and hs-CRP, serum for -70C and DNA(monthly) 
• Hemodialysis; 
• Give bottle for patient to collect 24hr urine output (to be collected at next dialysis) 
 
 
Visit 10 - 11; fortnightly i.e. weeks 28 - 30 
• Arrival at BHT (time of day dependent on hemodialysis scheme) 
• Adverse Event recording including any medication changes; 
• All blood tests will be taken prior to a dialysis session and after an inter-dialytic gap of 48hrs.  
• Hematology, clinical chemistry and hs-CRP, serum for -70C and DNA(monthly) 
• Hemodialysis; 
 
 
Protocol for Intravenous Iron Dosing (Venofer, iv) – Local Protocol 
 
Ferritin Dose of iv Fe Frequency 
<100 100mg Twice a week 
100-200 100mg Once a week 
200-500 100mg Once every 2 weeks 
>500  nil 
 
 
Protocol for ESA Dosing (Local Protocol): 
Target Hb range will be 10 -12g/dl. ESA dose will be increased or decreased by 25-50% depending 
on Hb (2 consecutive readings) 
Hb (g/dl) Dose change of ESA 
>15 Stop ESA and venesect 1 unit blood or discard 1 HD circuit aft HD 
14-15 Nil – ESA stopped 
13-14 Cut 50% 
12-13 Cut 25% 
9 – 10 Increase 25% 
<9 Increase 50% 
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5.5 Follow up Procedures  
Haematology and Chemistry will be checked every fortnight (+/- 3 days) – see 
schedule of blood tests. All blood tests will be taken prior to a dialysis session and 
preferably after an inter-dialytic gap of 48hrs. This “Off-Treatment Follow-up Period” 
will last for 1 month. 
5.6 Laboratory Assessments  
“Standard Lab” Tests for the study will be: Hb, Hct and CRP. 
Cytokine profiles and DNA telomere lengths will also be measured. 
However, we note that the standard care of HD patients at Barts Health Trust undergo 
regular monthly blood tests that include these and more extensive “LFT” and “Bone 
Profiles”. These results will be available to the researchers. 
 
Parameter Vacutainer Volume per 
sample (mL) 
Number of 
samples 
Total volume 
(mL) 
Clinical biochemistry 1x serum 7 12 84 
Blood to be taken if 
separate consent given 
permitting storage of 
blood 
 
1xserum 7 12 84 
1x EDTA 3.5 12 42 
Haematology 1x EDTA 3.5 12 42 
 
 
 
TOTAL 
VOLUME 
 
252 
 
 
5.7 Radiology Assessments  
Cardiovascular imaging will be performed at baseline and at 6 months. The effect 
IMP has on the following cardiovascular parameters will be examined: 
• mean target-to-background ratio across a substantial portion of artery 
(typically aorta, supraaortic vessels and femoral arteries) using 18-FDG-PET 
(time-of-flight). This will allow us to assess whether IMP has an anti-
inflamatory effect on the blood vessels 
• vascular stiffness measures (e.g. aortic distensibility at three levels of aorta 
(mmHg-1), pulse wave velocity (m/s) and carotid distensibility (mmHg-
1))using magnetic resonance (MR) imaging. 
For further details, refer to Appendix 1 and 2 
 
5.8 End of Study Definition  
This will be considered to be after the last visit of the last participant and 6 months 
after analysis of end-point evaluations. 
 
5.9 Procedures for unblinding (if applicable)  
Emergency Unblinding Procedures including Out of Hours: 
• Uncoding envelopes will be kept in the Renal Office (locked). Permission 
to access will be given by: Prof M Yaqoob or Dr S Fan or Research Clinic 
Fellow (to be appointed). Contact details will  be with switchboard at Barts 
Health NHS Trust.  
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• After a patient is unblinded, the patient will be given an option to undergo 
the end-point tests and the 1 month “off drug” follow up. 
 
Unblinding should only occur in the case of a medical emergency. 
 
5.10 Subject Withdrawal  
Subjects can leave the study at any time for any reason if they wish to do so without 
any consequences. The responsible investigator can also withdraw a subject if 
continuing participation is in his opinion deleterious for the subject’s well being. 
Subjects can also be withdrawn in case of protocol violations and non-compliance (as 
deemed significant by the investigators).  
 
5.11 Data Collection and Follow up for Withdrawn Subjects  
In case of withdrawal because of severe or serious adverse event haematological, 
blood chemistry and urine laboratory tests or other special examinations may be 
performed. 
 
Dropouts will not be re-included in the study. Their inclusion and treatment numbers 
must not be re-used. Dropouts due to withdrawal of informed consent or non-study 
drug related events might be replaced in order to obtain a sufficient number of 
subjects completing the study. The possible need for replacement of dropouts will be 
discussed by the primary investigator and responsible medical officer of the Sponsor.  
 
When a subject withdraws from the study, the subjects will be asked if they are 
willing to continue in the 1 month “non-treatment” study period. When a subject 
withdraws, the second radiological assessment may be conducted with patient 
consent. However, the patients are made aware in the PIS that audits of patients’ 
blood results are continuously performed as part of standard  NHS care within the 
Renal Unit at Barts Health Trust  and this will continue. 
 
 
All adverse events and concomitant medication will be entered in the CRF. 
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6 Laboratories (if applicable)  
6.1 Local Laboratories  
Laboratory for the Biochemistry and Haematology tests will be the Pathology 
Department at Barts Health NHS Trust. 
 
 
 
6.2 Sample Collection/Labelling/Logging  
The laboratory will be blinded to the study drug allocation. Patient samples will not 
be anonymised or coded. The results of study biochemistry and haematology tests will 
be available to clinicians looking after the patients for clinical governance reasons. 
 
Blood (if separate consent if given) will be stored at -70C (with a target of 60mins 
between phlebotomy and storing at -70C). 
Standard biochemical and haematological samples will be kept at room temp and 
delivered through the hospital portering system. 
 
All blood tests will be taken prior to a dialysis session and preferably after an inter-
dialytic gap of 48hrs.  
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7 Pharmacovigilance  
7.1    General Definitions 
7.1.1 Adverse Event (AE)/ Adverse Reaction (AR) / 
Serious Adverse Event (SAE) or Serious 
Adverse Reaction (SAR) 
Adverse events are defined as any undesirable experience occurring to a subject 
during a clinical trial, whether or not considered related to the investigational drug. 
All adverse events reported spontaneously by the subject or observed by the investiga-
tor or his staff will be recorded on the adverse event data collection form. The 
intensity of these adverse events will thereby be graded by the investigator on a three-
point scale as defined below: 
 
Mild discomfort noticed but no disruption of normal daily activity 
Moderate discomfort sufficient to reduce or affect normal daily activity 
Severe inability to work or perform daily activity 
 
The chronicity of the event will be classified by the investigator on a three-item scale 
as defined below: 
 
Single occasion single event with limited duration 
Intermittent several episodes of an event, each of limited duration 
Persistent event which remained indefinitely 
 
For each adverse event the relationship to drug (definite, probable, possible, 
unknown, definitely not) as judged by the investigator as well as eventual actions 
taken will be recorded. The occurrence of an adverse experience that is fatal, life-
threatening, disabling or requires or prolongs in-patient hospitalisation or causes 
congenital anomaly will be described according to guidelines as "serious" adverse. 
Important medical events that may not be immediately life threatening or result in 
death or hospitalisation may be considered a serious adverse event when, based on 
appropriate medical judgement, they may jeopardise the patient or may require 
medical or surgical intervention to prevent one of the outcomes listed above.  
 
 
 
7.2 Notification and reporting Adverse Events or Reactions 
If the AE is not defined as SERIOUS, the AE is recorded in the study file and the 
participant is followed up by the research team. The AE is documented in the 
participants’ medical notes and the CRF. 
 
7.3 Notification and Reporting of Serious Adverse 
Events/SUSAR  
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7.3.1  Serious Adverse Event (SAEs)  
All SAEs will be recorded in the subjects’ medical  notes, the CRF, the sponsor SAE 
form and reported to the Joint Research Management  Office (JRMO) within 24 hours of 
the CI or PI or co-investigators becoming aware of the event.  Nominated co-
investigators will be authorised to sign the SAE forms in the absence of the CI at the 
co-ordinating site or the PI at the participating sites.  
 
The following SAEs do not have to be reported but will be captured by the 
investigators: 
• Any routine surgery/procedure that is related to dialysis access (Peritoneal 
dialysis and haemodialyis, e.g. for malpositioned, non-functioning PD 
catheters or for creation of AV-graft fistulae). 
• Any surgery/procedure that had been planned prior to trial enrollment. 
• Any admissions for renal transplantations 
• Any admission that are known to be related to HD such as infections, 
inadequate dialysis, problems with access, hypotension, fluid overload. 
• Any admission for related to missed dialysis sessions. 
 
 
7.3.2 Suspected Unexpected Serious Adverse 
Reactions (SUSARs)  
Will be reported to the JRMO/ main REC within 48 hours of the CI or co-investigator 
becoming aware of the event. SUSARs should be reported to the sponsor (JRO 
Office) within 24 hours as the sponsor has a legal obligation to report this to the 
MHRA within 7 days (for fatal or life-threatening SUSARs) or 15 days for all other 
SUSARs. The CI will need to complete the SUSAR  form in conjunction with the 
sponsor SAE form to be sent to the MHRA by the sponsor.  
 
The original and any subsequent follow up of Serious Adverse Event Forms and 
SUSUAR forms (where applicable), together with the sending  confirmation sheet 
must be kept with the TMF at the study site. 
 
7.4 Urgent Safety Measures 
The CI may take urgent safety measures to ensure the safety and protection of the 
clinical trial subjects from any immediate hazard to their health and safety, in 
accordance with Regulation 30. The measures should be taken immediately. In this 
instance, the approval of the Licensing Authority Approval prior to implementing 
these safety measures is not required. However, it is the responsibility of the CI to 
inform the sponsor, Main Research Ethics Committee (via telephone) and the MHRA 
(via telephone for discussion with the medical assessor at the clinical trials unit) of 
this event immediately.  
 
The CI has an obligation to inform both the Sponsor,MHRA and Main Ethics 
Committee in writing within 3 days, in the form of a substantial amendment. The 
sponsor (JRMO) must be sent a copy of the correspondence with regards to this 
matter. 
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7.5 Annual Safety Reporting  
The Development Safety Update  Reports (DSUR) will be sent by the CI to the 
sponsor, the MREC and MHRA (the date of the anniversary is the date on the “notice 
of acceptance letter” from the MHRA) using the Sponsors DSUR template form. The 
CI will carry out a risk benefit analysis of the IMPs encompassing all events having 
arisen on the trial.  
 
The CI will send the Annual Progress Report to the main REC using the NRES 
template (the anniversary date is the date on the MREC “favourable opinion” letter 
from the MREC) and to the sponsor. 
 
Procedures for reporting blinded SUSARs 
Treatment code for the patient is broken in the reporting of a SUSAR. However, the 
blind should be maintained, where possible and appropriate, for staff that are involved 
in data analysis and interpretation.  
 
It is recommended that in the case of a blinded study, the case is assessed for 
seriousness, expectedness and causal relationship as if it was the tested IMP that 
caused the reaction. If the case appears to be a SUSAR then it should be unblinded . 
 
If the administered product is the tested IMP, the case would be reported as a SUSAR 
to the MHRA/ appropriate Main Research Ethics Committee. 
 
If the administered product is a comparator with a marketing authorisation, the 
adverse reaction should be reassessed for expectedness according to the study 
protocol. If the adverse reaction is unexpected then the SUSAR should be reported; 
otherwise it is an expected serious adverse reaction which still requires reporting to 
the sponsor within 24 hours. 
 
7.6 Overview of the Safety Reporting 
Process/Pharmacoviligance responsibilities 
The CI has the overall pharmacovigilance oversight responsibility. The CI has a duty 
to ensure that pharmacovigilance monitoring and reporting is conducted in accordance 
with the sponsor’s requirements.  
 
7.7 Pregnancy 
 
If a patient becomes pregnant whilst involved  in this  CTIMP, it is not considered to 
be an SAE or an AE. However, it is an event that requires monitoring and follow up. 
If a patient, or his partner, becomes pregnant whilst enrolled in a CTIMP in which the 
foetus has been exposed to an investigational medicinal product, immediate reporting 
to the sponsor is required (within one working day of the PI/CI becoming aware of the 
event) using a JRMO pregnancy template form. The CI/PI has the responsibility to 
ensure that the pregnancy form is completed and sent to the sponsor within the agreed 
timelines. Please state whether the patient can continue on the study or whether the 
patient has to be prematurely withdrawn from the study here. 
 
The PI/CI also must follow up the pregnancy until delivery as well as monitoring the 
development of the newborn for the appropriate time (1 month) after birth. Any 
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events that occur during this time that could be considered to be a SAE must be 
reported to the sponsor in line with section above, utilising the sponsor SAE reporting 
form. 
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8 Statistical Considerations 
Missing and spurious data 
Data will undergo review to identify missing and spurious data. The data review will 
be an integral part of the report and includes the decisions on and documentation of 
such data. 
Only subjects with a baseline sample and at least one sample obtained during the 
treatment phase will be included in the analysis. Subjects who have discontinued at 
any time will undergo safety evaluations; reasons for discontinuation will be 
evaluated. Statistical plan and methods to be employed 
The statistics of this study entails a “per protocol” analysis and an Intention to Treat 
analysis where the last follow-up data point is carried over. 
 
Selection of subjects to be included in the analysis 
For intention to treat analysis, all data that meaningfully contribute to the objectives 
of the study will be included. The data of all subjects will be included in the safety 
analysis. 
 
 
8.1 Primary Endpoint Efficacy Analysis  
We shall be compare dEPO/kg requirement between the 2 groups using unpaired 
student t-test. We expect that to compare the means of the run-in and last 2 visits of 
each patient will be used for primary end-point analyses (ITT), and the last 2 visits of 
each patient when taking IMP or placebo (Per Protocol). 
 
 
8.2 Sample Size  
From internal audit data on ESA usage, we assume the average dose of ESA will be 
12000iu/week (with SD=500) 
If the placebo group have Hb=10g/dl, the ESA/Hb ratio = 1200 
 
The study by Cooper et al showed that 4 months treatment increased Hb levels by 
25%. 
We wish to power this study to demonstrate that IMP will increase ESA response by 
5% 
 
If we assumed the SD for ESA/Hb = 100, this will mean that for an alpha level of 5% 
(95%CI) and a beta level of 5% (statistical power of 95%) we shall need 30 patients in 
each group. We assume that there will be a 50% drop out (transplantation and patient 
withdrawal) so we plan to recruit 100 patients 
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9 Data Handling & Record Keeping 
9.1 Confidentiality  
The Chief Investigator has a responsibility to ensure that patient confidentiality is 
protected and maintained. They must also ensure that their identities are protected 
from any unauthorised parties. Information with regards to study patients will be kept 
confidential and managed in accordance with the Data Protection Act, NHS Caldicott 
Guardian, The Research Governance Framework for Health and Social Care and 
Research Ethics Committee Approval. 
 
The Investigator as well as the study team must adhere to these parameters to ensure 
that the Patient’s identity is protected at every stage of their participation within the 
study. To ensure this is done accordingly, each patient, at time of consent must be 
allocated an unique screening number by either the PI or a member of the study team 
before undergoing any screening procedures.The patients initials (the first letter of 
their first name and the first letter of their last name) should be used as a means of de-
identifying  parameters. This information should be kept on a screening log, which 
should be updated accordingly throughout the study. Once the patient has completed 
screening procedures and is enrolled onto the study, the patient will be allocated a 
randomisation number and entered on an enrolment log. 
 
 
If any patient information needs to be sent to a third party (including 
correspondence/communication to central laboratories, CROs, sponsor) the PI and the 
study team should adhere to patient de-identified parameters. This includes the patient 
initials, date of birth, gender as well as the unique study ID/randomisation number. 
Any information that is to be collected by these third parties will utilise these coded 
details for any revelant documents as well as maintaining databases. 
 
• What identifiable information will be collected from the subjects? Nil 
expected. 
• Who will have access to the Information and why? Only researchers or those 
required for audit of study 
• The Chief Investigator is the ‘Custodian’ of the data. 
• Patient identifiable details will not be transferred outside the EU. 
• The patients will be anonymised with regards to any future publications 
relating to this study. 
 
9.2 Case Report Form  
CRF Data Collection Summary 
 Screening Consent Run-in Treatment Off-
Treatment 
FU 
Informed Consent  x    
Inclusion/Exclusion 
Criteria check  
x x    
Medical History Recorded 
(in full) 
x     
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Vital Signs (Blood 
Pressure) 
x  x x x 
PET-CT   x  x 
Cardiac MR   x  x 
Weight x  x x  
ESA dose x  x x X 
Current Medical 
Conditions  
  x x x 
Adverse Event    x x x 
Concomitant Medications  x  x x x 
Local Lab assessment  x  x x x 
Demographics (including 
Date of Birth and Gender)  
x     
 
9.3 Record Retention and Archiving 
During the course of research, all records are the responsibility of the Chief 
Investigator and must be kept in secure conditions. When the research trial is 
complete, it is a requirement of the Research Governance Framework and Trust 
Policy that the records are kept for a further 20 years. For trials involving BH Trust 
patients, undertaken by Trust staff, or sponsored by BHT,, the approved repository for 
long-term storage of local records is the Trust Modern Records Centre which is based 
at 9 Prescot Street.  
 
9.4 Compliance 
The CI will ensure that the trial is conducted in compliance with the principles of the 
Declaration of Helsinki (1996), the principles of GCP and in accordance with all 
applicable regulatory requirements including but not limited to the Research 
Governance Framework and the Medicines for Human Use (Clinical Trial) 
Regulations 2004, and all subsequent amendments, Trust and Research Office policies 
and procedures and any subsequent amendments. 
 
9.5 Clinical Governance Issues 
9.5.1 Ethical Considerations 
This protocol and any subsequent amendments, along with any accompanying 
material provided to the patient in addition to any advertising material will be 
submitted by the Investigator to an Independent Research Ethics Committee. Written 
Approval from the Committee must be obtained and subsequently submitted to the 
JRMO to obtain Final R&D approval, prior to any activity taking place or changes 
implemented. 
 
9.6 Quality Control and Quality Assurance 
9.6.1 Summary Monitoring Plan 
Refer to PEAR  Monitoring Plan for further details 
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The first monitoring visit is due within three months of the first patient being enrolled 
at a site.  Thereafter monitoring visits will occur every four months. The monitoring 
will be a combination of completion of self monitoring forms and a yearly onsite visit. 
  
Source data verification (SDV) will be performed, as detailed in the monitoring plan. 
This will involve direct access to patient notes and include the review of consent 
forms and other relevant investigational reports.  Missing data will be sought, unless 
confirmed as not available. 
 
Non-commercial central laboratories will be monitored though on site and self 
monitoring during their participating in the trial, as detailed in the monitoring plan. 
 
9.6.2 Audit and Inspection 
This study may be audited by representatives from the sponsor or IMP supplier.  The 
investigator will be informed of any audit outcome.  Investigators are obliged to 
cooperate in any audit, allowing the auditor direct access to all relevant documents 
and allocate his/her time and the time of his/her staff to the auditor to discuss any 
findings or issues.  Audit may occur at any time during or after completion of the 
study. 
 
Inspections may be carried out by the Competent Authority at any time and the 
investigator should notify the sponsor immediately if there are any such plans for an 
inspection. 
 
9.7 Serious Breaches in GCP or the Trial Protocol 
The sponsor of the Clinical Trial is responsible for notifying the licensing authority in 
writing of any serious breach of: 
 
The conditions and principles of GCP in connection with that trial; or 
The protocol relating to the trial, as amended from time to time in accordance with 
regulations 22 to 25, within 7 days of becoming aware of that breach. 
 
For the purposes of this regulation, a ‘serious breach’, is a breach which is likely to 
effect to a significant degree: 
The safety or physical or mental integrity of the subjects of the trials; or 
The scientific value of the trial. 
 
The CI is responsible for reporting any serious breaches to the sponsor (JRMO) 
within 24 hours. The sponsor will notify and report to the MHRA within 7 working 
days of becoming aware of the serious breach.     
 
9.8 Non-Compliance        
Is defined as a noted systematic lack of both the CI and the study staff adhering to 
SOPs/protocol/ICH-GCP and UK regulations, which leads to prolonged collection of 
deviations, breaches or suspected fraud. 
 
These non-compliances may be captured from a variety of different sources including 
monitoring visits, CRFs, communications and updates. The sponsor will maintain a 
log of the non-compliances to ascertain if there are any trends developing which to be 
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escalated. The sponsor will assess the non-compliances and action a timeframe in 
which they need to be dealt with. Each action will be given a different timeframe 
dependant on the severity. If the actions are not dealt with accordingly, the JRMO will 
agree an appropriate action, including an on-site audit. 
 
10 Trial Committees 
The chair the Data Safety Committee will not be an active member of PEAR. The 
committee will review the progress of the study and issues arising from the study. 
This will include review of SAE to determine if there are any trends that would 
suggest concerns about the conduct of the study. 
  
A separate Renal Research committee meets regularly throughout the year. Concerns 
of CI or study members about this study can be discussed at this forum to provide 
external expertise. 
 
11 Publication Policy  
Only anonymised data will be used for publication. We shall attempt to publish results 
in peer reviewed journals. 
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Appendix 1: PET Imaging Protocol 
Abbreviations 
CECM Centre for Experimental Cancer Medicine 
CT Computed tomography 
FDG Fluorodeoxyglucose 
IMP Investigational Medicinal Product 
MDT Multi Disciplinary Team 
PET Positron Emission Tomography 
SOP Standard Operating Procedures 
 
Contacts 
Study Team 
Chief Investigator 
 
Professor Magdi Yaqoob 
St. Bartholomew’s Hospital 
Barts Health NHS Trust 
London, EC1 7BE  
 
 
PET 
PET Experts 
 
Dr Jan Hikman 
St. Bartholomew’s Hospital 
Barts Health NHS Trust  
West Smithfield 
London, EC1 7BE  
 
Tel: 020 3465 5922 
Email: Jan.Hikmanl@bartsandthelondon.nhs.uk 
 
 
 
PET Physicist 
 
Dr. Yassine Bouchareb 
St. Bartholomew’s Hospital 
Barts Health NHS Trust  
West Smithfield 
London, EC1 7BE  
020 3465 6902 
Email:yassine.bouchareb@bartshealth.nhs.uk  
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PET Technologists  
 
Craig Copland 
St. Bartholomew’s Hospital  
Barts Health NHS Trust  
West Smithfield 
London, EC1 7BE  
020 3465 5883 
Email: craig.copland@bartshealth.nhs.uk  
 
Rob Punjani 
St. Bartholomew’s Hospital  
Barts Health NHS Trust  
West Smithfield 
London, EC1 7BE  
020 3465 5883 
Email: rob.punjani@bartshealth.nhs.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
This manual summarises the agreed PET protocol for assessing the whole body 
distribution of arterial inflammation in renal failure patients. The patients in this study 
will have confirmed renal failure and will be on dialysis. 
 
1.1. PET/CT 
All PET acquisitions should be accompanied by a low-dose CT procedure to allow for 
attenuation correction and co-localisation of PET data. The parameters of these CT 
acquisitions should be such that the estimated effective dose is no more than 5 mSv 
each.  
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1.2. FDG-PET/CT 
 
As plasma clearance in these patients is delayed, dynamic imaging from 0 to 60 
minutes over the area starting from the Arch of the Aorta (upper limit: arch of the 
Aorta and lower limit: the axial extent of PET Field-of-View) will be performed 
followed by whole body imaging at 90minutes’ 
 
1.2.1. Glucose Measurement 
Patients undergoing FDG-PET/CT should have a blood glucose measurement carried 
out prior to administration of 18F-FDG. FDG administration should only proceed if 
blood glucose is < 10.0 mmol/l. 
 
1.2.2. Dose 
The administered activity of 18F-FDG should be < 200 MBq due to renal failure in 
these patients. 200MBq must not be exceeded. 
1.2.3. Type of scan 
Helical CT acquisition for the low-dose CT from the base of the skull to the knee 
joints. 
Whole Body PET data: Multiple bed positions should be acquired from the knee 
joints to the base of the skull. The time per bed position should be 2 minutes and the 
PET data acquisition should not exceed a total of 30 minutes. 
 
1.2.4. Uptake period 
Dynamic scan start at injection time (20 seconds delay); followed by whole body scan 
at 90 minutes from injection time. 
1.2.5. Total Scan time 
 
No more than 1 x 60 minutes and 1 x 35 minutes (max. 30 min PET emission).  
Blood sampling: 3 samples (3mls each ) at minutes 1, 2 and 3 form the injection of 
activity; then 3 samples (3mls each) at minutes 5, 7 and 9 followed by 5 samples at 
19, 29, 39, 49 and 59 minutes) ( total 11 samples =33 mls blood smaple per scan) 
 
 
1.2.6. FDG-PET Local Analysis 
 
Image analysis will be performed on a dedicated workstation. Using the CT images, 
the vasculature will be divided into carotid arteries, the aorta, iliac and femoral 
arteries. The common and external iliac arteries will be combined and treated together 
as ‘‘iliac artery’’; similarly, the common femoral and superficial femoral arteries are 
amalgamated into the single label of ‘‘femoral artery.’’ The transition point between 
iliac and femoral arteries is the inguinal ligament. 
PEAR 
Protocol: PEAR_ PEAR_14Oct2015_v11-0 Page 40 of 41 
 
Arterial 18F-FDG uptake (as a measure of arterial inflammation) in the legs and neck 
are measured by drawing a region of interest (ROI) around the artery on every slice of 
the coregistered transaxial PET/CT images. On each image slice, the mean and 
maximum standardized uptake values (SUVs) of 18F-FDG in the ROI (containing the 
arterial wall and the lumen) are calculated as the mean and maximum pixel activity. 
The SUV is the decay-corrected tissue concentration of 18F-FDG (in kBq/g), adjusted 
for injected 18F-FDG dose and body weight (in kBq/g), and is a well-recognized 
method for quantification of 18F-FDG PET data. 
By averaging SUVs for all artery slices within an arterial territory, mean and 
maximum SUVs can be derived for each region. These SUVs are normalized to blood 
18F-FDG activity by division by an average blood ROI (at least 8 venous ROI 
measurements), estimated from either the inferior vena cava (leg studies) or the 
jugular vein (carotid studies). This calculation results in an arterial TBR measure, 
which is reported subsequently. 
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12 APPENDIX 2: Image Acquisition Form 
ACQUISITION DATA  
 
Type of Scan: 
 
FDG-PET/CT        
 
Scan acquired at: 
(Name of department / PET Centre) 
 
Patient initials:  
Patient date of birth:  
Patient trial number:  
Referring Consultant / Study 
Name or Code:  
Consultant telephone number:  
Consultant fax number:  
Hospital Address: 
 
 
Date of scan:  
 
15.2  Protocol: PEAR Study- Experimental outcomes 
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Full Title                                   PEAR study: experimental outcomes version 
 
 
Sponsor   
                                                          Queen Mary, University of London  
 
Contact person of the above sponsor 
organisations is: 
  
 Head of Research Resources 
Joint Research Management Office 
 5 Walden Street 
 London 
 E1 2EF 
 Phone: 020 7882 7260 
 Email: sponsorsrep@bartshealth.nhs.uk 
 
 
REC Reference  
 
Chief Investigator Prof. M.M. Yaqoob 
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18.  
2. GLOSSARY  of Terms and Abbreviations 
 
 
AE   Adverse Event   
AR   Adverse Reaction 
ASR   Annual Safety Report 
CA   Competent Authority 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
DMC   Data Monitoring Committee 
EC   European Commission 
GAfREC Governance Arrangements for NHS Research Ethics 
Committees 
ICF   Informed Consent Form 
JRMO   Joint Research Management Office 
NHS REC  National Health Service Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
Participant  An individual who takes part in a clinical trial 
PI   Principal Investigator 
PIS   Participant Information Sheet  
QA   Quality Assurance 
QC   Quality Control 
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
SAE   Serious Adverse Event 
SDV   Source Document Verification 
SOP   Standard Operating Procedure  
SSA   Site Specific Assessment 
TMG   Trial Management Group 
TSC   Trial Steering Committee 
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3. SIGNATURE PAGE 
 
 
Chief Investigator Agreement 
 
 
The clinical study as detailed within this research protocol (Version 1.0, dated 
14.Nov.2014), or any subsequent amendments will be conducted in accordance with 
the Research Governance Framework for Health & Social Care (2005), the World 
Medical Association Declaration of Helsinki (1996) and the current applicable 
regulatory requirements and any subsequent amendments of the appropriate 
regulations. 
 
Chief Investigator Name: Prof. M.M. Yaqoob 
Chief Investigator Site:  Royal London Hospital 
Signature and Date: 
 
 
 
 
 
 
Principal Investigator Agreement (if different from Chief investigator) 
 
 
The clinical study as detailed within this research protocol (Version 1.0, dated 
14.Nov.2014), or any subsequent amendments will be conducted in accordance with 
the Research Governance Framework for Health & Social Care (2005), the World 
Medical Association Declaration of Helsinki (1996) and the current applicable 
regulatory requirements and any subsequent amendments of the appropriate 
regulations. 
 
Principal Investigator Name: Dr. S. Fan 
Principal Investigator Site: Royal London Hospital 
Signature and Date: 
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4.    SUMMARY/SYNOPSIS 
 
 
Short Title PEAR study : experimental outcomes  
Methodology 
 
Laboratory analysis of blood samples stored for future research 
as a part of PEAR study 
 
Research Sites 
 
Barts Health NHS Trust- Royal London Hospital 
Objectives/Aims 
 
To study the effect of Pentoxifylline on cytokine levels, 
leucocyte DNA telomere length shortening and Highly sensitive 
c reactive protein compared to control group. 
 
Number of 
Participants/Patients 
69 
 
Main Inclusion Criteria 
 
Not applicable 
Statistical 
Methodology and 
Analysis (if applicable) 
 
Analysis will include descriptive statistics, t-test, Paired-t 
variance and covariance and use of non-parametric statistics 
when required. 
 
 
Proposed Start Date 15.Dec.2014 
 
 
Proposed End Date 15. Dec.2015 
Study Duration 
 
Not applicable 
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5. INTRODUCTION  
 
Anaemia is a common complication of End Stage Renal Disease (ESRD). This usually 
happens as a result of reduced production of erythropoietin hormone by the kidneys. Anaemia 
as a result of ESRD is treated by giving injections of erythropoiesis stimulating agents (ESAs) 
which have an action similar to natural erythropoietin. 
 
Some patients with ESRD are less responsive or resistant to the action of ESAs consequently 
requiring higher doses of ESAs. High ESA requirement is a surrogate marker of increased all 
cause cardiovascular mortality & morbidity in ESRD patients. Elevated levels of inflammatory 
cytokines as chronic inflammation is one of the major factors associated with ESA hypo-
responsiveness. DNA telomere length shortening is another surrogate marker for 
cardiovascular risks in haemodialysis patients which is associated with chronic inflammation. 
 
There is emerging evidence for Pentoxifylline, a non-selective phosphodiesterase inhibitor as 
a potential treatment for ESA hypo responsiveness. Pentoxifylline (used for twenty years in 
the treatment of peripheral and cerebral vascular diseases), has potent haemorheological and 
anti-inflammatory properties (secondary to inhibition of phosphodiesterases). Pentoxifylline is 
associated with reduction of pro inflammatory cytokines such as tumour necrosis factor 
(TNF)-α, Interferon (IFN)- γ and Interleukin (IL)- 6 in haemodialysis and CKD patients as well 
as improving haemoglobin. 
 
Currently a Single Centre randomized placebo controlled, double blinded study to see if 
Pentoxifylline can help End Stage Renal Disease Patients with Erythropoietin Resistance 
(PEAR study) is underway at Barts Health NHS Trust (Rec number: 12/LO/1635  
 EudraCT Number: 2011/006168/30).  
 
 As a part of this research, some patients recruited in the study have consented for additional 
blood tests to be taken during the course of the study for future research.  Therefore we 
intend to investigate effect of pentoxifylline on cytokine levels, inflammation and consequently 
on DNA telomere length shortening in our patient group. 
 
 
6. TRIAL OBJECTIVES 
 
Primary Endpoint  
 
To study the effect of pentoxifylline on cytokine levels in ESRD patients on haemodialysis with 
hypo-responsiveness to erythropoiesis stimulating agents or ESAs. 
 
Secondary Endpoint  
 
To study effect of pentoxifylline on leucocyte DNA telomere length shortening and highly 
sensitive CRP levels 
 
7. METHODOLOGY  
  
Inclusion Criteria  
 
Not applicable for the proposed study as we are aiming to analyse stored samples 
collected from consenting patients during PEAR study. 
 
Exclusion Criteria  
 
        Not applicable for the proposed study as we are aiming to analyse stored samples  
         collected from consenting patients during PEAR study. 
 
Study Design / Plan  
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Pseudo-anonymised samples for future research are stored in Human Tissue Authority (HTA) 
approved lab will be analysed for cytokine levels, highly sensitive c reactive protein and 
leukocyte DNA telomere length shortening. Pseudo-anonymised samples will be unblinded at 
the end of relevant laboratory investigations.  Unblinding of lab samples will be done after 
unblinding for PEAR study done. However samples shall remain pseudo-anonymised. 
Samples will be analysed in batches.  
 
 
8. STUDY PROCEDURES   
 
Blood samples are only taken from the participants of PEAR study who have consented for 
samples to be stored for future research. Samples are pseudo-anonymised before storage. 
Samples will be analysed in batches. Results and relevant pseudo-anonymised data will be 
stored in secured trust computers. Available results will be correlated with intervention in 
PEAR study once PEAR study data is unblinded.  
 
9. STATISTICAL CONSIDERATIONS  
 
This is a pilot study generating hypothesis. Sample size considerations do not apply as this 
project involves analysing samples stored for future research as a part of PEAR Study. 
Analysis will include descriptive statistics, t test, Paired t variance and covariance and use of 
non-parametric statistics when required. 
 
 
10. ETHICS  
 
This study does not raise any significant ethical issues. This study falls into criteria of studies 
which do not require any formal ethics review as per the National Research Ethics (NRES) 
guidelines.  
 
Patients have already consented for blood tests to be done and stored for future research. 
Anonymity shall be maintained (pseudo-anonymised). Samples shall be stored in HTA 
approved laboratory. 
 
11. SAFETY CONSIDERATIONS: 
There are no safety concerns.  
 
12. DATA HANDLING AND RECORD KEEPING:  
- Confidentiality 
 
Information related to participants should be kept confidential and managed in 
accordance with the Data Protection Act, NHS Caldecott Principles, The 
Research Governance Framework for Health and Social Care, and the 
conditions of Research Ethics Committee Approval. 
 
- Record Retention and Archiving 
 
When the research trial is complete, the data will be stored as per research 
Governance Framework and Trust Policy that the records are kept for a 
further 20 years.  
 
 
13. LABORATORIES : 
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Samples will be processed in Immunology/Serology Laboratory at Royal London Hospital. No 
additional laboratory preparation is required.  
 
Samples have already been pseudo-anonymised at the time of collection. A detailed log of 
samples taken to laboratory for analysis will be maintained. Optimal temperature conditions 
will be maintained during the transit to maintain viability of the samples.  
  
 
14.  PRODUCTS, DEVICES, TECHNIQUES AND TOOLS :  
 
Cytokine analysis 
 
Cytokine assays will be done using commercially supplied kits (R&D Systems) using standard 
manufacturer’s protocol for analysis. Initially the specific anti-cytokine antibody (capture 
antibody) is bound to a polystyrene microplate. Unbound capture antibody is then washed 
away. Plates are blocked and washed. Samples or standards are added and any chosen 
cytokine present is bound by the immobilized antibody. Unbound materials are then washed 
away. Streptavidin-Horseradish Peroxidase (HRP) is used to bind to the detection antibody. 
Unbound streptavidin-HRP is washed away. Tetramethylbenzidine (TMB) substrate solution 
is added to the wells and a blue colour develops in proportion to the amount of analyte 
present in the sample. Colour development is stopped turning the colour in the wells to 
yellow. The absorbance of the colour at 450 nm is measured. 
 
DNA telomere length analysis:  
 
 
Telomere length will be measured by a qPCR assay that compares the mean telomere repeat 
sequence copy number (T) to a reference single-copy gene copy number (S) in each sample 
which is then validated by comparison with Southern blot terminal restriction fragment 
analysis. PCRs to be conducted using a Qiagen Rotor-Gene Q real time PCR cycler (Qiagen, 
Manchester UK). Telomere length was measured in T/S ratio units. The relative quantity of 
the single copy gene (S) in each experimental sample was expressed as the level of dilution 
of the reference DNA sample needed to match it to the experimental sample with regard to 
the number of cycles of PCR needed to generate a given amount of single copy gene PCR 
product during the exponential phase of the PCR (T). For each experimental sample the ratio 
of these dilution factors is the relative telomere to single copy gene (T/S) ratio. Thus T/S = 1 
when the unknown DNA is identical to the reference DNA in its ratio of telomere repeat. 
 
15. SAFETY REPORTING  
 
Not applicable as research is done on samples already stored for future 
research.  
 
 
 
16. MONITORING &AUDITING 
 
Will be done as per according to the protocol, sponsor's standard operating procedures 
(SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement as directed 
by JRMO. 
 
 
17. TRIAL COMMITTEES 
 
This usually consists of the CI, PI and investigator Dr. Tarun Kaushik.  Trial 
Committee will meet at regular intervals to assess progress of the study.  
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18. FINANCE AND FUNDING 
Barts Cardiovascular Biomedical Research Unit (BRU) is funding the project.  
 
 
19. INDEMNITY  
 
Indemnity will be provided by the sponsor, 
Joint Research Management Office RMO,  
Queen Mary University of London, 
Queen Mary Innovation Centre, 
5, Walden Centre 
London E1 2EF.  
 
 
20. DISSEMINATION OF RESEARCH FINDINGS: 
 
Study results disseminated in internal report, conference presentations and peer 
reviewed scientific journals.  
 
 
 
Investigator: 
 
Dr. Tarun Kaushik 
Clinical Research Fellow 
Wlliam Harvey Research Institute 
Queen Mary University, London 
Charter House square, 
London EC1M 6BQ 
 
 
 
 
 
 
 
 
 
 
 
15.3 Protocol: PEAR Study- patient information sheet and  
                           consent form 
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Patient Information for Study: 
PEntoxifylline in Anaemia Resistant to erythropoietin (PEAR) 
 
Chief  Investigator:  Prof M Yaqoob, Barts Health NHS Trust  
Principal Investigator:   Dr Fan 
    
 
 ‘You are being invited to take part in a research study.  Before you decide it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully. Talk to others about the study if you wish.  
• Part 1 tells you the purpose of this study and what will happen to you if you take part.   
• Part 2 gives you more detailed information about the conduct of the study.  
Ask us if there is anything that is not clear or if you would like more information.  Take time to decide 
whether or not you wish to take part. 
 
Part 1. 
What is the purpose of the study? 
 
Pentoxifylline 
Pentoxifylline has been widely used for over 20 years to treat people with circulation 
problems (both of the legs and the brain). The drug is generally very safe.  
 
In addition to its effect on circulation, people have noticed that it also has potent anti-
inflammatory properties.  
 
Inflammation is often the reason why people on dialysis are anaemic (have low Hb) despite 
the use of a hormone called erythropoietin stimulating agent (ESA or otherwise commonly 
called EPO). A small study showed that this treatment could improve the Hb level of patients 
who did not originally respond to EPO. Unfortunately the study was small and needs to be 
repeated before we can be sure it is effective. 
 
Research Study Question 
We want to treat 2 groups of patients. One will receive Pentoxifylline and  the other will 
receive “placebo” (a “dummy tablet). We want to compare the Hb level of patients in the 2 
groups.  
 
 
Why have I been chosen? 
We have invited you to help us because you have been identified as requiring a high dose of 
EPO. This means that you are at risk of becoming anaemic or having side-effects from EPO. 
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Do I have to take part? 
‘No.  It is up to you to decide whether or not to take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You are still free to withdraw 
at any time and without giving a reason.  A decision to withdraw at any time, or a decision 
not to take part, will not affect the standard of care you receive’.  
 
What will happen to me if I take part? 
If you agree to take part, we will ask you to sign a consent form. 
 
Sometimes we don’t know which way of treating patients is best. To find out, we need to 
make comparisons between the different treatments. We put people into groups and give each 
group a different treatment; the results are compared to see if one is better. To try to make 
sure the groups are the same to start with, each patient is put into a group by chance 
(randomly). The results are then compared. 
 
We will randomly put you into either the Pentoxifylline or Placebo group. You will have a 
50:50 chance of being put into the Pentoxifylline treatment group, but neither you nor your 
doctor will know (the study is “blinded”).  
 
If you are in the study, you will be treated for 6 months. During these 6 months, you will be 
reviewed regularly by a member of the Research Team. We shall also take 2 extra blood tests 
every month (2 teaspoonfuls) from your dialysis machine. These blood tests are designed to 
look at how you respond to your EPO and how much “inflammation” is in your body. It also 
involves studying your DNA. At the end of the 6 months, you will stop the tablets, but we 
will still monitor your blood tests every 2 weeks for 2 months.  
 
You will also have special “X-Rays” that are designed to look at your heart and blood 
vessels. These tests will be done over a 2-hour period and you will be asked to attend the 
hospital. You will have an X-ray test before and at the end of the study. One of the X-ray test 
is called a “PET-CT”. This involves an injection of a radioactive dye. Blood will then be 
taken at regular intervals over 1 hour (about 60mLs). The level of radioactivity is 6 times the 
normal background radiation level in the UK. It will not affect your routine daily life. You 
will also have another special X-Ray called “Magnetic Resonance” (MRI) scan that looks at 
your heart. If you are afraid of being in closed spaces (claustrophobic) or if you have any 
metallic implants such as a hip replacement or a pacemaker, you must tell us as you will not 
be able to have this scan. 
 
Your general renal / dialysis care will not be affected. Your participation in this study will not 
affect the chances of you getting a kidney transplant.  
 
Expenses and payments: 
Most visits will be carried out when you come in for dialysis. There will be two extra visits 
for the specialized X-ray tests.  We shall arrange the transport for you or reimburse any extra 
travel costs that you incur. 
 
What do I have to do? 
If you agree to do this study, you will need to take the tablets we select for you once a day  
for 6 months. You will have a few extra blood tests (taken when you are on dialysis) and 
special X-rays that will require 2 extra visits to the hospital. If you have a problem or if you 
dislike your treatment, you can withdraw from the study at any time. Other aspects of your 
care will not be affected. 
The Timetable for what will happen is shown below: 
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Summary of Study Plan 
 
Screening 
Consent 
Run-in 
2 weeks 
Randomisation 
if meets all 
inclusion criteria 
6 months treatment with IMP or placebo 
IMP/placebo 
discontinued 
2 months FU 
without IMP or 
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Weekly 
bloods 
Monthly 
bloods 
Cardiovascular 
Imaging 
Cardiovascular 
Imaging 
Study Periods: 
Events: 
Procedures: 
Fortnightly 
bloods 
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What is the treatment that is being tested? 
Pentoxifylline is made by a company called Sanofi. It is mainly used to treat people who have 
circulatory problems. But there is some evidence that it will also help your haemoglobin 
level.  
 
What are the alternatives for treatment? 
EPO is used to correct low haemoglobin levels in patients with renal failure. Unfortunately, 
not everyone responds to this hormone or needs a very high dose that can cause side effects 
and problems. You have been identified as someone who requires high doses of EPO. People 
like you may benefit if we find a treatment that makes you respond to EPO better. 
 
 
What are the side effects of any treatment received when taking part? 
Pentoxifylline is widely used for patients with circulation problems. The drug can increase 
bleeding. The use of Asprin and other anti-coagulants is safe with Pentoxifylline. If you are 
concerned about bleeding or have an increased tendency to bleed, please let us know. 
 
Other side-effects are relatively rare but can include gastro-intestinal disturbance and 
headaches.  
 
Some people can be allergic to Pentoxifylline or the “Dummy drug” which is composed of 
cellulose. If you are known to be allergic to either please let us know as you are not suitable 
for the study. 
 
If you develop any side-effects or are concerned about the tablets/treatment, please contact us 
at any time. Details are provided below. 
 
What are the other possible disadvantages and risks of taking part? 
We think the risk of taking part is very low.  
 
It is possible that Pentoxifylline is not effective at improving your Hb, but we will not be 
stopping or reducing you EPO. 
 
If you have private medical insurance you should check with the company, before agreeing to 
take part in this study. 
 
Harm to the unborn child   
There is no evidence that Pentoxifylline is harmful to any unborn child. Nevertheless, we 
would advise that you take adequate precaution against getting pregnant during the study. 
 
If you think you may be pregnant, you should tell us. 
If you are trying to get pregnant, you should not take part in this study. 
 
If you are of child bearing age, we will ask if you have missed your periods or if you think 
you might be pregnant before we do any “X-rays”. If there is any doubt, we will do a 
pregnancy test before exposing you to “X-rays”. 
 
What are the possible benefits of taking part? 
We cannot promise the study will help you but the information we get might help improve 
the treatment of people on dialysis. 
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You have been identified as someone who does not respond well to EPO. This makes you at 
risk of becoming anaemic and getting side effects from EPO. If you are randomized to 
Pentoxifylline, you may respond better to EPO. If you are randomized to the “dummy” tablet, 
you will not get any potential benefit from Pentoxifylline. However, the study team will keep 
a close eye on your results throughout the study and make sure your treatment is adjusted 
according to the dialysis unit’s guidelines. This “study effect” has been seen in many 
different studies and can be quite significant. 
 
 
What happens when the research study stops? 
At the end of the study, you will stop your treatment. However, Pentoxifylline is a licenced 
drug and can be continued if you need it. 
 
 
What if there is a problem? Who can I contact? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this is given in Part 2.    
 
If you have any complaints or have any questions, please contact: 
 
 Research Nurse:        Mr. Wancheung Li (through Royal London Hospital switch board) 
Consultant in charge:        Tel:020 3594 2674 (Dr Fan) or 020 3594 2658 (Prof Yaqoob) 
 
In emergencies, please contact the Renal Registrar on call: Tel: 020 7377 7000 
 
Alternatively, you can contact: 
Patient Advice and Liaison Service (PALS) 
Telephone: 020 7943 1335, Minicom: 020 7943 1350 
E-mail: pals@bartsandthelondon.nhs.uk 
 
Will my taking part in the study be kept confidential?  
All information which is collected about you during the course of the research will be kept 
strictly confidential.  If you consent to take part in the research the people conducting the 
study will abide by the Data Protection Act 1988, and the rights you have under this Act.   
  All the information about your participation in this study will be kept confidential.  The 
details are included in Part 2.’ 
 
This completes Part 1 of the Information Sheet. 
If the information in Part 1 has interested you and you are considering participation, 
please continue to read the additional information in Part 2 before making any decision. 
 
 
Part 2  
 
What if relevant new information becomes available?   
 Sometimes during the course of a research project, new information becomes available about 
the treatment/drug that is being studied.  If this happens, your research doctor will tell you 
about it and discuss whether you want to or should continue in the study.  If you decide not to 
carry on, your research doctor will make arrangements for your care to continue.  If you 
decide to continue in the study you will be asked to sign an updated consent form. 
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Also, on receiving new information your research doctor might consider it to be in your best 
interests to withdraw you from the study.  He/she will explain the reasons and arrange for 
your care to continue. 
 
If the study is stopped for any other reason, you will be told why and your continuing care 
will be arranged. 
 
 
What will happen if I don’t want to carry on with the study? 
If you chose to withdraw from the study any information that has been already collected will 
be processed as part of the study. 
 
If you stop the treatment, we will ask if you are willing to have a 1-month “Off-Treatment” 
follow-up. This is important as we want to see what happens to your blood results and Hb 
levels after you come off the treatment. We shall also ask if you are willing to have the end of 
study “X-rays”.  
 
You are free to say “no” to the “off-treatment follow-up”, the extra blood tests or to the “X-
rays”. However, you should be aware that audits are conducted on a regular basis as required 
by Good Clinical Governance. Results of blood tests that are taken as part of your regular 
medical care will continue to contribute towards our audit and reporting to Department of 
Health mandated registries. 
 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with the 
researchers who will do their best to answer your questions (See contact details that are listed 
in Part 1 of this form).  If you remain unhappy and wish to complain formally, you can do 
this through the NHS Complaints Procedure.  Details can be obtained from the hospital. 
 
Harm:   
In the event that something does go wrong and you are harmed during the research study 
there are no special compensation arrangements.  If you are harmed and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation against 
Barts Health NHS Trust, but you may have to pay your legal costs.  The normal National 
Health Service complaints mechanisms will still be available to you (if appropriate).’ 
 
NHS Indemnity does not offer no-fault compensation i.e. for non-negligent harm, and NHS 
bodies are unable to agree in advance to pay compensation for non-negligent harm.  They are 
able to consider an ex-gratia payment in the case of a claim. 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential.  If you consent to take part in the research the people conducting the 
study will abide by the Data Protection Act 1988, and the rights you have under this Act.   
 
Information including details of your treatment and details about any infection you may 
develop during the study will be collected and entered into a database. This will be coded and 
the investigators will keep the code. People that are not involved in the study will not have 
access to the code. The information will be kept for 1520 years and in accordance with the 
sponsor policy. 
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Involvement of the General Practitioner/Family doctor (GP)  
Unless you object, we will inform your GP that you are taking part in this study and details 
about your treatment. We think this is important so they know what tablets you are taking.  
 
What will happen to the results of the research study? 
We hope the results of our study will be important to all doctors looking after patients 
undergoing HD. We will therefore publish the results and present the data at various 
meetings. However, at all times, your confidentiality will be protected. You will NOT be 
identified in any report/publication unless we ask you for specific permission. 
 
 
Who is organising and funding the research?   
Barts Health NHS Trust is organising and running this study.  
 
Who has reviewed the study?  
This study was given a favourable ethical opinion  for conduct in the NHS by the East 
London and The City Research Ethics Committee. The detailed study has also been carefully 
considered by an independent internal research committee of the Renal Unit at BHT 
 
You may wish to thank your participant for considering taking part or taking time to 
read this sheet. 
 
 
T H E  R O Y A L  H O S P I T A L  O F  S T  B A R T H O L O M E W ,  T H E  R O Y A L  L O N D O N  H O S P I T A L  A N D  T H E  L O N D O N  C H E S T  H O S P I T A L  N H S  
T R U S T  
 
Centre Number: :                    Patient Id:: 
CONSENT FORM 
 
Title of Project: PEntoxifylline in Anaemia Resistant to 
erythropoietin (PEAR) 
 
Name of Researcher: Prof M Yaqoob      Please initial box 
1. I confirm that I have read and understand the information sheet dated 29th Oct. 2013 for the above  
study. I have had the opportunity to consider the information, ask questions and have had these 
answered satisfactorily.           
                                                                                                                                               c 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, without 
giving any reason, without my medical care or legal rights being affected.            c 
 
3. I understand that relevant sections of any of my medical notes and data collected during the study, 
may be looked at by responsible individuals from Barts and The London or from regulatory 
authorities or from the NHS Trust, where it is relevant to my taking part in this research.  I give 
permission for these individuals to have access to my records.     c 
 
4. I agree to my GP being informed of my participation in the study.    c 
 
5. I agree to take part in the above study.        c 
 
6. I understand that blood will be taken during my treatment / investigation and will not be used for 
diagnostic purposes. I agree that this blood will be stored in a Research Tissue Bank for future research. 
 
 
 
________________________ ___________________ ______ 
Name of Patient Signature Date 
 
 
_________________________ ________________ ________ 
Name of Person taking consent Signature  Date 
 (if different from researcher) 
 
 
_________________________ ________________ ________ 
Researcher  Signature Date 
 
 
15.4 Ethics committee and MHRA approval 
 
 
 
NRES Committee London - City & East 
Bristol Research Ethics Committee Centre 
Whitefriars 
Level 3, Block B 
Lewins Mead 
Bristol 
BS1 2NT 
 
Tel: 01173421386 
Fax: 01173420445 
 
05 March 2013 
 
Professor Magdi Yaqoob 
Barts and The London 
The Royal London Hospital 
Whitechapel 
E1 1BB 
 
Dear Professor Yaqoob, 
 
Study title: A Single-Centre randomized placebo controlled, double 
blinded study of Pentoxifylline in End-Stage Renal 
Disease Patients with Erythropoeitin resistance 
REC reference: 12/LO/1635 
EudraCT number: 2011-006168-30 
Amendment number: AM01 Substantial Amendment 01 dated 04 Dec 2012 
Amendment date: 22 February 2013 
IRAS project ID: 103187 
 
The above amendment was reviewed by the Sub-Committee in correspondence.  
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
 Document  Version  Date  
Participant Consent Form: Participant Consent Form  4  28 August 2012  
Participant Information Sheet: Participant Information Sheet  4  28 August 2012  
European Commission Notification of Substantial Amendment Form  AM01 
Substantial 
Amendment 
01 dated 04 
Dec 2012  
22 February 2013  
Covering Letter    27 September 2012  
Protocol  7-1  27 November 2012  
  
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out 
the ethical review of clinical trials of investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics committees 
and the conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/  
 
12/LO/1635:     Please quote this number on all correspondence 
 
Yours sincerely, 
 
pp Dr Arthur T. Tucker 
Chair 
 
E-mail: nrescommittee.london-cityandeast@nhs.net 
 
 
Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to:  Mr Gerry  Leonard, Barts Health NHS Trust 
 
NRES Committee London - City & East 
 
Attendance at Sub-Committee of the REC meeting on 25 February 2013 
 
Name   Profession   Capacity    
Professor Atholl Johnston  Professor of Clinical Pharmacology  Expert  
Dr Arthur T. Tucker  Principal Clinical Scientist & Honorary 
Reader, (REC Chairman)  
Expert  
Professor David Wingate  Gastroenterologist  Expert  
  
Also in attendance:  
 
Name   Position (or reason for attending)   
Mr  Rajat Khullar  Committee Coordinator  
 
 

